



CRITERIOS DE AUTORIZACIÓN PREVIA

1° de enero - 31 de diciembre

2025



ABATACEPT SQ

Products Affected

- ORENCIA
- ORENCIA CLICKJECT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: RA: ONE OF THE FOLLOWING: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA, ENBREL, XELJANZ, RINVOQ, OR 2) TRIAL OF A TNF INHIBITOR AND PHYSICIAN HAS INDICATED THE PATIENT CANNOT USE A JAK INHIBITOR DUE TO THE BLACK BOX WARNING FOR INCREASED RISK OF MORTALITY, MALIGNANCIES, AND SERIOUS CARDIOVASCULAR EVENTS. PJIA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA, ENBREL, XELJANZ IR. PSA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA, STELARA, COSENTYX, ENBREL, TREMFYA, XELJANZ, RINVOQ, SKYRIZI. RENEWAL: RA, PJIA, PSA: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications | All FDA-approved Indications. |

| PA Criteria | Criteria Details |
|----------------------------|-------------------------|
| Off Label Uses | |
| Part B Prerequisite | No |

ABEMACICLIB

Products Affected

- VERZENIO

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ABIRATERONE

Products Affected

- *abiraterone*

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | METASTATIC HIGH-RISK CASTRATION-SENSITIVE PROSTATE CANCER, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: ONE OF THE FOLLOWING: 1) PREVIOUSLY RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ABIRATERONE SUBMICRONIZED

Products Affected

- YONSA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: ONE OF THE FOLLOWING: 1) PREVIOUSLY RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ACALABRUTINIB

Products Affected

- CALQUENCE
- CALQUENCE (ACALABRUTINIB MAL)

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ADAGRASIB

Products Affected

- KRAZATI

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ADALIMUMAB

Products Affected

- HADLIMA(CF)
- HADLIMA(CF) PUSH TOUCH
- HUMIRA PEN
- HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML
- HUMIRA(CF)
- HUMIRA(CF) PEN
- HUMIRA(CF) PEN CROHNS-UC-HS
- HUMIRA(CF) PEN PEDIATRIC UC
- HUMIRA(CF) PEN PSOR-UV-ADOL HS
- SIMLANDI(CF) AUTOINJECTOR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, OR GENITAL AREA. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: RA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA), ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST. UVEITIS: PRESCRIBED BY OR IN CONSULTATION WITH AN OPHTHALMOLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS. |

| PA Criteria | Criteria Details |
|----------------------------|---|
| Other Criteria | <p>INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. PJIA, PSA: TRIAL OF OR CONTRAINDICATION TO ONE DMARD. AS: TRIAL OF OR CONTRAINDICATION TO AN NSAID. PSO: TRIAL OF OR CONTRAINDICATION TO ONE CONVENTIONAL THERAPY SUCH AS A PUVA (PHOTOTHERAPY ULTRAVIOLET LIGHT A), UVB (ULTRAVIOLET LIGHT B), TOPICAL CORTICOSTEROIDS, CALCIPOTRIEN E, ACITRETIN, METHOTREXATE, OR CYCLOSPORINE. CD, UC: TRIAL OF OR CONTRAINDICATION TO ONE CONVENTIONAL THERAPY SUCH AS A CORTICOSTEROID (E.G., BUDESONIDE, METHYLPREDNISOLONE), AZATHIOPRINE, MERCAPTOPYRINE, METHOTREXATE, OR MESALAMINE. UVEITIS: NO ISOLATED ANTERIOR UVEITIS. RENEWAL: RA, PJIA, PSA, AS, PSO, HIDRADENITIS SUPPURATIVA, UVEITIS: CONTINUES TO BENEFIT FROM THE MEDICATION.</p> |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

AFATINIB

Products Affected

- GILOTRIF

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS. |
| Other Criteria | METASTATIC NSCLC WITH EGFR MUTATION; NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE-INHIBITOR. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

AKEEGA

Products Affected

- AKEEGA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | None |
| Required Medical Information | Diagnosis of deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC) AND used in combination with prednisone |
| Age Restrictions | 18 years or older |
| Prescriber Restrictions | Prescribed by or in consultation with an oncologist |
| Coverage Duration | 12 months |
| Other Criteria | None |
| Indications | Some FDA-approved Indications Only. |
| Off Label Uses | |
| Part B Prerequisite | No |

ALECTINIB

Products Affected

- ALECENSA

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ALPELISIB

Products Affected

- PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1), 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2)

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

AMBRISENTAN

Products Affected

- *ambrisentan*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: 1) DOCUMENTED CONFIRMATORY DIAGNOSIS BASED ON RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: A) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, B) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND C) PULMONARY VASCULAR RESISTANCE (PVR) OF 3 WOOD UNITS OR GREATER, AND 2) NYHA-WHO FUNCTIONAL CLASS II-IV SYMPTOMS. |
| Age Restrictions | |
| Prescriber Restrictions | PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | PAH: INITIAL: PATIENT DOES NOT HAVE IDIOPATHIC PULMONARY FIBROSIS. RENEWAL: 1) IMPROVEMENT FROM BASELINE IN THE 6-MINUTE WALK DISTANCE, OR 2) A STABLE 6-MINUTE WALK DISTANCE WITH A STABLE/IMPROVED WHO FUNCTIONAL CLASS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

AMIFAMPRIDINE

Products Affected

- FIRDAPSE

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

APALUTAMIDE

Products Affected

- ERLEADA ORAL TABLET 240 MG, 60 MG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC): (1) HIGH RISK PROSTATE CANCER (I.E., RAPIDLY INCREASING PROSTATE SPECIFIC ANTIGEN [PSA] LEVELS). NMCRPC, METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC): (1) RECEIVED A BILATERAL ORCHIECTOMY, (2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR (3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE ANALOG. RENEWAL: DIAGNOSIS OF NMCRPC OR MCSPC. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

APOMORPHINE

Products Affected

- *apomorphine*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | PARKINSONS DISEASE (PD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

APREMILAST

Products Affected

- OTEZLA ORAL TABLET 20 MG, 30 MG
- OTEZLA STARTER

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: MILD PLAQUE PSORIASIS (PSO): ONE OF THE FOLLOWING: 1) PSORIASIS COVERING 2 PERCENT OF BODY SURFACE AREA (BSA), 2) STATIC PHYSICIAN GLOBAL ASSESSMENT (SPGA) SCORE OF 2, OR 3) PSORIASIS AREA AND SEVERITY INDEX (PASI) SCORE OF 2 TO 9. MODERATE TO SEVERE PSO: 1) PSORIASIS COVERING 3 PERCENT OR MORE OF BSA, OR 2) PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, OR GENITAL AREA. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. BEHCETS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |

| PA Criteria | Criteria Details |
|----------------------------|--|
| Other Criteria | <p>INITIAL: PSA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA, STELARA, COSENTYX, ENBREL, TREMFYA, XELJANZ, RINVOQ, SKYRIZI. MILD PSO: TRIAL OF OR CONTRAINDICATION TO ONE CONVENTIONAL SYSTEMIC AGENT (E.G., METHOTREXATE, ACITRETIN, CYCLOSPORINE) AND ONE CONVENTIONAL TOPICAL AGENT (E.G., PUVA, UVB, TOPICAL CORTICOSTEROIDS). MODERATE TO SEVERE PSO: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA, STELARA, COSENTYX, ENBREL, SKYRIZI, TREMFYA. BEHCETS DISEASE: 1) PATIENT HAS ORAL ULCERS OR A HISTORY OF RECURRENT ORAL ULCERS BASED ON CLINICAL SYMPTOMS, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE OR MORE CONSERVATIVE TREATMENTS (E.G., COLCHICINE, TOPICAL CORTICOSTEROID, ORAL CORTICOSTEROID). RENEWAL: PSA, PSO, BEHCETS DISEASE: CONTINUES TO BENEFIT FROM THE MEDICATION.</p> |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ASCIMINIB

Products Affected

- SCEMBLIX

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND SCEMBLIX IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ATOGEPANT

Products Affected

- QULIPTA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | EPISODIC MIGRAINE PREVENTION: INITIAL: 1) TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREVENTIVE MIGRAINE TREATMENTS: DIVALPROEX SODIUM, TOPIRAMATE, PROPRANOLOL, TIMOLOL, AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: 1) REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY, AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

AUGTYRO

Products Affected

- AUGTYRO ORAL CAPSULE 40 MG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | None |
| Required Medical Information | |
| Age Restrictions | 12 years or older |
| Prescriber Restrictions | Prescribed by or in consultation with an oncologist |
| Coverage Duration | 12 months |
| Other Criteria | None |
| Indications | Some FDA-approved Indications Only. |
| Off Label Uses | |
| Part B Prerequisite | No |

AVACOPAN

Products Affected

- TAVNEOS

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | ANTI-NEUTROPHIL CYTOPLASMIC AUTOANTIBODY (ANCA)-ASSOCIATED VASCULITIS: INITIAL: ANCA SEROPOSITIVE (ANTI-PR3 OR ANTI-MPO). |
| Age Restrictions | |
| Prescriber Restrictions | ANCA-ASSOCIATED VASCULITIS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR NEPHROLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 6 MONTHS. |
| Other Criteria | ANCA-ASSOCIATED VASCULITIS: RENEWAL: CONTINUES TO BENEFIT FROM THERAPY. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

AVAPRITINIB

Products Affected

- AYVAKIT

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

AVATROMBOPAG

Products Affected

- DOPTELET (10 TAB PACK)
- DOPTELET (15 TAB PACK)
- DOPTELET (30 TAB PACK)

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: CHRONIC LIVER DISEASE (CLD): PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST, GASTROENTEROLOGIST, HEPATOLOGIST, IMMUNOLOGIST, ENDOCRINOLOGIST, OR A SURGEON. CHRONIC IMMUNE THROMBOCYTOPENIA (ITP): PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR IMMUNOLOGIST. |
| Coverage Duration | CLD: 1 MONTH. CHRONIC ITP: INITIAL: 2 MONTHS, RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: CLD: 1) PLANNED PROCEDURE 10 TO 13 DAYS AFTER INITIATION OF DOPTELET, AND 2) NOT RECEIVING OTHER THROMBOPOIETIN RECEPTOR AGONISTS (E.G., ROMIPLOSTIM, ELTROMBOPAG, ETC.). CHRONIC ITP: TRIAL OF OR CONTRAINDICATION TO CORTICOSTEROIDS OR IMMUNOGLOBULINS OR INSUFFICIENT RESPONSE TO SPLENECTOMY. RENEWAL: CHRONIC ITP: PATIENT HAD A CLINICAL RESPONSE. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

AXITINIB

Products Affected

- INLYTA ORAL TABLET 1 MG, 5 MG

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

AZACITIDINE

Products Affected

- ONUREG

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

AZTREONAM

Products Affected

- CAYSTON

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | 7 YEARS OF AGE OR OLDER |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

BECAPLERMIN

Products Affected

- REGRANEX

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | DIABETIC NEUROPATHIC ULCERS: PRESCRIBED BY OR IN CONSULTATION WITH A VASCULAR SURGEON, PODIATRIST, ENDOCRINOLOGIST, PHYSICIAN PRACTICING IN A SPECIALTY WOUND CLINIC OR INFECTIOUS DISEASE SPECIALIST. |
| Coverage Duration | 3 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

BEDAQUILINE

Products Affected

- SIRTURO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 24 WEEKS |
| Other Criteria | PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS (MDR-TB): SIRTURO USED IN COMBINATION WITH AT LEAST 3 OTHER ANTIBIOTICS FOR THE TREATMENT OF PULMONARY MDR-TB. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

BELIMUMAB

Products Affected

- BENLYSTA SUBCUTANEOUS

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. LUPUS NEPHRITIS (LN): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR NEPHROLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS |
| Other Criteria | INITIAL: SLE: CURRENTLY TAKING CORTICOSTEROIDS, ANTIMALARIALS, NSAIDS, OR IMMUNOSUPPRESSIVE AGENTS. RENEWAL: SLE: PATIENT HAD CLINICAL IMPROVEMENT. LN: IMPROVEMENT IN RENAL RESPONSE FROM BASELINE LABORATORY VALUES (I.E., EGFR OR PROTEINURIA) AND/OR CLINICAL PARAMETERS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

BELUMOSUDIL

Products Affected

- REZUROCK

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

BELZUTIFAN

Products Affected

- WELIREG

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

BENRALIZUMAB

Products Affected

- FASENRA
- FASENRA PEN

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | ASTHMA: INITIAL: BLOOD EOSINOPHIL LEVEL GREATER THAN OR EQUAL TO 150 CELLS/MCL WITHIN THE PAST 12 MONTHS. |
| Age Restrictions | |
| Prescriber Restrictions | ASTHMA: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN ALLERGY OR PULMONARY MEDICINE. |
| Coverage Duration | INITIAL: 4 MONTHS, RENEWAL: 12 MONTHS. |

| PA Criteria | Criteria Details |
|----------------------------|---|
| Other Criteria | <p>ASTHMA: INITIAL: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE, OR MAXIMALLY-TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, AND 2) ONE OF THE FOLLOWING: (A) PATIENT EXPERIENCED AT LEAST ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING 3 OR MORE DAYS WITHIN THE PAST 12 MONTHS OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR (B) PATIENT HAS POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, ANY NIGHT WAKING DUE TO ASTHMA, SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, ANY ACTIVITY LIMITATION DUE TO ASTHMA, AND 3) NOT CONCURRENTLY RECEIVING XOLAIR, DUPIXENT OR OTHER ANTI-IL5 BIOLOGICS WHEN THESE ARE USED FOR THE TREATMENT OF ASTHMA. RENEWAL: 1) NOT CONCURRENTLY RECEIVING XOLAIR, DUPIXENT OR OTHER ANTI-IL5 BIOLOGICS WHEN THESE ARE USED FOR THE TREATMENT OF ASTHMA, 2) CONTINUED USE OF ICS AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, AND 3) CLINICAL RESPONSE AS EVIDENCED BY ONE OF THE FOLLOWING: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE, OR (D) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS.</p> |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

BETAINE

Products Affected

- *betaine*

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

BEXAROTENE

Products Affected

- *bexarotene oral*
- *bexarotene topical*

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

BINIMETINIB

Products Affected

- MEKTOVI

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

BOSENTAN

Products Affected

- *bosentan*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: 1) DOCUMENTED CONFIRMATORY DIAGNOSIS BASED ON RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: A) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, B) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND C) PULMONARY VASCULAR RESISTANCE (PVR) OF 3 WOOD UNITS OR GREATER, AND 2) NYHA-WHO FUNCTIONAL CLASS II-IV SYMPTOMS. |
| Age Restrictions | |
| Prescriber Restrictions | PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | PAH: INITIAL: 1) DOES NOT HAVE ELEVATED LIVER ENZYMES (ALT, AST) MORE THAN 3 TIMES UPPER LIMIT OF NORMAL (ULN) OR INCREASE IN BILIRUBIN BY 2 OR MORE TIMES ULN, AND 2) NOT CONCURRENTLY TAKING CYCLOSPORINE A OR GLYBURIDE. RENEWAL: 1) NOT CONCURRENTLY TAKING CYCLOSPORINE A OR GLYBURIDE, 2) AGES 3 TO 17 YEARS OF AGE: A) DEMONSTRATED IMPROVEMENT IN PVR, OR B) REMAINED STABLE OR SHOWN IMPROVEMENT IN EXERCISE ABILITY, 3) AGES 18 YEARS OR OLDER: A) IMPROVEMENT FROM BASELINE IN THE 6-MINUTE WALK DISTANCE, OR B) A STABLE 6-MINUTE WALK DISTANCE WITH A STABLE/IMPROVED WHO FUNCTIONAL CLASS. |
| Indications | All FDA-approved Indications. |

| PA Criteria | Criteria Details |
|----------------------------|-------------------------|
| Off Label Uses | |
| Part B Prerequisite | No |

BOSUTINIB

Products Affected

- BOSULIF ORAL CAPSULE 100 MG, 50 MG
- BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | PREVIOUSLY TREATED (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND BOSULIF IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE. |
| Indications | Some FDA-approved Indications Only. |
| Off Label Uses | |
| Part B Prerequisite | No |

BRIGATINIB

Products Affected

- ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG
- ALUNBRIG ORAL TABLETS,DOSE PACK

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

BRONCHITOL

Products Affected

- BRONCHITOL

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Diagnosis of Cystic fibrosis of the lung |
| Age Restrictions | |
| Prescriber Restrictions | Prescribed by or in consultation with a pulmonologist or prescribing practitioner is from a CF center accredited by the Cystic Fibrosis Foundation |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

C1 ESTERASE INHIBITOR-HAEGARDA

Products Affected

- HAEGARDA SUBCUTANEOUS RECON SOLN 2,000 UNIT, 3,000 UNIT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | HEREDITARY ANGIOEDEMA (HAE): INITIAL: DIAGNOSIS CONFIRMED BY COMPLEMENT TESTING. |
| Age Restrictions | |
| Prescriber Restrictions | HAE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST, IMMUNOLOGIST, OR ALLERGIST. |
| Coverage Duration | INITIAL AND RENEWAL: 12 MONTHS. |
| Other Criteria | HAE: INITIAL: NOT ON CONCURRENT TREATMENT WITH ALTERNATIVE PROPHYLACTIC AGENT FOR HAE ATTACKS. RENEWAL: 1) IMPROVEMENT COMPARED TO BASELINE IN HAE ATTACKS (I.E., REDUCTIONS IN ATTACK FREQUENCY OR ATTACK SEVERITY), AND 2) NOT ON CONCURRENT TREATMENT WITH ALTERNATIVE PROPHYLACTIC AGENT FOR HAE ATTACKS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

CABOZANTINIB

Products Affected

- COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1), 140 MG/DAY(80 MG X1-20 MG X3), 60 MG/DAY (20 MG X 3/DAY)

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

CABOZANTINIB S-MALATE - CABOMETYX

Products Affected

- CABOMETYX ORAL TABLET 20 MG, 40 MG, 60 MG

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

CANNABIDIOL

Products Affected

- EPIDIOLEX

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | DRAVET SYNDROME (DS), LENNOX-GASTAUT SYNDROME (LGS), TUBEROUS SCLEROSIS COMPLEX (TSC): PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST. |
| Coverage Duration | INITIAL: 12 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: LENNOX-GASTAUT SYNDROME (LGS): TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING ANTIEPILEPTIC MEDICATIONS: RUFINAMIDE, FELBAMATE, CLOBAZAM, TOPIRAMATE, LAMOTRIGINE, CLONAZEPAM. RENEWAL: DS, LGS, TSC: CONFIRMATION OF DIAGNOSIS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

CAPLACIZUMAB YHDP

Products Affected

- CABLIVI INJECTION KIT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | ACQUIRED THROMBOTIC THROMBOCYTOPENIA PURPURA (ATTP): PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST |
| Coverage Duration | 12 MONTHS |
| Other Criteria | ATTP: CABLIVI WAS PREVIOUSLY INITIATED AS PART OF THE FDA APPROVED TREATMENT REGIMEN IN COMBINATION WITH PLASMA EXCHANGE AND IMMUNOSUPPRESSIVE THERAPY WITHIN AN INPATIENT SETTING. THE PATIENT HAS NOT EXPERIENCED MORE THAN TWO RECURRENCES OF ATTP WHILE ON CABLIVI THERAPY (I.E., NEW DROP IN PLATELET COUNT REQUIRING REPEAT PLASMA EXCHANGE DURING 30 DAYS POST-PLASMA EXCHANGE THERAPY [PEX] AND UP TO 28 DAYS OF EXTENDED THERAPY). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

CAPMATINIB

Products Affected

- TABRECTA

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

CARGLUMIC ACID

Products Affected

- *carglumic acid*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: ACUTE, CHRONIC HYPERAMMONEMIA (HA) DUE TO N ACETYLGLUTAMATE SYNTHASE (NAGS) DEFICIENCY: NAGS GENE MUTATION IS CONFIRMED BY BIOCHEMICAL OR GENETIC TESTING. ACUTE HA DUE TO PROPIONIC ACIDEMIA (PA): 1) CONFIRMED BY THE PRESENCE OF ELEVATED METHYLCITRIC ACID AND NORMAL METHYLMALONIC ACID, OR 2) GENETIC TESTING CONFIRMING MUTATION IN THE PCCA OR PCCB GENE. ACUTE HA DUE TO METHYLMALONIC ACIDEMIA (MMA): 1) CONFIRMED BY THE PRESENCE OF ELEVATED METHYLMALONIC ACID, METHYLCITRIC ACID, OR 2) GENETIC TESTING CONFIRMING MUTATION IN THE MMUT, MMA, MMAB OR MMADHC GENES. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | ACUTE HA DUE TO NAGS/PA/MMA: 7 DAYS. CHRONIC HA DUE TO NAGS: INITIAL: 6 MOS, RENEWAL: 12 MOS. |
| Other Criteria | RENEWAL: CHRONIC HA DUE TO NAGS: PATIENT HAS SHOWN CLINICAL IMPROVEMENT. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

CERITINIB

Products Affected

- ZYKADIA

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

CERTOLIZUMAB PEGOL

Products Affected

- CIMZIA SUBCUTANEOUS SYRINGE
KIT 400 MG/2 ML (200 MG/ML X 2)

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, OR GENITAL AREA. NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN (CRP) LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI). |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS), NR-AXSPA: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. CROHNS DISEASE (CD): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |

| PA Criteria | Criteria Details |
|----------------------------|---|
| Other Criteria | <p>INITIAL: RA: ONE OF THE FOLLOWING: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA, ENBREL, XELJANZ, RINVOQ, OR 2) TRIAL OF A TNF INHIBITOR AND PHYSICIAN HAS INDICATED THE PATIENT CANNOT USE A JAK INHIBITOR DUE TO THE BLACK BOX WARNING FOR INCREASED RISK OF MORTALITY, MALIGNANCIES, AND SERIOUS CARDIOVASCULAR EVENTS. PSA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA, STELARA, COSENTYX, ENBREL, TREMFYA, XELJANZ, RINVOQ, SKYRIZI. PSO: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA, STELARA, COSENTYX, ENBREL, SKYRIZI, TREMFYA. AS: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA, COSENTYX, ENBREL, XELJANZ, RINVOQ. CD: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA, STELARA, SKYRIZI. NR-AXSPA: TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, RINVOQ. PATIENTS WHO ARE PREGNANT, BREASTFEEDING, OR TRYING TO BECOME PREGNANT ARE EXCLUDED FROM STEP CRITERIA FOR ALL INDICATIONS. RENEWAL: RA, PSA, AS, PSO, NR-AXSPA: CONTINUES TO BENEFIT FROM THE MEDICATION.</p> |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

CLADRIBINE

Products Affected

- MAVENCLAD (10 TABLET PACK)
- MAVENCLAD (4 TABLET PACK)
- MAVENCLAD (5 TABLET PACK)
- MAVENCLAD (6 TABLET PACK)
- MAVENCLAD (7 TABLET PACK)
- MAVENCLAD (8 TABLET PACK)
- MAVENCLAD (9 TABLET PACK)

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | INITIAL/RENEWAL: 48 WEEKS. |
| Other Criteria | MS: INITIAL: HAS NOT RECEIVED A TOTAL OF TWO YEARS OF MAVENCLAD TREATMENT (I.E., TWO YEARLY TREATMENT COURSES OF 2 CYCLES IN EACH). RENEWAL: 1) HAS DEMONSTRATED CLINICAL BENEFIT COMPARED TO PRE-TREATMENT BASELINE, 2) DOES NOT HAVE LYMPHOPENIA, AND 3) HAS NOT RECEIVED A TOTAL OF TWO YEARS OF MAVENCLAD TREATMENT (I.E., TWO YEARLY TREATMENT COURSES OF 2 CYCLES IN EACH). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

CLOBAZAM-SYMPAZAN

Products Affected

- SYMPAZAN

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | LENNOX-GASTAUT SYNDROME (LGS): THERAPY IS PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST. |
| Coverage Duration | 12 MONTHS |
| Other Criteria | LGS: 1) PATIENT IS UNABLE TO TAKE TABLETS OR SUSPENSION, AND 2) TRIAL OF OR CONTRAINDICATION TO A FORMULARY CLOBAZAM AGENT. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

COBIMETINIB

Products Affected

- COTELLIC

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

CORTICOTROPIN

Products Affected

- ACTHAR
- ACTHAR SELFJECT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | INITIAL: NOT APPROVED FOR DIAGNOSTIC PURPOSES. |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: ALL FDA APPROVED INDICATIONS EXCEPT INFANTILE SPASMS AND MULTIPLE SCLEROSIS (MS): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, ALLERGIST/IMMUNOLOGIST, OPHTHALMOLOGIST, PULMONOLOGIST OR NEPHROLOGIST. |
| Coverage Duration | INFANTILE SPASMS AND MS: 28 DAYS. ALL OTHER FDA APPROVED INDICATIONS: INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: ALL FDA APPROVED INDICATIONS EXCEPT INFANTILE SPASMS: TRIAL OF OR CONTRAINDICATION TO INTRAVENOUS (IV) CORTICOSTEROIDS. RENEWAL: ALL FDA APPROVED INDICATIONS EXCEPT INFANTILE SPASMS AND MS: DEMONSTRATED CLINICAL BENEFIT WHILE ON THERAPY AS INDICATED BY SYMPTOM RESOLUTION AND/OR NORMALIZATION OF LABORATORY TESTS. PART B BEFORE PART D STEP THERAPY, APPLIES ONLY TO BENEFICIARIES IN AN MA-PD PLAN. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | Yes |

CRIZOTINIB

Products Affected

- XALKORI ORAL CAPSULE
- XALKORI ORAL PELLET 150 MG, 20 MG, 50 MG

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | Some FDA-approved Indications Only. |
| Off Label Uses | |
| Part B Prerequisite | No |

CYSTEAMINE HYDROCHLORIDE

Products Affected

- CYSTARAN

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

DABRAFENIB

Products Affected

- TAFINLAR ORAL CAPSULE

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

DACOMITINIB

Products Affected

- VIZIMPRO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | METASTATIC NSCLC: NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE-INHIBITOR. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

DALFAMPRIDINE

Products Affected

- *dalfampridine*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | MULTIPLE SCLEROSIS (MS): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST. |
| Coverage Duration | INITIAL: 3 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | MS: INITIAL: HAS SYMPTOMS OF A WALKING DISABILITY SUCH AS MILD TO MODERATE BILATERAL LOWER EXTREMITY WEAKNESS OR UNILATERAL WEAKNESS PLUS LOWER EXTREMITY OR TRUNCAL ATAXIA. RENEWAL: IMPROVEMENT IN WALKING ABILITY. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

DAROLUTAMIDE

Products Affected

- NUBEQA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | INITIAL AND RENEWAL: 12 MONTHS. |
| Other Criteria | <p>INITIAL: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC): PATIENT HAS HIGH RISK PROSTATE CANCER (I.E., RAPIDLY INCREASING PROSTATE SPECIFIC ANTIGEN [PSA] LEVELS) AND ONE OF THE FOLLOWING: 1) PREVIOUSLY RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.</p> <p>METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC): 1) PREVIOUSLY RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.</p> <p>RENEWAL: NMCRPC: NO ADDITIONAL CRITERIA REQUIRED. MHSPC: 1) PREVIOUSLY RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.</p> |
| Indications | All FDA-approved Indications. |

| PA Criteria | Criteria Details |
|----------------------------|-------------------------|
| Off Label Uses | |
| Part B Prerequisite | No |

DASATINIB

Products Affected

- SPRYCEL ORAL TABLET 100 MG, 140 MG, 20 MG, 50 MG, 70 MG, 80 MG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | PREVIOUSLY TREATED Ph+ CML: MUTATIONAL ANALYSIS PRIOR TO INITIATION AND SPRYCEL IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

DECITABINE/CEDAZURIDINE

Products Affected

- INQOVI

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

DEFERASIROX

Products Affected

- *deferasirox*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: CHRONIC IRON OVERLOAD DUE TO BLOOD TRANSFUSIONS: SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 1000 MCG/L (AT LEAST TWO LAB VALUES IN THE PREVIOUS THREE MONTHS). NON-TRANSFUSION DEPENDENT THALASSEMIA (NTDT): 1) SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 300 MCG/L (AT LEAST TWO LAB VALUES IN THE PREVIOUS THREE MONTHS) AND 2) LIVER IRON CONCENTRATION (LIC) OF 5 MG FE/G DRY WEIGHT OR GREATER. RENEWAL: CHRONIC IRON OVERLOAD DUE TO BLOOD TRANSFUSIONS: SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 500 MCG/L (AT LEAST TWO LAB VALUES IN THE PREVIOUS THREE MONTHS). NTDT: 1) SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 300 MCG/L (AT LEAST TWO LAB VALUES IN THE PREVIOUS THREE MONTHS) OR 2) LIC OF 3 MG FE/G DRY WEIGHT OR GREATER. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: CHRONIC IRON OVERLOAD: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR HEMATOLOGIST/ONCOLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS |
| Other Criteria | INITIAL FOR ALL INDICATIONS: FORMULARY VERSION OF DEFERASIROX SPRINKLE: TRIAL OF OR CONTRAINDICATION TO GENERIC DEFERASIROX TABLET OR TABLET FOR ORAL SUSPENSION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

DEFERIPRONE

Products Affected

- *deferiprone*
- FERRIPROX (2 TIMES A DAY)
- FERRIPROX ORAL SOLUTION

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | TRANSFUSIONAL IRON OVERLOAD: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR HEMATOLOGIST/ONCOLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS |
| Other Criteria | INITIAL: TRANSFUSIONAL IRON OVERLOAD DUE TO THALASSEMIA SYNDROMES: 1) TRIAL OF, CONTRAINDICATION, INTOLERABLE TOXICITIES, OR CLINICALLY SIGNIFICANT ADVERSE EFFECTS TO ONE OF THE FOLLOWING: FORMULARY VERSION OF DEFERASIROX OR DEFEROXAMINE, OR 2) CURRENT CHELATION THERAPY (I.E., FORMULARY VERSION OF DEFERASIROX OR DEFEROXAMINE) IS INADEQUATE. TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS: TRIAL OF OR CONTRAINDICATION TO A FORMULARY VERSION OF DEFERASIROX OR DEFEROXAMINE. RENEWAL (ALL INDICATIONS): SERUM FERRITIN LEVELS CONSISTENTLY ABOVE 500MCG/L (AT LEAST TWO LAB VALUES IN THE PREVIOUS THREE MONTHS). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

DENOSUMAB-XGEVA

Products Affected

- XGEVA

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

DEUTETRABENAZINE

Products Affected

- AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG, 24 MG, 30 MG, 36 MG, 42 MG, 48 MG, 6 MG
- AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 12 MG, 18 MG, 24 MG, 30 MG, 36 MG, 42 MG, 48 MG, 6 MG
- AUSTEDO XR TITRATION KT(WK1-4)

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | HUNTINGTON DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR MOVEMENT DISORDER SPECIALIST. TARDIVE DYSKINESIA: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, PSYCHIATRIST, OR MOVEMENT DISORDER SPECIALIST. |
| Coverage Duration | 12 MONTHS |
| Other Criteria | TARDIVE DYSKINESIA: PATIENT HAS A HISTORY OF USING AGENTS THAT CAUSE TARDIVE DYSKINESIA. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

DICLOFENAC GEL

Products Affected

- *diclofenac sodium topical gel 3 %*

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

DICLOFENAC TOPICAL SOLUTION

Products Affected

- *diclofenac sodium topical solution in metered-dose pump*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 MONTHS |
| Other Criteria | OSTEOARTHRITIS OF THE KNEE: TRIAL OF OR CONTRAINDICATION TO A FORMULARY VERSION OF DICLOFENAC SODIUM 1% TOPICAL GEL AND A FORMULARY VERSION OF DICLOFENAC SODIUM 1.5% TOPICAL DROPS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

DIMETHYL FUMARATE

Products Affected

- *dimethyl fumarate oral capsule, delayed release(dr/ec) 120 mg, 120 mg (14)- 240 mg (46), 240 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

DIROXIMEL FUMARATE

Products Affected

- VUMERITY

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

DRONABINOL

Products Affected

- *dronabinol*

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 MONTHS |
| Other Criteria | NAUSEA AND VOMITING ASSOCIATED WITH CANCER CHEMOTHERAPY: TRIAL OF OR CONTRAINDICATION TO ONE ANTIEMETIC THERAPY. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D FOR THE INDICATION OF NAUSEA AND VOMITING ASSOCIATED WITH CANCER CHEMOTHERAPY. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

DROXIDOPA

Products Affected

- *droxidopa*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | NEUROGENIC ORTHOSTATIC HYPOTENSION (NOH): INITIAL: 1) BASELINE BLOOD PRESSURE READINGS WHILE THE PATIENT IS SITTING AND ALSO WITHIN 3 MINUTES OF STANDING FROM A SUPINE POSITION. 2) A DECREASE OF AT LEAST 20 MMHG IN SYSTOLIC BLOOD PRESSURE OR 10 MMHG DIASTOLIC BLOOD PRESSURE WITHIN THREE MINUTES AFTER STANDING FROM A SITTING POSITION. |
| Age Restrictions | |
| Prescriber Restrictions | NOH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR CARDIOLOGIST. |
| Coverage Duration | INITIAL: 3 MONTHS RENEWAL: 12 MONTHS |
| Other Criteria | NOH: RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

DUPILUMAB

Products Affected

- DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML, 300 MG/2 ML SYRINGE 100 MG/0.67 ML, 200 MG/1.14 ML, 300 MG/2 ML
- DUPIXENT SYRINGE SUBCUTANEOUS

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: EOSINOPHILIC ASTHMA: BLOOD EOSINOPHIL LEVEL GREATER THAN OR EQUAL TO 150 CELLS/MCL WITHIN THE PAST 12 MONTHS. EOSINOPHILIC ESOPHAGITIS (EOE): DIAGNOSIS CONFIRMED BY ESOPHAGOGASTRODUODENOSCOPY (EGD) WITH BIOPSY. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: AD, PN: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST, ALLERGIST OR IMMUNOLOGIST. ASTHMA: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN ALLERGY OR PULMONARY MEDICINE. CRSWNP: PRESCRIBED BY OR IN CONSULTATION WITH AN OTOLARYNGOLOGIST, ALLERGIST OR IMMUNOLOGIST. EOE: PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST, ALLERGIST, OR IMMUNOLOGIST. |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

DUVELISIB

Products Affected

- COPIKTRA

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

EDARAVONE

Products Affected

- RADICAVA ORS STARTER KIT SUSP

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | AMYOTROPHIC LATERAL SCLEROSIS (ALS): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR ALS SPECIALIST AT AN ALS SPECIALTY CENTER OR CARE CLINIC. |
| Coverage Duration | ALS: INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS. |
| Other Criteria | ALS: INITIAL: 1) DURATION OF DISEASE (FROM ONSET OF SYMPTOMS) IS LESS THAN OR EQUAL TO 2 YEARS, 2) NORMAL RESPIRATORY FUNCTION, 3) HAS MILD TO MODERATE ALS WITH A SCORE OF 2 OR HIGHER IN ALL OF THE FOLLOWING 12 ITEMS OF THE AMYOTROPHIC LATERAL SCLEROSIS FUNCTIONAL RATING SCALE REVISED (ALSFRRS-R): SPEECH, SALIVATION, SWALLOWING, HANDWRITING, CUTTING FOOD, DRESSING AND HYGIENE, TURNING IN BED, WALKING, CLIMBING STAIRS, DYSPNEA, ORTHOPNEA, RESPIRATORY INSUFFICIENCY, AND 4) TRIAL OF RILUZOLE TABLET OR CURRENTLY TAKING RILUZOLE TABLET. RENEWAL: 1) DOES NOT REQUIRE INVASIVE VENTILATION, AND 2) HAS IMPROVED BASELINE FUNCTIONAL ABILITY OR HAS MAINTAINED A SCORE OF 2 OR HIGHER IN ALL 12 ITEMS OF THE ALSFRRS-R. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

ELACESTRANT

Products Affected

- ORSERDU ORAL TABLET 345 MG, 86 MG

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ELAGOLIX SODIUM

Products Affected

- ORLISSA ORAL TABLET 150 MG, 200 MG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: DIAGNOSIS IS CONFIRMED VIA SURGICAL OR DIRECT VISUALIZATION (E.G., PELVIC ULTRASOUND) OR HISTOPATHOLOGICAL CONFIRMATION (E.G., LAPAROSCOPY OR LAPAROTOMY) IN THE LAST 10 YEARS. |
| Age Restrictions | MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: 18 YEARS OF AGE OR OLDER. |
| Prescriber Restrictions | MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN OBSTETRICIAN/GYNECOLOGIST. |
| Coverage Duration | MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS. |
| Other Criteria | MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: 1) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, AND 2) TRIAL OF OR CONTRAINDICATION TO A NSAID AND PROGESTIN-CONTAINING PREPARATION. RENEWAL: 1) IMPROVEMENT IN PAIN ASSOCIATED WITH ENDOMETRIOSIS WHILE ON THERAPY, AND 2) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ELAPEGADEMASE-LVLR

Products Affected

- REVCovi

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | ADENOSINE DEAMINASE SEVERE COMBINED IMMUNE DEFICIENCY (ADA-SCID): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH IMMUNOLOGIST, HEMATOLOGIST/ONCOLOGIST, OR PHYSICIAN SPECIALIZING IN INHERITED METABOLIC DISORDERS |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | ADA-SCID: INITIAL: ADA-SCID AS MANIFESTED BY ONE OF THE FOLLOWING: (1) CONFIRMATORY GENETIC TEST OR (2) SUGGESTIVE LABORATORY FINDINGS (E.G., ELEVATED DEOXYADENOSINE NUCLEOTIDE [DAXP] LEVELS, LYMPHOPENIA) AND HALLMARK SIGNS/SYMPTOMS (E.G., RECURRENT INFECTIONS, FAILURE TO THRIVE, PERSISTENT DIARRHEA). RENEWAL: 1) IMPROVEMENT OR MAINTENANCE OF IMMUNE FUNCTION FROM BASELINE, AND 2) HAS NOT RECEIVED SUCCESSFUL HCT OR GENE THERAPY. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ELEXACAFITOR-TEZACAFITOR-IVACAFITOR

Products Affected

- TRIKAFTA ORAL TABLETS, SEQUENTIAL

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | CYSTIC FIBROSIS (CF): INITIAL: CONFIRMED MUTATION IN CFTR GENE ACCEPTABLE FOR THE TREATMENT OF CYSTIC FIBROSIS. |
| Age Restrictions | |
| Prescriber Restrictions | CF: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CYSTIC FIBROSIS EXPERT. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: LIFETIME. |
| Other Criteria | CF: RENEWAL: 1) MAINTAINED, IMPROVED, OR DEMONSTRATED LESS THAN EXPECTED DECLINE IN FEV1 OR BODY MASS INDEX (BMI), OR 2) REDUCTION IN NUMBER OF PULMONARY EXACERBATIONS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ELIGLUSTAT

Products Affected

- CERDELGA

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ELTROMBOPAG

Products Affected

- PROMACTA ORAL POWDER IN PACKET 12.5 MG, 25 MG
- PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: ITP: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR IMMUNOLOGIST. |
| Coverage Duration | ITP: INITIAL: 2 MO, RENEWAL: 12 MO. HEPATITIS C, SEVERE APLASTIC ANEMIA: 12 MO. |
| Other Criteria | INITIAL: PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA PURPURA (ITP): TRIAL OF OR CONTRAINDICATION TO CORTICOSTEROIDS, IMMUNOGLOBULINS, OR AN INSUFFICIENT RESPONSE TO SPLENECTOMY. ALL INDICATIONS: APPROVAL FOR PROMACTA ORAL SUSPENSION PACKETS REQUIRES A TRIAL OF PROMACTA TABLETS OR PATIENT IS UNABLE TO TAKE TABLET FORMULATION. RENEWAL: ITP: PATIENT HAS SHOWN A CLINICAL RESPONSE. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ENASIDENIB

Products Affected

- IDHIFA

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ENCORAFENIB

Products Affected

- BRAFTOVI

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ENTRECTINIB

Products Affected

- ROZLYTREK ORAL CAPSULE 100 MG, 200 MG
- ROZLYTREK ORAL PELLETS IN PACKET

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | Some FDA-approved Indications Only. |
| Off Label Uses | |
| Part B Prerequisite | No |

ENZALUTAMIDE

Products Affected

- XTANDI ORAL CAPSULE
- XTANDI ORAL TABLET 40 MG, 80 MG

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

EPOETIN ALFA-EPBX

Products Affected

- RETACRIT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/2 ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML, 40,000 UNIT/ML

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: CHRONIC KIDNEY DISEASE (CKD), ANEMIA RELATED TO ZIDOVUDINE, OR CANCER CHEMOTHERAPY: HEMOGLOBIN LEVEL OF LESS THAN 10G/DL. ELECTIVE, NON-CARDIAC, NON-VASCULAR SURGERY: HEMOGLOBIN LEVEL LESS THAN 13G/DL. RENEWAL: CKD: 1) HEMOGLOBIN LEVEL IS LESS THAN 10G/DL, OR 2) HEMOGLOBIN LEVEL HAS REACHED 10G/DL AND DOSE REDUCTION/INTERRUPTION IS REQUIRED TO REDUCE THE NEED FOR BLOOD TRANSFUSIONS. ANEMIA RELATED TO ZIDOVUDINE: HEMOGLOBIN LEVEL BETWEEN 10G/DL AND 12G/DL. CANCER CHEMOTHERAPY: 1) HEMOGLOBIN LEVEL OF LESS THAN 10 G/DL, OR 2) THE HEMOGLOBIN LEVEL DOES NOT EXCEED A LEVEL NEEDED TO AVOID RBC TRANSFUSION. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | ANEMIA FROM CHEMO/CKD WITHOUT DIALYSIS/ZIDOVUDINE: INITIAL/RENEWAL: 12 MONTHS. SURGERY: 1 MONTH. |
| Other Criteria | RENEWAL: CKD: NOT RECEIVING DIALYSIS TREATMENT. THIS DRUG MAY BE EITHER BUNDLED WITH AND COVERED UNDER END STAGE RENAL DISEASE DIALYSIS RELATED SERVICES OR COVERED UNDER MEDICARE D DEPENDING UPON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE AND SETTING OF THE DRUG TO MAKE THE DETERMINATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

ERDAFITINIB

Products Affected

- BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ERLOTINIB

Products Affected

- *erlotinib oral tablet 100 mg, 150 mg, 25 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | METASTATIC NSCLC WITH EGFR MUTATION; NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE-INHIBITOR. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ETANERCEPT

Products Affected

- ENBREL MINI
- ENBREL SUBCUTANEOUS SOLUTION
- ENBREL SUBCUTANEOUS SYRINGE
- ENBREL SURECLICK

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE OR GENITAL AREA. |
| Age Restrictions | INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS), PSORIATIC ARTHRITIS (PSA): 18 YEARS OR OLDER. |
| Prescriber Restrictions | INITIAL: RA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA), AS: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSA: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE: IS REQUIRED. PJIA, PSA: TRIAL OF OR CONTRAINDICATION TO ONE DMARD. AS: TRIAL OF OR CONTRAINDICATION TO AN NSAID. PSO: TRIAL OF OR CONTRAINDICATION TO ONE CONVENTIONAL THERAPY SUCH AS A PUVA (PHOTOTHERAPY ULTRAVIOLET LIGHT A), UVB (ULTRAVIOLET LIGHT B), TOPICAL CORTICOSTEROIDS, CALCIPOTRIENE, ACITRETIN, METHOTREXATE, OR CYCLOSPORINE. RENEWAL: RA, PJIA, PSA, AS, PSO: CONTINUES TO BENEFIT FROM THE MEDICATION. |

| PA Criteria | Criteria Details |
|----------------------------|-------------------------------|
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

EVEROLIMUS

Products Affected

- *everolimus (antineoplastic) oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*
- *everolimus (antineoplastic) oral tablet for suspension*
- *torpenz oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

FEDRATINIB

Products Affected

- INREBIC

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS |
| Other Criteria | MYELOFIBROSIS: INITIAL: TRIAL OF OR CONTRAINDICATION TO JAKAFI (RUXOLITINIB). RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

FENTANYL CITRATE

Products Affected

- *fentanyl citrate buccal lozenge on a handle*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | CANCER RELATED PAIN: 1) CURRENTLY ON A MAINTENANCE DOSE OF CONTROLLED-RELEASE OPIOID PAIN MEDICATION, AND 2) TRIAL OF OR CONTRAINDICATION TO AT LEAST ONE IMMEDIATE-RELEASE ORAL OPIOID PAIN AGENT OR PATIENT HAS DIFFICULTY SWALLOWING TABLETS/CAPSULES. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

FEZOLINETANT

Products Affected

- VEOZAH

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | MENOPAUSAL VASOMOTOR SYMPTOMS (VMS): INITIAL: 1) EXPERIENCES 7 OR MORE HOT FLASHES PER DAY, AND 2) TRIAL OF OR CONTRAINDICATION TO HORMONAL THERAPY (E.G., ESTRADIOL TRANSDERMAL PATCH, ORAL CONJUGATED ESTROGENS). RENEWAL: 1) CONTINUED NEED FOR VMS TREATMENT (I.E., PERSISTENT HOT FLASHES), AND 2) REDUCTION IN VMS FREQUENCY OR SEVERITY DUE TO VEOZAH TREATMENT. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

FILGRASTIM-AAFI

Products Affected

- NIVESTYM

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST. |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

FILGRASTIM-SNDZ

Products Affected

- ZARXIO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST. |
| Coverage Duration | 12 MONTHS |
| Other Criteria | TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT: NIVESTYM. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

FINERENONE

Products Affected

- KERENDIA

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

FINGOLIMOD

Products Affected

- *fingolimod*
- GILENYA ORAL CAPSULE 0.25 MG

| PA Criteria | Criteria Details |
|------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

FIRMAGON

Products Affected

- FIRMAGON KIT W DILUENT SYRINGE
SUBCUTANEOUS RECON SOLN 120
MG, 80 MG

| PA Criteria | Criteria Details |
|-------------------------------------|---------------------------------------|
| Exclusion Criteria | |
| Required Medical Information | Diagnosis of advanced prostate cancer |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

FREMANEZUMAB-VFRM

Products Affected

- AJOVY AUTOINJECTOR
- AJOVY SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS. |
| Other Criteria | MIGRAINE PREVENTION: INITIAL: 1) TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREVENTIVE MIGRAINE TREATMENTS: DIVALPROEX SODIUM, TOPIRAMATE, PROPRANOLOL, TIMOLOL, AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: 1) REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY, AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

FRUZAQLA

Products Affected

- FRUZAQLA ORAL CAPSULE 1 MG, 5 MG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | None |
| Required Medical Information | Diagnosis of metastatic colorectal cancer (mCRC) and all of the following: A.) patient has been previously treated with fluoropyrimidine, oxaliplatin, irinotecan-based chemotherapy, B.) an anti-VEGF therapy, and C.) if RAS wild-type and medically appropriate, patient has also been previously treated with anti-EGFR therapy |
| Age Restrictions | 18 years of age and older |
| Prescriber Restrictions | Prescribed by or in consultation with an oncologist or hematologist |
| Coverage Duration | 3 months |
| Other Criteria | None |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

FUTIBATINIB

Products Affected

- LYTGOBI ORAL TABLET 12 MG/DAY (4 MG X 3), 16 MG/DAY (4 MG X 4), 20 MG/DAY (4 MG X 5)

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | INTRAHEPATIC CHOLANGIOCARCINOMA (ICCA): COMPLETE A COMPREHENSIVE OPHTHALMOLOGICAL EXAMINATION, INCLUDING OPTICAL COHERENCE TOMOGRAPHY (OCT), PRIOR TO THE INITIATION OF THERAPY AND AT THE RECOMMENDED SCHEDULED INTERVALS. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

GALCANEZUMAB-GNLM

Products Affected

- EMGALITY PEN
- EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 120 MG/ML, 300 MG/3 ML (100 MG/ML X 3)

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | INITIAL: MIGRAINE PREVENTION: 6 MOS. EPISODIC CLUSTER HEADACHE: 3 MOS. RENEWAL (ALL): 12 MOS. |
| Other Criteria | INITIAL: MIGRAINE PREVENTION: 1) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREVENTIVE MIGRAINE TREATMENTS: DIVALPROEX SODIUM, TOPIRAMATE, PROPRANOLOL, TIMOLOL. RENEWAL: MIGRAINE PREVENTION: 1) REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY, AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. EPISODIC CLUSTER HEADACHE: IMPROVEMENT IN EPISODIC CLUSTER HEADACHE FREQUENCY AS COMPARED TO BASELINE. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

GANAXOLONE

Products Affected

- ZTALMY

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

GEFITINIB

Products Affected

- *gefitinib*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | METASTATIC NSCLC WITH EGFR MUTATION; NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE-INHIBITOR. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

GILTERITINIB

Products Affected

- XOSPATA

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

GLASDEGIB

Products Affected

- DAURISMO ORAL TABLET 100 MG, 25 MG

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

GLATIRAMER

Products Affected

- *glatiramer subcutaneous syringe 20 mg/ml, 40 mg/ml*
- *glatopa subcutaneous syringe 20 mg/ml, 40 mg/ml*

| PA Criteria | Criteria Details |
|------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

GLECAPREVIR/PIBRENTASVIR

Products Affected

- MAVYRET ORAL PELLETS IN PACKET
- MAVYRET ORAL TABLET

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | HCV RNA LEVEL WITHIN PAST 6 MONTHS |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE. |
| Other Criteria | 1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, 2) TRIAL OF A PREFERRED FORMULARY ALTERNATIVE INCLUDING HARVONI OR EPCLUSA WHEN THESE AGENTS ARE CONSIDERED ACCEPTABLE FOR TREATMENT OF THE SPECIFIC GENOTYPE PER AASLD/IDSA GUIDANCE, 3) NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING MEDICATIONS: CARBAMAZEPINE, RIFAMPIN, ETHINYL ESTRADIOL-CONTAINING MEDICATION, ATAZANAVIR, DARUNAVIR, LOPINAVIR, RITONAVIR, EFAVIRENZ, ATORVASTATIN, LOVASTATIN, SIMVASTATIN, ROSUVASTATIN AT DOSES GREATER THAN 10MG, CYCLOSPORINE AT DOSES GREATER THAN 100MG PER DAY, EPCLUSA, HARVONI, VOSEVI, OR ZEPATIER, 4) PATIENT MUST NOT HAVE PRIOR FAILURE OF A DAA REGIMEN WITH NS5A INHIBITOR AND HCV PROTEASE INHIBITOR, AND 5) DOES NOT HAVE MODERATE OR SEVERE HEPATIC IMPAIRMENT (CHILD PUGH B OR C). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

GLP1 AGONISTS

Products Affected

- MOUNJARO
 - OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG (2 MG/3 ML), 1 MG/DOSE (4 MG/3 ML), 2
 - RYBELSUS
 - TRULICITY
- MG/DOSE (8 MG/3 ML)

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Must meet all of the following 1.) The drug is prescribed for an FDA-approved indication, 2.) For a diagnosis of Type 2 Diabetes Mellitus the patient has a trial and failure, contraindication or intolerance to metformin |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

GUSELKUMAB

Products Affected

- TREMFYA SUBCUTANEOUS AUTO-INJECTOR
- TREMFYA SUBCUTANEOUS SYRINGE 100 MG/ML

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE OR GENITAL AREA. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS |
| Other Criteria | INITIAL: PSA: TRIAL OF OR CONTRAINDICATION TO ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG). PSO: TRIAL OF OR CONTRAINDICATION ONE CONVENTIONAL THERAPY SUCH AS A PUVA (PHOTOTHERAPY ULTRAVIOLET LIGHT A), UVB (ULTRAVIOLET LIGHT B), TOPICAL CORTICOSTEROIDS, CALCIPOTRIENE, ACITRETIN, METHOTREXATE, OR CYCLOSPORINE. RENEWAL: PSO, PSA: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

HIGH CONCENTRATION ORAL OPIOID SOLUTIONS

Products Affected

- *morphine concentrate oral solution*
- *oxycodone oral concentrate*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | OPIOID TOLERANT: 12 MONTHS. HOSPICE, PALLIATIVE CARE OR END OF LIFE CARE: LIFETIME. |
| Other Criteria | 1) OPIOID TOLERANT (I.E. PREVIOUS USE OF 60 MG ORAL MORPHINE PER DAY, 25 MCG TRANSDERMAL FENTANYL PER HOUR, 30 MG ORAL OXYCODONE PER DAY, 8 MG ORAL HYDROMORPHONE PER DAY, 25 MG ORAL OXYMORPHONE PER DAY, 60 MG ORAL HYDROCODONE PER DAY, OR AN EQUIANALGESIC DOSE OF ANOTHER OPIOID) AND HAS TROUBLE SWALLOWING OPIOID TABLETS, CAPSULES, OR LARGE VOLUMES OF LIQUID, OR 2) ENROLLED IN HOSPICE OR PALLIATIVE CARE OR END OF LIFE CARE. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

IBRUTINIB

Products Affected

- IMBRUVICA ORAL CAPSULE 140 MG, 280 MG, 420 MG
70 MG
- IMBRUVICA ORAL SUSPENSION
- IMBRUVICA ORAL TABLET 140 MG,

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ICATIBANT

Products Affected

- *icatibant*
- *sajazir*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | HEREDITARY ANGIOEDEMA (HAE): DIAGNOSIS CONFIRMED BY COMPLEMENT TESTING. |
| Age Restrictions | |
| Prescriber Restrictions | HAE: PRESCRIBED BY OR IN CONSULTATION WITH AN ALLERGIST, IMMUNOLOGIST, OR HEMATOLOGIST. |
| Coverage Duration | 12 MONTHS |
| Other Criteria | HAE: NO CONCURRENT USE WITH OTHER MEDICATIONS FOR TREATMENT OF ACUTE HAE ATTACKS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

IDELALISIB

Products Affected

- ZYDELIG

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

IMATINIB

Products Affected

- *imatinib oral tablet 100 mg, 400 mg*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | ADJUVANT GASTROINTESTINAL STROMAL TUMOR TREATMENT: 36 MONTHS. ALL OTHER DIAGNOSES: 12 MONTHS. |
| Other Criteria | PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA: PATIENT HAS NOT RECEIVED A PREVIOUS TREATMENT WITH ANOTHER TYROSINE KINASE INHIBITOR. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

INSULIN SUPPLIES PAYMENT DETERMINATION

Products Affected

- 1ST TIER UNIFINE PENTP 5MM 31G
- 1ST TIER UNIFINE PNTIP 4MM 32G
- 1ST TIER UNIFINE PNTIP 6MM 31G
- 1ST TIER UNIFINE PNTIP 8MM 31G STRL,SINGLE-USE,SHRT
- 1ST TIER UNIFINE PNTP 29GX1/2"
- 1ST TIER UNIFINE PNTP 31GX3/16
- 1ST TIER UNIFINE PNTP 32GX5/32
- ABOUTTIME PEN NEEDLE 30G X 8MM
- ABOUTTIME PEN NEEDLE 31G X 5MM
- ABOUTTIME PEN NEEDLE 31G X 8MM
- ABOUTTIME PEN NEEDLE 32G X 4MM
- ADVOCATE INS 0.3 ML 30GX5/16"
- ADVOCATE INS 0.3 ML 31GX5/16"
- ADVOCATE INS 0.5 ML 30GX5/16"
- ADVOCATE INS 0.5 ML 31GX5/16"
- ADVOCATE INS 1 ML 31GX5/16"
- ADVOCATE INS SYR 0.3 ML 29GX1/2
- ADVOCATE INS SYR 0.5 ML 29GX1/2
- ADVOCATE INS SYR 1 ML 29GX1/2"
- ADVOCATE INS SYR 1 ML 30GX5/16
- ADVOCATE PEN NDL 12.7MM 29G
- ADVOCATE PEN NEEDLE 32G 4MM
- ADVOCATE PEN NEEDLE 4MM 33G
- ADVOCATE PEN NEEDLES 5MM 31G
- ADVOCATE PEN NEEDLES 8MM 31G
- ALCOHOL 70% SWABS
- ALCOHOL PADS
- ALCOHOL PREP SWABS
- AQINJECT PEN NEEDLE 31G 5MM
- AQINJECT PEN NEEDLE 32G 4MM
- ASSURE ID DUO PRO NDL 31G 5MM
- ASSURE ID DUO-SHIELD 30GX3/16"
- ASSURE ID DUO-SHIELD 30GX5/16"
- ASSURE ID INSULIN SAFETY SYRINGE 1 ML 29 GAUGE X 1/2"
- ASSURE ID PEN NEEDLE 30GX3/16"
- ASSURE ID PEN NEEDLE 30GX5/16"
- ASSURE ID PEN NEEDLE 31GX3/16"
- ASSURE ID PRO PEN NDL 30G 5MM
- ASSURE ID SYR 0.5 ML 29GX1/2" (RX)
- ASSURE ID SYR 0.5 ML 31GX15/64"
- ASSURE ID SYR 1 ML 31GX15/64"
- BD AUTOSHIELD DUO NDL 5MMX30G
- BD ECLIPSE 30GX1/2" SYRINGE
- BD ECLIPSE NEEDLE 30GX1/2" (OTC)
- BD INS SYR 0.3 ML 8MMX31G(1/2)
- BD INS SYRINGE 1/2 ML 6MMX31G (ONLY FOR 500 UNIT/ML INSULIN)
- BD INS SYRN UF 1 ML 12.7MMX30G NOT FOR RETAIL SALE
- BD INSULIN SYR 1 ML 25GX1"
- BD INSULIN SYR 1 ML 25GX5/8"
- BD INSULIN SYR 1 ML 26GX1/2"
- BD INSULIN SYR 1 ML 27GX12.7MM
- BD INSULIN SYR 1 ML 27GX5/8" MICRO-FINE
- BD INSULIN SYRINGE 1 ML W/O NEEDLE
- BD LUER-LOK SYRINGE 1 ML
- BD NANO 2 GEN PEN NDL 32G 4MM
- BD SAFETGLD INS 0.3 ML 29G 13MM
- BD SAFETGLD INS 0.5 ML 13MMX29G
- BD SAFETYGLD INS 0.3 ML 31G 8MM
- BD SAFETYGLD INS 0.5 ML 30G 8MM
- BD SAFETYGLD INS 1 ML 29G 13MM
- BD SAFETYGLID INS 1 ML 6MMX31G
- BD SAFETYGLIDE SYRINGE 27GX5/8
- BD SAFTYGLD INS 0.3 ML 6MMX31G
- BD SAFTYGLD INS 0.5 ML 29G 13MM
- BD SAFTYGLD INS 0.5 ML 6MMX31G
- BD SINGLE USE SWAB
- BD UF MICRO PEN NEEDLE 6MMX32G
- BD UF MINI PEN NEEDLE 5MMX31G
- BD UF NANO PEN NEEDLE 4MMX32G
- BD UF ORIG PEN NDL 12.7MMX29G
- BD UF SHORT PEN NEEDLE 8MMX31G
- BD VEO INS 0.3 ML 6MMX31G (1/2)
- BD VEO INS SYRING 1 ML 6MMX31G
- BD VEO INS SYRN 0.3 ML 6MMX31G
- BD VEO INS SYRN 0.5 ML 6MMX31G
- BORDERED GAUZE 2"X2"

- CAREFINE PEN NEEDLE 12.7MM 29G
- CAREFINE PEN NEEDLE 4MM 32G
- CAREFINE PEN NEEDLE 5MM 32G
- CAREFINE PEN NEEDLE 6MM 31G
- CAREFINE PEN NEEDLE 8MM 30G
- CAREFINE PEN NEEDLES 6MM 32G
- CAREFINE PEN NEEDLES 8MM 31G
- CARETOUCH ALCOHOL 70% PREP PAD
- CARETOUCH PEN NEEDLE 29G 12MM
- CARETOUCH PEN NEEDLE 31GX1/4"
- CARETOUCH PEN NEEDLE 31GX3/16"
- CARETOUCH PEN NEEDLE 31GX5/16"
- CARETOUCH PEN NEEDLE 32GX3/16"
- CARETOUCH PEN NEEDLE 32GX5/32"
- CARETOUCH SYR 0.3 ML 31GX5/16"
- CARETOUCH SYR 0.5 ML 30GX5/16"
- CARETOUCH SYR 0.5 ML 31GX5/16"
- CARETOUCH SYR 1 ML 28GX5/16"
- CARETOUCH SYR 1 ML 29GX5/16"
- CARETOUCH SYR 1 ML 30GX5/16"
- CARETOUCH SYR 1 ML 31GX5/16"
- CLICKFINE 31G X 5/16" NEEDLES 8MM, UNIVERSAL
- CLICKFINE PEN NEEDLE 32GX5/32" 32GX4MM, STERILE
- CLICKFINE UNIVERSAL 31G X 1/4" 6MM, STORE BRAND
- COMFORT EZ 0.3 ML 31G 15/64"
- COMFORT EZ 0.5 ML 31G 15/64"
- COMFORT EZ INS 0.3 ML 30GX1/2"
- COMFORT EZ INS 0.3 ML 30GX5/16"
- COMFORT EZ INS 1 ML 31G 15/64"
- COMFORT EZ INS 1 ML 31GX5/16"
- COMFORT EZ INSULIN SYR 0.3 ML
- COMFORT EZ INSULIN SYR 0.5 ML
- COMFORT EZ PEN NEEDLE 12MM 29G
- COMFORT EZ PEN NEEDLES 4MM 32G SINGLE USE, MICRO
- COMFORT EZ PEN NEEDLES 4MM 33G
- COMFORT EZ PEN NEEDLES 5MM 31G MINI
- COMFORT EZ PEN NEEDLES 5MM 32G SINGLE USE,MINI,HRI
- COMFORT EZ PEN NEEDLES 5MM 33G
- COMFORT EZ PEN NEEDLES 6MM 31G
- COMFORT EZ PEN NEEDLES 6MM 32G
- COMFORT EZ PEN NEEDLES 6MM 33G
- COMFORT EZ PEN NEEDLES 8MM 31G SHORT
- COMFORT EZ PEN NEEDLES 8MM 32G
- COMFORT EZ PEN NEEDLES 8MM 33G
- COMFORT EZ PRO PEN NDL 30G 8MM
- COMFORT EZ PRO PEN NDL 31G 4MM
- COMFORT EZ PRO PEN NDL 31G 5MM
- COMFORT EZ SYR 0.3 ML 29GX1/2"
- COMFORT EZ SYR 0.5 ML 28GX1/2"
- COMFORT EZ SYR 0.5 ML 29GX1/2"
- COMFORT EZ SYR 0.5 ML 30GX1/2"
- COMFORT EZ SYR 1 ML 28GX1/2"
- COMFORT EZ SYR 1 ML 29GX1/2"
- COMFORT EZ SYR 1 ML 30GX1/2"
- COMFORT EZ SYR 1 ML 30GX5/16"
- COMFORT POINT PEN NDL 31GX1/3"
- COMFORT POINT PEN NDL 31GX1/6"
- COMFORT TOUCH PEN NDL 31G 4MM
- COMFORT TOUCH PEN NDL 31G 5MM
- COMFORT TOUCH PEN NDL 31G 6MM
- COMFORT TOUCH PEN NDL 31G 8MM
- COMFORT TOUCH PEN NDL 32G 4MM
- COMFORT TOUCH PEN NDL 32G 5MM
- COMFORT TOUCH PEN NDL 32G 6MM
- COMFORT TOUCH PEN NDL 32G 8MM
- COMFORT TOUCH PEN NDL 33G 4MM
- COMFORT TOUCH PEN NDL 33G 6MM
- COMFORT TOUCH PEN NDL 33GX5MM
- CURAD GAUZE PADS 2" X 2"
- CURITY ALCOHOL PREPS 2 PLY, MEDIUM
- CURITY GAUZE SPONGES (12 PLY)-200/BAG
- CURITY GUAZE PADS 1'S(12 PLY)
- DERMACEA 2"X2" GAUZE 12 PLY, USP TYPE VII
- DERMACEA GAUZE 2"X2" SPONGE 8 PLY
- DERMACEA NON-WOVEN 2"X2" SPNGE
- DROPLET 0.5 ML 29GX12.5MM(1/2)
- DROPLET 0.5 ML 30GX12.5MM(1/2)
- DROPLET INS 0.3 ML 29GX12.5MM
- DROPLET INS 0.3 ML 30GX12.5MM
- DROPLET INS 0.5 ML 30GX6MM(1/2)
- DROPLET INS 0.5 ML 30GX8MM(1/2)
- DROPLET INS 0.5 ML 31GX6MM(1/2)

- DROPLET INS 0.5 ML 31GX8MM(1/2)
- DROPLET INS SYR 0.3 ML 30GX6MM
- DROPLET INS SYR 0.3 ML 30GX8MM
- DROPLET INS SYR 0.3 ML 31GX6MM
- DROPLET INS SYR 0.3 ML 31GX8MM
- DROPLET INS SYR 1 ML 29GX12.5MM
- DROPLET INS SYR 1 ML 30GX12.5MM
- DROPLET INS SYR 1 ML 30GX6MM
- DROPLET INS SYR 1 ML 30GX8MM
- DROPLET INS SYR 1 ML 31GX6MM
- DROPLET INS SYR 1 ML 31GX8MM
- DROPLET MICRON 34G X 9/64"
- DROPLET PEN NEEDLE 29GX1/2"
- DROPLET PEN NEEDLE 29GX3/8"
- DROPLET PEN NEEDLE 30GX5/16"
- DROPLET PEN NEEDLE 31GX1/4"
- DROPLET PEN NEEDLE 31GX3/16"
- DROPLET PEN NEEDLE 31GX5/16"
- DROPLET PEN NEEDLE 32GX1/4"
- DROPLET PEN NEEDLE 32GX3/16"
- DROPLET PEN NEEDLE 32GX5/16"
- DROPLET PEN NEEDLE 32GX5/32"
- DROPSAFE ALCOHOL 70% PREP PADS
- DROPSAFE INS SYR 0.3 ML 31G 6MM
- DROPSAFE INS SYR 0.3 ML 31G 8MM
- DROPSAFE INS SYR 0.5 ML 31G 6MM
- DROPSAFE INS SYR 0.5 ML 31G 8MM
- DROPSAFE INSUL SYR 1 ML 31G 6MM
- DROPSAFE INSUL SYR 1 ML 31G 8MM
- DROPSAFE INSULN 1 ML 29G 12.5MM
- DROPSAFE PEN NEEDLE 31GX1/4"
- DROPSAFE PEN NEEDLE 31GX3/16"
- DROPSAFE PEN NEEDLE 31GX5/16"
- DRUG MART ULTRA COMFORT SYR
- EASY CMFT SFTY PEN NDL 31G 5MM
- EASY CMFT SFTY PEN NDL 31G 6MM
- EASY CMFT SFTY PEN NDL 32G 4MM
- EASY COMFORT 0.3 ML 31G 1/2"
- EASY COMFORT 0.3 ML 31G 5/16"
- EASY COMFORT 0.3 ML SYRINGE
- EASY COMFORT 0.5 ML 30GX1/2"
- EASY COMFORT 0.5 ML 31GX5/16"
- EASY COMFORT 0.5 ML 32GX5/16"
- EASY COMFORT 0.5 ML SYRINGE
- EASY COMFORT 1 ML 31GX5/16"
- EASY COMFORT 1 ML 32GX5/16"
- EASY COMFORT ALCOHOL 70% PAD
- EASY COMFORT INSULIN 1 ML SYR
- EASY COMFORT PEN NDL 31GX1/4"
- EASY COMFORT PEN NDL 31GX3/16"
- EASY COMFORT PEN NDL 31GX5/16"
- EASY COMFORT PEN NDL 32GX5/32"
- EASY COMFORT PEN NDL 33G 4MM
- EASY COMFORT PEN NDL 33G 5MM
- EASY COMFORT PEN NDL 33G 6MM
- EASY COMFORT SYR 1 ML 30GX1/2"
- EASY GLIDE INS 0.3 ML 31GX6MM
- EASY GLIDE INS 0.5 ML 31GX6MM
- EASY GLIDE INS 1 ML 31GX6MM
- EASY GLIDE PEN NEEDLE 4MM 33G
- EASY TOUCH 0.3 ML SYR 30GX1/2"
- EASY TOUCH 0.5 ML SYR 27GX1/2"
- EASY TOUCH 0.5 ML SYR 29GX1/2"
- EASY TOUCH 0.5 ML SYR 30GX1/2"
- EASY TOUCH 0.5 ML SYR 30GX5/16
- EASY TOUCH 1 ML SYR 27GX1/2"
- EASY TOUCH 1 ML SYR 29GX1/2"
- EASY TOUCH 1 ML SYR 30GX1/2"
- EASY TOUCH ALCOHOL 70% PADS
GAMMA-STERILIZED
- EASY TOUCH FLIPLOK 1 ML 27GX0.5
- EASY TOUCH INSULIN 1 ML 29GX1/2
- EASY TOUCH INSULIN 1 ML 30GX1/2
- EASY TOUCH INSULIN SYR 0.3 ML
- EASY TOUCH INSULIN SYR 0.5 ML
- EASY TOUCH INSULIN SYR 1 ML
- EASY TOUCH INSULIN SYR 1 ML
RETRACTABLE
- EASY TOUCH INSULN 1 ML 29GX1/2"
- EASY TOUCH INSULN 1 ML 30GX1/2"
- EASY TOUCH INSULN 1 ML 30GX5/16
- EASY TOUCH INSULN 1 ML 31GX5/16
- EASY TOUCH LUER LOK INSUL 1 ML
- EASY TOUCH PEN NEEDLE 29GX1/2"
- EASY TOUCH PEN NEEDLE 30GX5/16
- EASY TOUCH PEN NEEDLE 31GX1/4"
- EASY TOUCH PEN NEEDLE 31GX3/16
- EASY TOUCH PEN NEEDLE 31GX5/16
- EASY TOUCH PEN NEEDLE 32GX1/4"
- EASY TOUCH PEN NEEDLE 32GX3/16
- EASY TOUCH PEN NEEDLE 32GX5/32
- EASY TOUCH SAF PEN NDL 29G 5MM
- EASY TOUCH SAF PEN NDL 29G 8MM
- EASY TOUCH SAF PEN NDL 30G 5MM

- EASY TOUCH SAF PEN NDL 30G 8MM
- EASY TOUCH SYR 0.5 ML 28G 12.7MM
- EASY TOUCH SYR 0.5 ML 29G 12.7MM
- EASY TOUCH SYR 1 ML 27G 16MM
- EASY TOUCH SYR 1 ML 28G 12.7MM
- EASY TOUCH SYR 1 ML 29G 12.7MM
- EASY TOUCH UNI-SLIP SYR 1 ML
- EASYTOUCH SAF PEN NDL 30G 6MM
- EMBRACE PEN NEEDLE 29G 12MM
- EMBRACE PEN NEEDLE 30G 5MM
- EMBRACE PEN NEEDLE 30G 8MM
- EMBRACE PEN NEEDLE 31G 5MM
- EMBRACE PEN NEEDLE 31G 6MM
- EMBRACE PEN NEEDLE 31G 8MM
- EMBRACE PEN NEEDLE 32G 4MM
- EQL INSULIN 0.3 ML SYRINGE SHORT NEEDLE
- EQL INSULIN 0.5 ML SYRINGE SHORT NEEDLE
- EQL INSULIN 1 ML SYRINGE SHORT NEEDLE
- FIFTY50 INS 0.5 ML 31GX5/16" SHORT NEEDLE (OTC)
- FIFTY50 INS SYR 1 ML 31GX5/16" SHORT NEEDLE (OTC)
- FIFTY50 PEN 31G X 3/16" NEEDLE (OTC)
- FP INSULIN 1 ML SYRINGE
- FREESTYLE PREC 0.5 ML 30GX5/16
- FREESTYLE PREC 0.5 ML 31GX5/16
- FREESTYLE PREC 1 ML 30GX5/16"
- FREESTYLE PREC 1 ML 31GX5/16"
- GAUZE PAD TOPICAL BANDAGE 2 X 2 "
- GNP ULT C 0.3 ML 29GX1/2" (1/2) 1/2 UNIT
- GNP ULTRA COMFORT 0.5 ML SYR
- GNP ULTRA COMFORT 1 ML SYRINGE
- GNP ULTRA COMFORT 3/10 ML SYR
- HEALTHWISE INS 0.3 ML 30GX5/16"
- HEALTHWISE INS 0.3 ML 31GX5/16"
- HEALTHWISE INS 0.5 ML 30GX5/16"
- HEALTHWISE INS 0.5 ML 31GX5/16"
- HEALTHWISE INS 1 ML 30GX5/16"
- HEALTHWISE INS 1 ML 31GX5/16"
- HEALTHWISE PEN NEEDLE 31G 5MM
- HEALTHWISE PEN NEEDLE 31G 8MM
- HEALTHWISE PEN NEEDLE 32G 4MM
- HEALTHY ACCENTS PENTIP 4MM 32G
- HEALTHY ACCENTS PENTIP 5MM 31G
- HEALTHY ACCENTS PENTIP 6MM 31G
- HEALTHY ACCENTS PENTIP 8MM 31G
- HEALTHY ACCENTS PENTIP 12MM 29G
- HEB INCONTROL ALCOHOL 70% PADS
- INCONTROL PEN NEEDLE 12MM 29G
- INCONTROL PEN NEEDLE 4MM 32G
- INCONTROL PEN NEEDLE 5MM 31G
- INCONTROL PEN NEEDLE 6MM 31G
- INCONTROL PEN NEEDLE 8MM 31G
- INSULIN SYR 0.3 ML 31GX1/4(1/2)
- INSULIN SYRIN 0.3 ML 30GX1/2" SHORT NEEDLE
- INSULIN SYRIN 0.5 ML 28GX1/2" (OTC)
- INSULIN SYRIN 0.5 ML 29GX1/2" (OTC)
- INSULIN SYRIN 0.5 ML 30GX1/2" SHORT NEEDLE (OTC)
- INSULIN SYRIN 0.5 ML 30GX5/16" SHORT NEEDLE (OTC)
- INSULIN SYRING 0.5 ML 27G 1/2" INNER
- INSULIN SYRINGE 0.3 ML
- INSULIN SYRINGE 0.3 ML 31GX1/4
- INSULIN SYRINGE 0.5 ML
- INSULIN SYRINGE 0.5 ML 31GX1/4
- INSULIN SYRINGE 1 ML
- INSULIN SYRINGE 1 ML 27G 1/2" INNER
- INSULIN SYRINGE 1 ML 28G 1/2" INNER (RX)
- INSULIN SYRINGE 1 ML 30GX1/2" (RX)
- INSULIN SYRINGE 1 ML 30GX5/16" SHORT NEEDLE (OTC)
- INSULIN SYRINGE 1 ML 31GX1/4"
- INSULIN SYRINGE-NEEDLE U-100 SYRINGE 0.3 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2", 1/2 ML 28 GAUGE
- INSUPEN 30G ULTRAFIN NEEDLE
- INSUPEN 31G ULTRAFIN NEEDLE
- INSUPEN 32G 6MM PEN NEEDLE
- INSUPEN 32G 8MM PEN NEEDLE
- INSUPEN PEN NEEDLE 29GX12MM
- INSUPEN PEN NEEDLE 31GX3/16"
- INSUPEN PEN NEEDLE 32GX4MM
- INSUPEN PEN NEEDLE 33GX4MM

- IV ANTISEPTIC WIPES
- KENDALL ALCOHOL 70% PREP PAD
- LISCO SPONGES 100/BAG
- LITE TOUCH 31GX1/4" PEN NEEDLE
- LITE TOUCH INSULIN 0.5 ML SYR
- LITE TOUCH INSULIN 1 ML SYR
- LITE TOUCH INSULIN SYR 1 ML
- LITE TOUCH PEN NEEDLE 29G
- LITE TOUCH PEN NEEDLE 31G
- LITETOUCH INS 0.3 ML 29GX1/2"
- LITETOUCH INS 0.3 ML 30GX5/16"
- LITETOUCH INS 0.3 ML 31GX5/16"
- LITETOUCH INS 0.5 ML 31GX5/16"
- LITETOUCH SYR 0.5 ML 28GX1/2"
- LITETOUCH SYR 0.5 ML 29GX1/2"
- LITETOUCH SYR 0.5 ML 30GX5/16"
- LITETOUCH SYRIN 1 ML 28GX1/2"
- LITETOUCH SYRIN 1 ML 29GX1/2"
- LITETOUCH SYRIN 1 ML 30GX5/16"
- MAGELLAN INSUL SYRINGE 0.3 ML
- MAGELLAN INSUL SYRINGE 0.5 ML
- MAGELLAN INSULIN SYR 0.3 ML
- MAGELLAN INSULIN SYR 0.5 ML
- MAGELLAN INSULIN SYRINGE 1 ML
- MAXI-COMFORT INS 0.5 ML 28G
- MAXI-COMFORT INS 1 ML 28GX1/2"
- MAXICOMFORT II PEN NDL 31GX6MM
- MAXICOMFORT INS 0.5 ML 27GX1/2"
- MAXICOMFORT INS 1 ML 27GX1/2"
- MAXICOMFORT PEN NDL 29G X 5MM
- MAXICOMFORT PEN NDL 29G X 8MM
- MICRODOT PEN NEEDLE 31GX6MM
- MICRODOT PEN NEEDLE 32GX4MM
- MICRODOT PEN NEEDLE 33GX4MM
- MICRODOT READYGARD NDL 31G 5MM OUTER
- MINI PEN NEEDLE 32G 4MM
- MINI PEN NEEDLE 32G 5MM
- MINI PEN NEEDLE 32G 6MM
- MINI PEN NEEDLE 32G 8MM
- MINI PEN NEEDLE 33G 4MM
- MINI PEN NEEDLE 33G 5MM
- MINI PEN NEEDLE 33G 6MM
- MINI ULTRA-THIN II PEN NDL 31G STERILE
- MONOJECT 0.5 ML SYRN 28GX1/2"
- MONOJECT 1 ML SYRN 27X1/2"
- MONOJECT 1 ML SYRN 28GX1/2" (OTC)
- MONOJECT INSUL SYR U100 (OTC)
- MONOJECT INSUL SYR U100 .5ML, 29GX1/2" (OTC)
- MONOJECT INSUL SYR U100 0.5 ML CONVERTS TO 29G (OTC)
- MONOJECT INSUL SYR U100 1 ML
- MONOJECT INSUL SYR U100 1 ML 3'S, 29GX1/2" (OTC)
- MONOJECT INSUL SYR U100 1 ML W/O NEEDLE (OTC)
- MONOJECT INSULIN SYR 0.3 ML
- MONOJECT INSULIN SYR 0.3 ML (OTC)
- MONOJECT INSULIN SYR 0.5 ML
- MONOJECT INSULIN SYR 0.5 ML (OTC)
- MONOJECT INSULIN SYR 1 ML 3'S (OTC)
- MONOJECT INSULIN SYR U-100
- MONOJECT SYRINGE 0.3 ML
- MONOJECT SYRINGE 0.5 ML
- MONOJECT SYRINGE 1 ML
- NOVOFINE 30
- NOVOFINE 32G NEEDLES
- NOVOFINE PLUS PEN NDL 32GX1/6"
- NOVOTWIST NEEDLE 32G 5MM
- PC UNIFINE PENTIPS 8MM NEEDLE SHORT
- PEN NEEDLE 30G 5MM OUTER
- PEN NEEDLE 30G 8MM INNER
- PEN NEEDLE 30G X 5/16"
- PEN NEEDLE, DIABETIC NEEDLE 29 GAUGE X 1/2"
- PEN NEEDLES 12MM 29G 29GX12MM, STRL
- PEN NEEDLES 4MM 32G
- PEN NEEDLES 6MM 31G 31GX6MM, STRL
- PEN NEEDLES 8MM 31G 31GX8MM, STRL,SHORT (OTC)
- PENTIPS PEN NEEDLE 29G 1/2"
- PENTIPS PEN NEEDLE 31G 1/4"
- PENTIPS PEN NEEDLE 31GX3/16" MINI, 5MM
- PENTIPS PEN NEEDLE 31GX5/16" SHORT, 8MM
- PENTIPS PEN NEEDLE 32G 1/4"
- PENTIPS PEN NEEDLE 32GX5/32" 4MM

- PIP PEN NEEDLE 31G X 5MM
- PIP PEN NEEDLE 32G X 4MM
- PREVENT PEN NEEDLE 31GX1/4"
- PREVENT PEN NEEDLE 31GX5/16"
- PRO COMFORT 0.5 ML 30GX1/2"
- PRO COMFORT 0.5 ML 30GX5/16"
- PRO COMFORT 0.5 ML 31GX5/16"
- PRO COMFORT 1 ML 30GX1/2"
- PRO COMFORT 1 ML 30GX5/16"
- PRO COMFORT 1 ML 31GX5/16"
- PRO COMFORT ALCOHOL 70% PADS
- PRO COMFORT PEN NDL 31GX5/16"
- PRO COMFORT PEN NDL 32G X 1/4"
- PRO COMFORT PEN NDL 4MM 32G
- PRO COMFORT PEN NDL 5MM 32G
- PRODIGY INS SYR 1 ML 28GX1/2"
- PRODIGY SYRNG 0.5 ML 31GX5/16"
- PRODIGY SYRNGE 0.3 ML 31GX5/16"
- PURE CMFT SFTY PEN NDL 31G 5MM
- PURE CMFT SFTY PEN NDL 31G 6MM
- PURE CMFT SFTY PEN NDL 32G 4MM
- PURE COMFORT ALCOHOL 70% PADS
- PURE COMFORT PEN NDL 32G 4MM
- PURE COMFORT PEN NDL 32G 5MM
- PURE COMFORT PEN NDL 32G 6MM
- PURE COMFORT PEN NDL 32G 8MM
- RAYA SURE PEN NEEDLE 29G 12MM
- RAYA SURE PEN NEEDLE 31G 4MM
- RAYA SURE PEN NEEDLE 31G 5MM
- RAYA SURE PEN NEEDLE 31G 6MM
- RELI-ON INSULIN 0.5 ML SYR
- RELI-ON INSULIN 1 ML SYR
- RELION INS SYR 0.3 ML 31GX6MM
- RELION INS SYR 0.5 ML 31GX6MM
- RELION INS SYR 1 ML 31GX15/64"
- RELION MINI PEN 31G X 1/4" NDL
- RELION NEEDLES
- RELION PEN NEEDLES
- SAFESNAP INS SYR UNITS-100 0.3 ML 30GX5/16",10X10
- SAFESNAP INS SYR UNITS-100 0.5 ML 29GX1/2",10X10
- SAFESNAP INS SYR UNITS-100 0.5 ML 30GX5/16",10X10
- SAFESNAP INS SYR UNITS-100 1 ML 28GX1/2",10X10
- SAFESNAP INS SYR UNITS-100 1 ML 29GX1/2",10X10
- SAFETY PEN NEEDLE 31G 4MM
- SAFETY PEN NEEDLE 5MM X 31G
- SAFETY SYRINGE 0.5 ML 30G 1/2"
- SECURESAFE PEN NDL 30GX5/16" OUTER
- SECURESAFE SYR 0.5 ML 29G 1/2" OUTER
- SECURESAFE SYRNG 1 ML 29G 1/2" OUTER
- SKY SAFETY PEN NEEDLE 30G 5MM
- SKY SAFETY PEN NEEDLE 30G 8MM
- SM ULT CFT 0.3 ML 31GX5/16(1/2)
- STERILE PADS 2" X 2"
- SURE CMFT SFTY PEN NDL 31G 6MM
- SURE CMFT SFTY PEN NDL 32G 4MM
- SURE COMFORT 0.5 ML SYRINGE
- SURE COMFORT 1 ML SYRINGE
- SURE COMFORT 3/10 ML SYRINGE
- SURE COMFORT 3/10 ML SYRINGE INSULIN SYRINGE
- SURE COMFORT 30G PEN NEEDLE
- SURE COMFORT ALCOHOL PREP PADS
- SURE COMFORT INS 0.3 ML 31GX1/4
- SURE COMFORT INS 0.5 ML 31GX1/4
- SURE COMFORT INS 1 ML 31GX1/4"
- SURE COMFORT PEN NDL 29GX1/2" 12.7MM
- SURE COMFORT PEN NDL 31G 5MM
- SURE COMFORT PEN NDL 31G 8MM
- SURE COMFORT PEN NDL 32G 4MM
- SURE COMFORT PEN NDL 32G 6MM
- SURE-FINE PEN NEEDLES 12.7MM
- SURE-FINE PEN NEEDLES 5MM
- SURE-FINE PEN NEEDLES 8MM
- SURE-JECT INSU SYR U100 0.3 ML
- SURE-JECT INSU SYR U100 0.5 ML
- SURE-JECT INSU SYR U100 1 ML
- SURE-JECT INSUL SYR U100 1 ML
- SURE-JECT INSULIN SYRINGE 1 ML
- SURE-PREP ALCOHOL PREP PADS
- TECHLITE 0.3 ML 29GX12MM (1/2)
- TECHLITE 0.3 ML 30GX12MM (1/2)
- TECHLITE 0.3 ML 30GX8MM (1/2)
- TECHLITE 0.3 ML 31GX6MM (1/2)
- TECHLITE 0.3 ML 31GX8MM (1/2)
- TECHLITE 0.5 ML 29GX12MM (1/2)

- TECHLITE 0.5 ML 30GX12MM (1/2)
- TECHLITE 0.5 ML 30GX8MM (1/2)
- TECHLITE 0.5 ML 31GX6MM (1/2)
- TECHLITE 0.5 ML 31GX8MM (1/2)
- TECHLITE INS SYR 1 ML 29GX12MM
- TECHLITE INS SYR 1 ML 30GX12MM
- TECHLITE INS SYR 1 ML 30GX8MM
- TECHLITE INS SYR 1 ML 31GX6MM
- TECHLITE INS SYR 1 ML 31GX8MM
- TECHLITE PEN NEEDLE 29GX1/2"
- TECHLITE PEN NEEDLE 29GX3/8"
- TECHLITE PEN NEEDLE 31GX1/4"
- TECHLITE PEN NEEDLE 31GX3/16"
- TECHLITE PEN NEEDLE 31GX5/16"
- TECHLITE PEN NEEDLE 32GX1/4"
- TECHLITE PEN NEEDLE 32GX5/16"
- TECHLITE PEN NEEDLE 32GX5/32"
- TECHLITE PLUS PEN NDL 32G 4MM
- TERUMO INS SYRINGE U100-1 ML
- TERUMO INS SYRINGE U100-1/2 ML
- TERUMO INS SYRINGE U100-1/3 ML
- TERUMO INS SYRNG U100-1/2 ML
- THINPRO INS SYRIN U100-0.3 ML
- THINPRO INS SYRIN U100-0.5 ML
- THINPRO INS SYRIN U100-1 ML
- TOPCARE CLICKFINE 31G X 1/4"
- TOPCARE CLICKFINE 31G X 5/16"
- TOPCARE ULTRA COMFORT SYRINGE
- TRUE CMFRT PRO 0.5 ML 30G 5/16"
- TRUE CMFRT PRO 0.5 ML 31G 5/16"
- TRUE CMFRT PRO 0.5 ML 32G 5/16"
- TRUE CMFT SFTY PEN NDL 31G 5MM
- TRUE CMFT SFTY PEN NDL 31G 6MM
- TRUE CMFT SFTY PEN NDL 32G 4MM
- TRUE COMFORT 0.5 ML 30G 1/2"
- TRUE COMFORT 0.5 ML 30G 5/16"
- TRUE COMFORT 0.5 ML 31G 5/16"
- TRUE COMFORT 0.5 ML 31GX5/16"
- TRUE COMFORT 1 ML 31GX5/16"
- TRUE COMFORT ALCOHOL 70% PADS
- TRUE COMFORT PEN NDL 31G 8MM
- TRUE COMFORT PEN NDL 31GX5MM
- TRUE COMFORT PEN NDL 31GX6MM
- TRUE COMFORT PEN NDL 32G 5MM
- TRUE COMFORT PEN NDL 32G 6MM
- TRUE COMFORT PEN NDL 32GX4MM
- TRUE COMFORT PEN NDL 33G 4MM
- TRUE COMFORT PEN NDL 33G 5MM
- TRUE COMFORT PEN NDL 33G 6MM
- TRUE COMFORT PRO 1 ML 30G 1/2"
- TRUE COMFORT PRO 1 ML 30G 5/16"
- TRUE COMFORT PRO 1 ML 31G 5/16"
- TRUE COMFORT PRO 1 ML 32G 5/16"
- TRUE COMFORT PRO ALCOHOL PADS
- TRUE COMFORT SFTY 1 ML 30G 1/2"
- TRUE COMFRT PRO 0.5 ML 30G 1/2"
- TRUE COMFRT SFTY 1 ML 30G 5/16"
- TRUE COMFRT SFTY 1 ML 31G 5/16"
- TRUE COMFRT SFTY 1 ML 32G 5/16"
- TRUEPLUS PEN NEEDLE 29G 12MM
- TRUEPLUS PEN NEEDLE 31G 5MM
- TRUEPLUS PEN NEEDLE 31G 8MM
- TRUEPLUS PEN NEEDLE 31G X 1/4"
- TRUEPLUS PEN NEEDLE 32GX5/32"
- TRUEPLUS SYR 0.3 ML 29GX1/2"
- TRUEPLUS SYR 0.3 ML 30GX5/16"
- TRUEPLUS SYR 0.3 ML 31GX5/16"
- TRUEPLUS SYR 0.5 ML 28GX1/2"
- TRUEPLUS SYR 0.5 ML 29GX1/2"
- TRUEPLUS SYR 0.5 ML 30GX5/16"
- TRUEPLUS SYR 0.5 ML 31GX5/16"
- TRUEPLUS SYR 1 ML 28GX1/2"
- TRUEPLUS SYR 1 ML 29GX1/2"
- TRUEPLUS SYR 1 ML 30GX5/16"
- TRUEPLUS SYR 1 ML 31GX5/16"
- ULTICAR INS 0.3 ML 31GX1/4(1/2)
- ULTICARE INS 1 ML 31GX1/4"
- ULTICARE INS SYR 0.3 ML 30G 8MM
- ULTICARE INS SYR 0.3 ML 31G 6MM
- ULTICARE INS SYR 0.3 ML 31G 8MM
- ULTICARE INS SYR 0.5 ML 31G 6MM
- ULTICARE INS SYR 1 ML 30GX1/2"
- ULTICARE PEN NEEDLE 31GX3/16"
- ULTICARE PEN NEEDLE 6MM 31G
- ULTICARE PEN NEEDLE 8MM 31G
- ULTICARE PEN NEEDLES 12MM 29G
- ULTICARE PEN NEEDLES 4MM 32G MICRO, 32GX4MM
- ULTICARE PEN NEEDLES 6MM 32G
- ULTICARE SAFE PEN NDL 30G 8MM
- ULTICARE SAFE PEN NDL 5MM 30G
- ULTICARE SYR 0.3 ML 29G 12.7MM
- ULTICARE SYR 0.3 ML 30GX1/2"
- ULTICARE SYR 0.3 ML 31GX5/16"

- SHORT NDL
- ULTICARE SYR 0.5 ML 30GX1/2"
- ULTICARE SYR 0.5 ML 31GX5/16"
- SHORT NDL
- ULTICARE SYR 1 ML 31GX5/16"
- ULTIGUARD SAFE 1 ML 30G 12.7MM
- ULTIGUARD SAFE0.3 ML 30G 12.7MM
- ULTIGUARD SAFE0.5 ML 30G 12.7MM
- ULTIGUARD SAFEPACK 1 ML 31G 8MM
- ULTIGUARD SAFEPACK 29G 12.7MM
- ULTIGUARD SAFEPACK 31G 5MM
- ULTIGUARD SAFEPACK 31G 6MM
- ULTIGUARD SAFEPACK 31G 8MM
- ULTIGUARD SAFEPACK 32G 4MM
- ULTIGUARD SAFEPACK 32G 6MM
- ULTIGUARD SAFEPK 0.3 ML 31G 8MM
- ULTIGUARD SAFEPK 0.5 ML 31G 8MM
- ULTILET ALCOHOL STERL SWAB
- ULTILET INSULIN SYRINGE 0.3 ML
- ULTILET INSULIN SYRINGE 0.5 ML
- ULTILET INSULIN SYRINGE 1 ML
- ULTILET PEN NEEDLE
- ULTILET PEN NEEDLE 4MM 32G
- ULTRA COMFORT 0.3 ML SYRINGE
- ULTRA COMFORT 0.5 ML 28GX1/2"
- CONVERTS TO 29G
- ULTRA COMFORT 0.5 ML 29GX1/2"
- ULTRA COMFORT 0.5 ML SYRINGE
- ULTRA COMFORT 1 ML 31GX5/16"
- ULTRA COMFORT 1 ML SYRINGE
- ULTRA FLO 0.3 ML 30G 1/2" (1/2)
- ULTRA FLO 0.3 ML 30G 5/16"(1/2)
- ULTRA FLO 0.3 ML 31G 5/16"(1/2)
- ULTRA FLO PEN NEEDLE 31G 5MM
- ULTRA FLO PEN NEEDLE 31G 8MM
- ULTRA FLO PEN NEEDLE 32G 4MM
- ULTRA FLO PEN NEEDLE 33G 4MM
- ULTRA FLO PEN NEEDLES 12MM 29G
- ULTRA FLO SYR 0.3 ML 29GX1/2"
- ULTRA FLO SYR 0.3 ML 30G 5/16"
- ULTRA FLO SYR 0.3 ML 31G 5/16"
- ULTRA FLO SYR 0.5 ML 29G 1/2"
- ULTRA THIN PEN NDL 32G X 4MM
- ULTRA-THIN II 1 ML 31GX5/16"
- ULTRA-THIN II INS 0.3 ML 30G
- ULTRA-THIN II INS 0.3 ML 31G
- ULTRA-THIN II INS 0.5 ML 29G
- ULTRA-THIN II INS 0.5 ML 30G
- ULTRA-THIN II INS 0.5 ML 31G
- ULTRA-THIN II INS SYR 1 ML 29G
- ULTRA-THIN II INS SYR 1 ML 30G
- ULTRA-THIN II PEN NDL 29GX1/2"
- ULTRA-THIN II PEN NDL 31GX5/16"
- ULTRACARE INS 0.3 ML 30GX5/16"
- ULTRACARE INS 0.3 ML 31GX5/16"
- ULTRACARE INS 0.5 ML 30GX1/2"
- ULTRACARE INS 0.5 ML 30GX5/16"
- ULTRACARE INS 0.5 ML 31GX5/16"
- ULTRACARE INS 1 ML 30G X 5/16"
- ULTRACARE INS 1 ML 30GX1/2"
- ULTRACARE INS 1 ML 31G X 5/16"
- ULTRACARE PEN NEEDLE 31GX1/4"
- ULTRACARE PEN NEEDLE 31GX3/16"
- ULTRACARE PEN NEEDLE 31GX5/16"
- ULTRACARE PEN NEEDLE 32GX1/4"
- ULTRACARE PEN NEEDLE 32GX3/16"
- ULTRACARE PEN NEEDLE 32GX5/32"
- ULTRACARE PEN NEEDLE 33GX5/32"
- UNIFINE PEN NEEDLE 32G 4MM
- UNIFINE PENTIPS 12MM 29G
- 29GX12MM, STRL
- UNIFINE PENTIPS 31GX3/16"
- 31GX5MM,STRL,MINI
- UNIFINE PENTIPS 32GX1/4"
- UNIFINE PENTIPS 32GX5/32"
- 32GX4MM, STRL, NANO
- UNIFINE PENTIPS 33GX5/32"
- UNIFINE PENTIPS 6MM 31G
- UNIFINE PENTIPS MAX 30GX3/16"
- UNIFINE PENTIPS NEEDLES 29G
- UNIFINE PENTIPS PLUS 29GX1/2"
- 12MM
- UNIFINE PENTIPS PLUS 30GX3/16"
- UNIFINE PENTIPS PLUS 31GX1/4"
- ULTRA SHORT, 6MM
- UNIFINE PENTIPS PLUS 31GX3/16"
- MINI
- UNIFINE PENTIPS PLUS 31GX5/16"
- SHORT
- UNIFINE PENTIPS PLUS 32GX5/32"
- UNIFINE PENTIPS PLUS 33GX5/32"
- UNIFINE PROTECT 30G 5MM
- UNIFINE PROTECT 30G 8MM
- UNIFINE PROTECT 32G 4MM

- UNIFINE SAFECONTROL 30G 5MM
- UNIFINE SAFECONTROL 30G 8MM
- UNIFINE SAFECONTROL 31G 5MM
- UNIFINE SAFECONTROL 31G 6MM
- UNIFINE SAFECONTROL 31G 8MM
- UNIFINE SAFECONTROL 32G 4MM
- UNIFINE ULTRA PEN NDL 31G 5MM
- UNIFINE ULTRA PEN NDL 31G 6MM
- UNIFINE ULTRA PEN NDL 31G 8MM
- UNIFINE ULTRA PEN NDL 32G 4MM
- VANISHPOINT 0.5 ML 30GX1/2" SY OUTER
- VANISHPOINT INS 1 ML 30GX3/16"
- VANISHPOINT U-100 29X1/2 SYR
- VERIFINE INS SYR 1 ML 29G 1/2"
- VERIFINE PEN NEEDLE 29G 12MM
- VERIFINE PEN NEEDLE 31G 5MM
- VERIFINE PEN NEEDLE 31G X 6MM
- VERIFINE PEN NEEDLE 31G X 8MM
- VERIFINE PEN NEEDLE 32G 6MM
- VERIFINE PEN NEEDLE 32G X 4MM
- VERIFINE PEN NEEDLE 32G X 5MM
- VERIFINE PLUS PEN NDL 31G 5MM
- VERIFINE PLUS PEN NDL 31G 8MM
- VERIFINE PLUS PEN NDL 32G 4MM
- VERIFINE PLUS PEN NDL 32G 4MM-SHARPS CONTAINER
- VERIFINE SYRING 0.5 ML 29G 1/2"
- VERIFINE SYRING 1 ML 31G 5/16"
- VERIFINE SYRNG 0.3 ML 31G 5/16"
- VERIFINE SYRNG 0.5 ML 31G 5/16"
- VERSALON ALL PURPOSE SPONGE 25'S,N-STERILE,3PLY
- WEBCOL ALCOHOL PREPS 20'S,LARGE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | None |
| Required Medical Information | ONLY COVERED UNDER PART D WHEN USED CONCURRENTLY WITH INSULIN. |
| Age Restrictions | |
| Prescriber Restrictions | None |
| Coverage Duration | LIFETIME |
| Other Criteria | ONLY COVERED UNDER PART D WHEN USED CONCURRENTLY WITH INSULIN. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

INTERFERON FOR MS-AVONEX

Products Affected

- AVONEX INTRAMUSCULAR PEN INJECTOR KIT
- AVONEX INTRAMUSCULAR SYRINGE KIT
- AVONEX PEN 30 MCG/0.5 ML

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

INTERFERON FOR MS-BETASERON

Products Affected

- BETASERON SUBCUTANEOUS KIT

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

INTERFERON GAMMA-1B

Products Affected

- ACTIMMUNE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: CHRONIC GRANULOMATOUS DISEASE (CGD): PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST, INFECTIOUS DISEASE SPECIALIST, OR IMMUNOLOGIST. SEVERE MALIGNANT OSTEOPETROSIS (SMO): PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST OR HEMATOLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS |
| Other Criteria | RENEWAL: CGD, SMO: 1) DEMONSTRATED CLINICAL BENEFIT COMPARED TO BASELINE, AND 2) HAS NOT RECEIVED HEMATOPOIETIC CELL TRANSPLANTATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ITRACONAZOLE SOLUTION

Products Affected

- *itraconazole oral solution*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 MONTHS |
| Other Criteria | ESOPHAGEAL CANDIDIASIS AND OROPHARYNGEAL CANDIDIASIS: TRIAL OF OR CONTRAINDICATION TO FLUCONAZOLE. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

IVACAFTOR

Products Affected

- KALYDECO ORAL GRANULES IN PACKET 25 MG, 5.8 MG, 50 MG, 75 MG
- KALYDECO ORAL TABLET

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | CYSTIC FIBROSIS (CF): INITIAL: CONFIRMED MUTATION IN CFTR GENE ACCEPTABLE FOR THE TREATMENT OF CYSTIC FIBROSIS |
| Age Restrictions | |
| Prescriber Restrictions | CF: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CYSTIC FIBROSIS EXPERT |
| Coverage Duration | INITIAL: 12 MONTHS. RENEWAL: LIFETIME |
| Other Criteria | CF: INITIAL: NOT HOMOZYGOUS FOR F508DEL MUTATION IN CFTR GENE. RENEWAL: 1) MAINTAINED, IMPROVED, OR DEMONSTRATED LESS THAN EXPECTED DECLINE IN FEV1 OR BODY MASS INDEX (BMI), OR 2) REDUCTION IN NUMBER OF PULMONARY EXACERBATIONS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

IVERMECTIN

Products Affected

- *ivermectin oral*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Prevention or treatment of COVID-19 |
| Required Medical Information | Diagnosis of one of the following: A.) Strongyloidiasis of the intestinal tract or B.) Onchocerciasis |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 1 month |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

IVOSIDENIB

Products Affected

- TIBSOVO

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

IWILFIN

Products Affected

- IWILFIN

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | None |
| Required Medical Information | Diagnosis of high-risk neuroblastoma to be used to reduce the risk of relapse in adult and pediatric patients who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy |
| Age Restrictions | None |
| Prescriber Restrictions | Prescribed by or in consultation with an oncologist |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | Some FDA-approved Indications Only. |
| Off Label Uses | |
| Part B Prerequisite | No |

IXAZOMIB

Products Affected

- NINLARO

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

LANADELUMAB

Products Affected

- TAKHZYRO SUBCUTANEOUS (150 MG/ML) SOLUTION
- TAKHZYRO SUBCUTANEOUS SYRINGE 150 MG/ML, 300 MG/2 ML (150 MG/ML)

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | HEREDITARY ANGIOEDEMA (HAE): INITIAL: DIAGNOSIS CONFIRMED BY COMPLEMENT TESTING. |
| Age Restrictions | |
| Prescriber Restrictions | HAE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ALLERGIST, IMMUNOLOGIST, OR HEMATOLOGIST. |
| Coverage Duration | 12 MONTHS |
| Other Criteria | HAE: INITIAL: NOT ON CONCURRENT TREATMENT WITH ALTERNATIVE PROPHYLACTIC AGENT FOR HAE ATTACKS. RENEWAL: 1) IMPROVEMENT COMPARED TO BASELINE IN HAE ATTACKS (I.E., REDUCTIONS IN ATTACK FREQUENCY OR ATTACK SEVERITY), AND 2) NOT ON CONCURRENT TREATMENT WITH ALTERNATIVE PROPHYLACTIC AGENT FOR HAE ATTACKS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

LAPATINIB

Products Affected

- *lapatinib*

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

LAROTRECTINIB

Products Affected

- VITRAKVI ORAL CAPSULE 100 MG, 25 MG
- VITRAKVI ORAL SOLUTION

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | APPROVAL FOR VITRAKVI ORAL SOLUTION: TRIAL OF VITRAKVI CAPSULES OR PATIENT IS UNABLE TO TAKE CAPSULE FORMULATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

LEDIPASVIR-SOFOSBUVIR

Products Affected

- HARVONI ORAL PELLETS IN PACKET
33.75-150 MG, 45-200 MG
- *ledipasvir-sofosbuvir*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | HCV RNA LEVEL WITHIN PAST 6 MONTHS. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE. |
| Other Criteria | 1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, AND 2) NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING: CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, ROSUVASTATIN, TIPRANA VIR/RITONAVIR, SOFOSBUVIR (AS A SINGLE AGENT), EPCLUSA, ZEPATIER, MAVYRET, OR VOSEVI. REQUESTS FOR HARVONI 45MG-200MG PELLETS: PATIENT IS UNABLE TO SWALLOW TABLETS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

LENALIDOMIDE

Products Affected

- *lenalidomide*

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

LENVATINIB

Products Affected

- LENVIMA

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

LETERMIVIR

Products Affected

- PREVYMIS ORAL

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 4 MONTHS |
| Other Criteria | NONE |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

LEUPROLIDE

Products Affected

- *leuprolide subcutaneous kit*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | NONE |
| Coverage Duration | 12 MONTHS |
| Other Criteria | BVD DETERMINATION AS REQUIRED PER CMS GUIDANCE |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

LEUPROLIDE DEPOT

Products Affected

- *leuprolide (3 month)*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

LEUPROLIDE-ELIGARD

Products Affected

- ELIGARD
- ELIGARD (3 MONTH)
- ELIGARD (4 MONTH)
- ELIGARD (6 MONTH)

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

LEUPROLIDE-LUPRON DEPOT

Products Affected

- LUPRON DEPOT
- LUPRON DEPOT (3 MONTH)
- LUPRON DEPOT (4 MONTH)
- LUPRON DEPOT (6 MONTH)

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: ENDOMETRIOSIS: DIAGNOSIS IS CONFIRMED VIA SURGICAL OR DIRECT VISUALIZATION (E.G., PELVIC ULTRASOUND) OR HISTOPATHOLOGICAL CONFIRMATION (E.G., LAPAROSCOPY OR LAPAROTOMY) IN THE LAST 10 YEARS. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: ENDOMETRIOSIS: PRESCRIBED BY OR IN CONSULTATION WITH AN OBSTETRICIAN/GYNECOLOGIST. |
| Coverage Duration | PROSTATE CA: 12 MOS. UTERINE FIBROIDS: 3 MOS. ENDOMETRIOSIS: INITIAL/RENEWAL: 6 MOS. |
| Other Criteria | INITIAL: ENDOMETRIOSIS: 1) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, 2) TRIAL OF OR CONTRAINDICATION TO NSAID AND PROGESTIN-CONTAINING PREPARATION, AND 3) HAS NOT RECEIVED A TOTAL OF 12 MONTHS OF TREATMENT PER LIFETIME. RENEWAL: ENDOMETRIOSIS: 1) IMPROVEMENT OF PAIN RELATED TO ENDOMETRIOSIS WHILE ON THERAPY, 2) RECEIVING CONCOMITANT ADD-BACK THERAPY (I.E., COMBINATION ESTROGEN-PROGESTIN OR PROGESTIN-ONLY CONTRACEPTIVE PREPARATION), 3) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, AND 4) HAS NOT RECEIVED A TOTAL OF 12 MONTHS OF TREATMENT PER LIFETIME. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

LEVODOPA

Products Affected

- INBRIJA INHALATION CAPSULE,
W/INHALATION DEVICE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | PARKINSONS DISEASE (PD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

L-GLUTAMINE

Products Affected

- ENDARI
- *glutamine (sickle cell)*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | SICKLE CELL DISEASE(SCD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST |
| Coverage Duration | INITIAL: 12 MONTHS. RENEWAL: LIFETIME. |
| Other Criteria | SCD: INITIAL: PATIENTS 18 YEARS OR OLDER: ONE OF THE FOLLOWING: 1) AT LEAST 2 SICKLE CELL CRISES IN THE PAST YEAR, 2) SICKLE-CELL ASSOCIATED SYMPTOMS WHICH ARE INTERFERING WITH ACTIVITIES OF DAILY LIVING, OR 3) HISTORY OF OR HAS RECURRENT ACUTE CHEST SYNDROME. PATIENTS 5 TO 17 YEARS: APPROVED WITHOUT ADDITIONAL CRITERIA. RENEWAL: HAS MAINTAINED OR EXPERIENCED REDUCTION IN ACUTE COMPLICATIONS OF SICKLE CELL DISEASE. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

LIDOCAINE

Products Affected

- *lidocaine hcl mucous membrane solution 4 % (40 mg/ml)*
- *lidocaine topical adhesive patch,medicated 5 %*
- *lidocaine topical ointment*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

LIDOCAINE PRILOCAINE

Products Affected

- *lidocaine-prilocaine topical cream*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | THIS DRUG MAY BE EITHER BUNDLED WITH AND COVERED UNDER END STAGE RENAL DISEASE DIALYSIS RELATED SERVICES OR COVERED UNDER MEDICARE D DEPENDING UPON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE AND SETTING OF THE DRUG TO MAKE THE DETERMINATION. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

LORLATINIB

Products Affected

- LORBRENA ORAL TABLET 100 MG, 25 MG

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

LOTILANER

Products Affected

- XDEM VY

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | DEMODEX BLEPHARITIS: 18 YEARS OF AGE OR OLDER |
| Prescriber Restrictions | |
| Coverage Duration | 6 WEEKS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

LUMACAFITOR-IVACAFITOR

Products Affected

- ORKAMBI ORAL GRANULES IN PACKET
- ORKAMBI ORAL TABLET

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: CYSTIC FIBROSIS (CF); CONFIRMED MUTATION IN CFTR GENE ACCEPTABLE FOR THE TREATMENT OF CF. |
| Age Restrictions | |
| Prescriber Restrictions | CF: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CF EXPERT. |
| Coverage Duration | INITIAL: 6 MONTHS, RENEWAL: LIFETIME. |
| Other Criteria | CF: RENEWAL: MAINTAINED, IMPROVED, OR DEMONSTRATED LESS THAN EXPECTED DECLINE IN FEV1 OR BODY MASS INDEX (BMI), OR REDUCTION IN NUMBER OF PULMONARY EXACERBATIONS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

MACITENTAN

Products Affected

- OPSUMIT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: 1) DOCUMENTED CONFIRMATORY DIAGNOSIS BASED ON RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: A) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, B) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND C) PULMONARY VASCULAR RESISTANCE (PVR) OF 3 WOOD UNITS OR GREATER, AND 2) NYHA-WHO FUNCTIONAL CLASS II-IV SYMPTOMS. |
| Age Restrictions | |
| Prescriber Restrictions | PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | PAH: RENEWAL: 1) IMPROVEMENT FROM BASELINE IN THE 6-MINUTE WALK DISTANCE, OR 2) A STABLE 6-MINUTE WALK DISTANCE WITH A STABLE/IMPROVED WHO FUNCTIONAL CLASS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

MARIBAVIR

Products Affected

- LIVTENCITY

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

MEPOLIZUMAB

Products Affected

- NUCALA SUBCUTANEOUS AUTO-INJECTOR
- NUCALA SUBCUTANEOUS RECON SOLN
- NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML, 40 MG/0.4 ML

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: ASTHMA: BLOOD EOSINOPHIL LEVEL GREATER THAN OR EQUAL TO 150 CELLS/MCL WITHIN THE PAST 12 MONTHS. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: ASTHMA: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN PULMONARY OR ALLERGY MEDICINE. NASAL POLYPS: PRESCRIBED BY OR IN CONSULTATION WITH AN OTOLARYNGOLOGIST, ALLERGIST OR IMMUNOLOGIST. |
| Coverage Duration | INITIAL: ASTHMA: 4 MO. NASAL POLYPS: 6 MO. OTHERS: 12 MO. RENEWAL: NASAL POLYPS, ASTHMA: 12 MO. |
| Other Criteria | NONE |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

METHYLNALTREXONE

Products Affected

- RELISTOR SUBCUTANEOUS SOLUTION
- RELISTOR SUBCUTANEOUS SYRINGE
12 MG/0.6 ML, 8 MG/0.4 ML

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | ADVANCED ILLNESS: OPIOID-INDUCED CONSTIPATION. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 MONTHS FOR PATIENTS RECEIVING PALLIATIVE CARE, 12 MONTHS FOR CHRONIC, NON-CANCER PAIN. |
| Other Criteria | ADVANCED ILLNESS: PATIENT IS RECEIVING PALLIATIVE CARE. CHRONIC NON-CANCER PAIN: PATIENT HAS BEEN TAKING OPIOIDS FOR AT LEAST 4 WEEKS AND HAD A PREVIOUS TRIAL OF OR CONTRAINDICATION TO NALOXEGOL (MOVANTIK) AND LUBIPROSTONE (AMITIZA). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

METHYLNALTREXONE ORAL

Products Affected

- RELISTOR ORAL

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | OPIOID INDUCED CONSTIPATION WITH CHRONIC NON-CANCER PAIN: 1) HAS BEEN TAKING OPIOIDS FOR AT LEAST 4 WEEKS, AND 2) TRIAL OF OR CONTRAINDICATION TO NALOXEGOL (MOVANTIK) AND LUBIPROSTONE (AMITIZA). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

MIDOSTAURIN

Products Affected

- RYDAPT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | ACUTE MYELOID LEUKEMIA: 6 MONTHS. ADVANCED SYSTEMIC MASTOCYTOSIS: 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

MIFEPRISTONE

Products Affected

- *mifepristone oral tablet 300 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | CUSHINGS SYNDROME (CS): INITIAL: DIAGNOSIS CONFIRMED BY ONE OF THE FOLLOWING: 1) 24-HR URINE FREE CORTISOL (2 OR MORE TESTS TO CONFIRM), 2) OVERNIGHT 1MG DEXAMETHASONE TEST, OR 3) LATE NIGHT SALIVARY CORTISOL (2 OR MORE TESTS TO CONFIRM). |
| Age Restrictions | |
| Prescriber Restrictions | CS: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST. |
| Coverage Duration | INITIAL AND RENEWAL: 12 MONTHS. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

MIGALASTAT

Products Affected

- GALAFOLD

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | FABRY DISEASE: INITIAL: PATIENT IS SYMPTOMATIC OR HAS EVIDENCE OF INJURY FROM GL-3 TO THE KIDNEY, HEART, OR CENTRAL NERVOUS SYSTEM RECOGNIZED BY LABORATORY, HISTOLOGICAL, OR IMAGING FINDINGS. |
| Age Restrictions | |
| Prescriber Restrictions | FABRY DISEASE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEPHROLOGIST, CARDIOLOGIST, OR SPECIALIST IN GENETICS OR INHERITED METABOLIC DISORDERS. |
| Coverage Duration | INITIAL: 6 MOS. RENEWAL: 12 MOS. |
| Other Criteria | FABRY DISEASE: INITIAL: NOT CONCURRENTLY USING ENZYME REPLACEMENT THERAPY (I.E. FABRAZYME), RENEWAL: 1) PATIENT HAS DEMONSTRATED IMPROVEMENT OR STABILIZATION, AND 2) NOT CONCURRENTLY USING ENZYME REPLACEMENT THERAPY (I.E. FABRAZYME). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

MIGLUSTAT

Products Affected

- *miglustat*

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

MILTEFOSINE

Products Affected

- IMPAVIDO

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

NAFARELIN

Products Affected

- SYNAREL

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: ENDOMETRIOSIS: DIAGNOSIS IS CONFIRMED VIA SURGICAL OR DIRECT VISUALIZATION (E.G., PELVIC ULTRASOUND) OR HISTOPATHOLOGICAL CONFIRMATION (E.G., LAPAROSCOPY OR LAPAROTOMY) IN THE LAST 10 YEARS. CENTRAL PRECOCIOUS PUBERTY (CPP): FEMALES: ELEVATED LEVELS OF FOLLICLE-STIMULATING HORMONE (FSH) GREATER THAN 4.0 MIU/ML AND LUTEINIZING HORMONE (LH) LEVEL GREATER THAN 0.2 TO 0.3 MIU/ML AT DIAGNOSIS. MALES: ELEVATED LEVELS OF FSH GREATER THAN 5.0 MIU/ML AND LH LEVEL GREATER THAN 0.2 TO 0.3 MIU/ML AT DIAGNOSIS. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: ENDOMETRIOSIS: PRESCRIBED BY OR IN CONSULTATION WITH AN OBSTETRICIAN/GYNECOLOGIST. CPP: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST. |
| Coverage Duration | ENDOMETRIOSIS: 6 MONTHS. CPP: INITIAL/RENEWAL: 12 MONTHS. |

| PA Criteria | Criteria Details |
|----------------------------|---|
| Other Criteria | <p>INITIAL: ENDOMETRIOSIS: 1) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, 2) TRIAL OF OR CONTRAINDICATION TO NSAID AND PROGESTIN-CONTAINING PREPARATION, AND 3) HAS NOT RECEIVED A TOTAL OF 6 MONTHS OF TREATMENT PER LIFETIME. CPP: FEMALES: 1) YOUNGER THAN 8 YEARS OF AGE AT ONSET OF CPP, AND 2) DOCUMENTATION OF PUBERTAL STAGING USING THE TANNER SCALE FOR BREAST DEVELOPMENT (STAGE 2 OR ABOVE) AND PUBIC HAIR GROWTH (STAGE 2 OR ABOVE). MALES: 1) YOUNGER THAN 9 YEARS OF AGE AT ONSET OF CPP, AND 2) DOCUMENTATION OF PUBERTAL STAGING USING THE TANNER SCALE FOR GENITAL DEVELOPMENT (STAGE 2 OR ABOVE) AND PUBIC HAIR GROWTH (STAGE 2 OR ABOVE). RENEWAL: CPP: 1) TANNER SCALE STAGING AT INITIAL DIAGNOSIS OF CPP HAS STABILIZED OR REGRESSED DURING THREE SEPARATE MEDICAL VISITS IN THE PREVIOUS YEAR, AND 2) HAS NOT REACHED ACTUAL AGE WHICH CORRESPONDS TO CURRENT PUBERTAL AGE.</p> |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

NARCOLEPSY AGENTS

Products Affected

- *armodafinil*
- *modafinil oral tablet 100 mg, 200 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

NERATINIB MALEATE

Products Affected

- NERLYNX

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | EARLY-STAGE (STAGE I-III) BREAST CANCER: MEDICATION IS BEING REQUESTED WITHIN 2 YEARS OF COMPLETING THE LAST TRASTUZUMAB DOSE. ALL OTHER FDA APPROVED INDICATIONS ARE COVERED WITHOUT ADDITIONAL CRITERIA, EXCEPT THOSE CRITERIA IN THE FDA APPROVED LABEL. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

NILOTINIB

Products Affected

- TASIGNA ORAL CAPSULE 150 MG, 200 MG, 50 MG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | PREVIOUSLY TREATED CML: MUTATIONAL ANALYSIS PRIOR TO INITIATION AND TASIGNA IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

NINTEDANIB

Products Affected

- OFEV

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Diagnosis of one of the following A.) Idiopathic pulmonary fibrosis (IPF), B.) Systemic sclerosis-associated interstitial lung disease (ILD), or C.) Chronic fibrosing interstitial lung disease with a progressive phenotype |
| Age Restrictions | 18 years of age and older |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

NIRAPARIB

Products Affected

- ZEJULA ORAL TABLET

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER: 1) ZEJULA WILL BE USED AS MONOTHERAPY, AND 2) ZEJULA IS STARTED NO LATER THAN 8 WEEKS AFTER THE MOST RECENT PLATINUM-CONTAINING REGIMEN. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

NITISINONE

Products Affected

- *nitisinone oral capsule 10 mg, 2 mg, 5 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | HEREDITARY TYROSINEMIA TYPE 1 (HT-1): INITIAL: DIAGNOSIS CONFIRMED BY ELEVATED URINARY OR PLASMA SUCCINYLACETONE LEVELS OR A MUTATION IN THE FUMARYLACETOACETATE HYDROLASE GENE. RENEWAL: URINARY OR PLASMA SUCCINYLACETONE LEVELS HAVE DECREASED FROM BASELINE WHILE ON TREATMENT WITH NITISINONE. |
| Age Restrictions | |
| Prescriber Restrictions | HT-1: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PRESCRIBER SPECIALIZING IN INHERITED METABOLIC DISEASES. |
| Coverage Duration | INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

OFATUMUMAB-SQ

Products Affected

- KESIMPTA PEN

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

OGSIVEO

Products Affected

- OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | None |
| Required Medical Information | Diagnosis of progressing desmoid tumors who require systemic treatment |
| Age Restrictions | 18 years or older |
| Prescriber Restrictions | Prescribed by or in consultation with an oncologist |
| Coverage Duration | 12 months |
| Other Criteria | None |
| Indications | Some FDA-approved Indications Only. |
| Off Label Uses | |
| Part B Prerequisite | No |

OJEMDA

Products Affected

- OJEMDA ORAL SUSPENSION FOR RECONSTITUTION
- OJEMDA ORAL TABLET

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Diagnosis of relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation |
| Age Restrictions | |
| Prescriber Restrictions | Prescribed by or in consultation with an oncologist |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

OJJAARA

Products Affected

- OJJAARA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | None |
| Required Medical Information | Diagnosis of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [postpolycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia. |
| Age Restrictions | 18 years of age and older |
| Prescriber Restrictions | Prescribed by or in consultation with an oncologist or hematologist |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

OLANZAPINE/SAMIDORPHAN

Products Affected

- LYBALVI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | SCHIZOPHRENIA/BIPOLAR I: PRESCRIBED BY OR IN CONSULTATION WITH A PSYCHIATRIST |
| Coverage Duration | 12 MONTHS |
| Other Criteria | SCHIZOPHRENIA: (1) PATIENT IS AT HIGH RISK OF WEIGHT GAIN AND (2) TRIAL OF OR CONTRAINDICATION TO LATUDA OR ONE OF THE FOLLOWING ORAL ANTIPSYCHOTICS: RISPERIDONE, CLOZAPINE TABLET, OLANZAPINE, IMMEDIATE RELEASE QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE. BIPOLAR I: (1) PATIENT IS AT HIGH RISK OF WEIGHT GAIN AND (2) TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING ORAL ANTIPSYCHOTICS: RISPERIDONE, OLANZAPINE, IMMEDIATE RELEASE QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

OLAPARIB

Products Affected

- LYNPARZA

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | NONE |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

OLUTASIDENIB

Products Affected

- REZLIDHIA

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

OMALIZUMAB

Products Affected

- XOLAIR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: ASTHMA: POSITIVE SKIN PRICK OR BLOOD TEST (E.G., ELISA, FEIA) TO A PERENNIAL AEROALLERGEN AND A BASELINE IGE SERUM LEVEL GREATER THAN OR EQUAL TO 30 IU/ML. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL AND RENEWAL: CHRONIC IDIOPATHIC URTICARIA (CIU): PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN ALLERGY OR PULMONARY MEDICINE, DERMATOLOGY OR IMMUNOLOGY. INITIAL: NASAL POLYPS: PRESCRIBED BY OR IN CONSULTATION WITH AN OTOLARYNGOLOGIST, ALLERGIST OR IMMUNOLOGIST. ASTHMA: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN ALLERGY OR PULMONARY MEDICINE. |
| Coverage Duration | 12 MONTHS |

| PA Criteria | Criteria Details |
|-----------------------|---|
| Other Criteria | <p>INITIAL: CIU: TRIAL OF OR CONTRAINDICATION TO A MAXIMALLY TOLERATED DOSE OF AN H1 ANTI-HISTAMINE AND STILL EXPERIENCES HIVES ON MOST DAYS OF THE WEEK. NASAL POLYPS: 1) PREVIOUS 90 DAY TRIAL OF ONE TOPICAL NASAL CORTICOSTEROID, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE PREFERRED AGENT: NUCALA, DUPIXENT. ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, 2) ONE OF THE FOLLOWING: (A) PATIENT EXPERIENCED AT LEAST ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING 3 OR MORE DAYS WITHIN THE PAST 12 MONTHS OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR (B) PATIENT HAS POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, ANY NIGHT WAKING DUE TO ASTHMA, SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, ANY ACTIVITY LIMITATION DUE TO ASTHMA, 3) NOT CONCURRENTLY RECEIVING DUPIXENT OR OTHER ANTI-IL5 BIOLOGICS WHEN THESE ARE USED FOR THE TREATMENT OF ASTHMA.</p> <p>RENEWAL: CIU: DIAGNOSIS OF CIU. NASAL POLYPS: CLINICAL BENEFIT COMPARED TO BASELINE. ASTHMA: 1) NOT CONCURRENTLY RECEIVING DUPIXENT OR OTHER ANTI-IL5 BIOLOGICS WHEN THESE ARE USED FOR THE TREATMENT OF ASTHMA, 2) CONTINUED USE OF ICS AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, AND 3) CLINICAL RESPONSE AS EVIDENCED BY ONE OF THE FOLLOWING: A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, C) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-</p> |
| | RELATED SYMPTOMS, OR D) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

OSIMERTINIB

Products Affected

- TAGRISSO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | EGFR EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS NON-SMALL CELL LUNG CANCER (NSCLC) AND METASTATIC NSCLC WITH EGFR T790M MUTATION: NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE-INHIBITOR. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PACRITINIB

Products Affected

- VONJO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS |
| Other Criteria | MYELOFIBROSIS: RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PALBOCICLIB

Products Affected

- IBRANCE

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PASIREOTIDE DIASPARTATE

Products Affected

- SIGNIFOR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | CUSHINGS DISEASE (CD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS. |
| Other Criteria | CD: RENEWAL: 1) CONTINUED IMPROVEMENT OF CUSHINGS DISEASE, AND 2) MAINTAINED TOLERABILITY TO SIGNIFOR. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PAZOPANIB

Products Affected

- *pazopanib*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | ADVANCED SOFT TISSUE SARCOMA (STS): NOT USED FOR ADIPOCYTIC STS OR GASTROINTESTINAL STROMAL TUMORS (GIST) |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PDE5 INHIBITORS FOR PULMONARY ARTERIAL HYPERTENSION

Products Affected

- *alyq*
- *sildenafil (pulm.hypertension) oral tablet*
- *tadalafil (pulm. hypertension)*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Any of the following A.) Nitrate therapy, including intermittent use, B.) Concomitant use with riociguat or other guanylate cyclase stimulators, C.) Concomitant use with HIV protease inhibitors or elvitegravir/cobicistat/tenofovir/emtricitabine |
| Required Medical Information | Diagnosis of pulmonary arterial hypertension (WHO Group I), confirmed by right heart catheterization or Doppler echocardiogram if patient is unable to undergo a right heart catheterization (e.g., patient is frail, elderly, etc.) |
| Age Restrictions | |
| Prescriber Restrictions | PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST. THIS CRITERIA DOES NOT APPLY TO SILDENAFIL FOR AGES 1 TO 17 YEARS. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS |
| Other Criteria | NOT CONCURRENTLY OR INTERMITTENTLY TAKING ORAL ERECTILE DYSFUNCTION AGENTS (E.G. CIALIS, VIAGRA), ANY ORGANIC NITRATES IN ANY FORM, OR GUANYLATE CYCLASE STIMULATORS |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PEGFILGRASTIM

Products Affected

- NEULASTA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | NON MYELOID MALIGNANCY, ACUTE RADIATION EXPOSURE: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST. |
| Coverage Duration | 12 MONTHS |
| Other Criteria | NON MYELOID MALIGNANCY: TRIAL OF OR CONTRAINDICATION TO NYVEPRIA. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PEGFILGRASTIM - APGF

Products Affected

- NYVEPRIA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | NON MYELOID MALIGNANCY: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST. |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PEGFILGRASTIM - CBQV

Products Affected

- UDENYCA
- UDENYCA AUTOINJECTOR

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | NON MYELOID MALIGNANCY: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST. |
| Coverage Duration | 12 MONTHS |
| Other Criteria | NON MYELOID MALIGNANCY: TRIAL OF OR CONTRAINDICATION TO NYVEPRIA. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PEGFILGRASTIM - JMDB

Products Affected

- FULPHILA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | NON MYELOID MALIGNANCY: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST. |
| Coverage Duration | 12 MONTHS |
| Other Criteria | NON MYELOID MALIGNANCY: TRIAL OF OR CONTRAINDICATION TO NYVEPRIA |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PEGVISOMANT

Products Affected

- SOMAVERT

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PEMIGATINIB

Products Affected

- PEMAZYRE

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PENICILLAMINE

Products Affected

- *penicillamine oral tablet*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | <p>INITIAL: WILSONS DISEASE: CONFIRMED BY ONE OF THE FOLLOWING: 1) PLASMA COPPER-PROTEIN CERULOPLASMIN IS LESS THAN 20MG/DL, 2) LIVER BIOPSY POSITIVE FOR AN ABNORMALLY HIGH CONCENTRATION OF COPPER (GREATER THAN 250MCG/G DRY WEIGHT) OR THE PRESENCE OF KAYSER-FLEISCHER RINGS, OR 3) CONFIRMATION BY GENETIC TESTING FOR ATP7B MUTATIONS. CYSTINURIA: PATIENT HAS NEPHROLITHIASIS AND ONE OR MORE OF THE FOLLOWING: 1) STONE ANALYSIS SHOWING PRESENCE OF CYSTEINE, 2) IDENTIFICATION OF PATHOGNOMONIC HEXAGONAL CYSTINE CRYSTALS ON URINALYSIS, OR 3) POSITIVE FAMILY HISTORY OF CYSTINURIA WITH POSITIVE CYANIDE-NITROPRUSSIDE SCREEN.</p> |
| Age Restrictions | |
| Prescriber Restrictions | <p>WILSONS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A HEPATOLOGIST OR GASTROENTEROLOGIST. CYSTINURIA: PRESCRIBED BY OR IN CONSULTATION WITH A NEPHROLOGIST. RHEUMATOID ARTHRITIS (RA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.</p> |
| Coverage Duration | <p>INITIAL: 12 MONTHS, RENEWAL: LIFETIME.</p> |

| PA Criteria | Criteria Details |
|----------------------------|--|
| Other Criteria | <p>INITIAL: WILSONS DISEASE: 1) KNOWN FAMILY HISTORY OF WILSONS DISEASE OR PHYSICAL EXAMINATION CONSISTENT WITH WILSONS DISEASE, AND 2) REQUESTS FOR FORMULARY VERSION OF PENICILLAMINE CAPSULE REQUIRE A TRIAL OF OR CONTRAINDICATION TO PENICILLAMINE TABLET (DEPEN). CYSTINURIA: REQUESTS FOR FORMULARY VERSION OF PENICILLAMINE CAPSULE REQUIRES A TRIAL OF OR CONTRAINDICATION TO PENICILLAMINE TABLET (DEPEN) AND A FORMULARY VERSION OF TIOPRONIN (THIOLA)/THIOLA EC. RA: 1) NO HISTORY OR OTHER EVIDENCE OF RENAL INSUFFICIENCY, 2) TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED, AND 3) REQUESTS FOR FORMULARY VERSION OF PENICILLAMINE CAPSULE REQUIRES A TRIAL OF OR CONTRAINDICATION TO PENICILLAMINE TABLET (DEPEN). RENEWAL: RA: 1) NO HISTORY OR OTHER EVIDENCE OF RENAL INSUFFICIENCY, 2) EXPERIENCED OR MAINTAINED IMPROVEMENT IN TENDER JOINT COUNT OR SWOLLEN JOINT COUNT COMPARED TO BASELINE. WILSONS DISEASE, CYSTINURIA: PATIENT CONTINUES TO BENEFIT FROM THE MEDICATION.</p> |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PIMAVANSERIN

Products Affected

- NUPLAZID

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | PSYCHOSIS IN PARKINSONS DISEASE (PD): INITIAL: 18 YEARS OR OLDER |
| Prescriber Restrictions | PSYCHOSIS IN PD: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, GERIATRICIAN, OR A BEHAVIORAL HEALTH SPECIALIST (E.G., PSYCHIATRIST). |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | PSYCHOSIS IN PD: RENEWAL: IMPROVEMENT IN PSYCHOSIS SYMPTOMS FROM BASELINE AND DEMONSTRATES A CONTINUED NEED FOR TREATMENT. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PIRFENIDONE

Products Affected

- *pirfenidone oral capsule*
- *pirfenidone oral tablet 267 mg, 534 mg, 801 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Diagnosis of idiopathic pulmonary fibrosis |
| Age Restrictions | 18 years of age and older |
| Prescriber Restrictions | Prescribed by or in consultation with a pulmonologist |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PIRTOBRUTINIB

Products Affected

- JAYPIRCA ORAL TABLET 100 MG, 50 MG

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

POMALIDOMIDE

Products Affected

- POMALYST

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PONATINIB

Products Affected

- ICLUSIG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | CML: MUTATIONAL ANALYSIS PRIOR TO INITIATION AND ICLUSIG IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

POSACONAZOLE

Products Affected

- *posaconazole oral*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | OROPHARYNGEAL CANDIDIASIS (OPC): 3 MONTHS. PROPHYLAXIS: 6 MONTHS. TREATMENT: 12 WEEKS. |
| Other Criteria | NONE |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

POSACONAZOLE-POWDERMIX

Products Affected

- NOXAFIL ORAL SUSP, DELAYED
RELEASE FOR RECON

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 MONTHS |
| Other Criteria | PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTION: INABILITY TO SWALLOW TABLETS. CONTINUATION OF THERAPY AFTER HOSPITAL DISCHARGE REQUIRES NO EXTRA CRITERIA. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PRALSETINIB

Products Affected

- GAVRETO

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PYRIMETHAMINE

Products Affected

- *pyrimethamine*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | TOXOPLASMOSIS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN INFECTIOUS DISEASE SPECIALIST. |
| Coverage Duration | TOXOPLASMOSIS: INITIAL: 8 WEEKS, RENEWAL: 6 MOS. |
| Other Criteria | TOXOPLASMOSIS: RENEWAL: ONE OF THE FOLLOWING: (1) PERSISTENT CLINICAL DISEASE (HEADACHE, NEUROLOGICAL SYMPTOMS, OR FEVER) AND PERSISTENT RADIOGRAPHIC DISEASE (ONE OR MORE MASS LESIONS ON BRAIN IMAGING), OR (2) CD4 COUNT LESS THAN 200 CELLS/MM3 AND CURRENTLY TAKING AN ANTI-RETROVIRAL THERAPY IF HIV POSITIVE. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

QUININE

Products Affected

- *quinine sulfate*

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

REGORAFENIB

Products Affected

- STIVARGA

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

RELUGOLIX

Products Affected

- ORGOVYX

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

RIBOCICLIB

Products Affected

- KISQALI FEMARA CO-PACK ORAL TABLET 200 MG/DAY(200 MG X 1)-2.5 MG, 400 MG/DAY(200 MG X 2)-2.5 MG, 600 MG/DAY(200 MG X 3)-2.5 MG
- KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1), 400 MG/DAY (200 MG X 2) , 600 MG/DAY (200 MG X 3)

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | ADVANCED OR METASTATIC BREAST CANCER: TRIAL OF OR CONTRAINDICATION TO VERZENIO OR IBRANCE WHERE INDICATIONS ALIGN. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

RIFAXIMIN

Products Affected

- XIFAXAN ORAL TABLET 200 MG, 550 MG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | TRAVELERS DIARRHEA/HE: 12 MOS. IBS-D: 8 WKS. |
| Other Criteria | RIFAXIMIN 550 MG TABLETS: HE: TRIAL OF OR CONTRAINDICATION TO LACTULOSE OR CONCURRENT LACTULOSE THERAPY. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

RIMEGEPANT

Products Affected

- NURTEC ODT

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: ACUTE MIGRAINE TREATMENT: TRIAL OF OR CONTRAINDICATION TO ONE TRIPTAN (E.G., SUMATRIPTAN, RIZATRIPTAN). EPISODIC MIGRAINE PREVENTION: 1) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREVENTIVE MIGRAINE TREATMENTS: DIVALPROEX SODIUM, TOPIRAMATE, PROPRANOLOL, TIMOLOL. RENEWAL: ACUTE MIGRAINE TREATMENT: 1) IMPROVEMENT FROM BASELINE IN A VALIDATED ACUTE TREATMENT PATIENT-REPORTED OUTCOME QUESTIONNAIRE, OR 2) THERAPY WORKS CONSISTENTLY IN MAJORITY OF MIGRAINE ATTACKS. EPISODIC MIGRAINE PREVENTION: 1) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION, AND 2) REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

RIOCIGUAT

Products Affected

- ADEMPAS

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: PULMONARY ARTERIAL HYPERTENSION (PAH): 1) CONFIRMATORY DIAGNOSIS BASED ON RIGHT HEART CATHETERIZATION: A) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, B) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) 15 MMHG OR LESS, AND C) PULMONARY VASCULAR RESISTANCE (PVR) 3 WOOD UNITS OR GREATER, AND 2) NYHA-WHO FUNCTIONAL CLASS (FC) II-IV SYMPTOMS. PERSISTENT/RECURRENT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) WHO GROUP 4: NYHA-WHO FUNCTIONAL CLASS II-IV SYMPTOMS. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: PAH, CTEPH: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST. |
| Coverage Duration | INITIAL AND RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: PAH: NOT CONCURRENTLY TAKING NITRATES, NITRIC OXIDE DONORS, PHOSPHODIESTERASE INHIBITORS, OR NON-SPECIFIC PDE INHIBITORS. CTEPH: 1) NOT CONCURRENTLY TAKING NITRATES, NITRIC OXIDE DONORS, OR ANY PDE INHIBITORS, AND 2) NOT A CANDIDATE FOR SURGERY OR HAS INOPERABLE CTEPH OR HAS PERSISTENT OR RECURRENT DISEASE AFTER SURGICAL TREATMENT. RENEWAL: PAH, CTEPH: 1) IMPROVEMENT FROM BASELINE IN THE 6-MINUTE WALK DISTANCE OR A STABLE 6-MINUTE WALK DISTANCE WITH A STABLE/IMPROVED WHO FUNCTIONAL CLASS, AND 2) NOT CONCURRENTLY TAKING NITRATES, NITRIC OXIDE DONORS, PHOSPHODIESTERASE INHIBITORS, OR NON-SPECIFIC PDE INHIBITORS. |

| PA Criteria | Criteria Details |
|----------------------------|-------------------------------|
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

RIPRETINIB

Products Affected

- QINLOCK

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

RISANKIZUMAB-RZAA

Products Affected

- SKYRIZI SUBCUTANEOUS PEN INJECTOR
- SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML
- SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML), 360 MG/2.4 ML (150 MG/ML)

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: PLAQUE PSORIASIS (PSO): PLAQUE PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE OR GENITAL AREA. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. CROHNS DISEASE (CD): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: PSO: TRIAL OF OR CONTRAINDICATION TO ONE CONVENTIONAL THERAPY SUCH AS PUVA (PHOTOTHERAPY ULTRAVIOLET LIGHT A), UVB (ULTRAVIOLET LIGHT B), TOPICAL CORTICOSTEROIDS, CALCIPOTRIENE, ACITRETIN, METHOTREXATE, OR CYCLOSPORINE. PSA: TRIAL OF OR CONTRAINDICATION TO ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG). CD: TRIAL OF OR CONTRAINDICATION TO ONE CONVENTIONAL THERAPY SUCH AS A CORTICOSTEROID (E.G., BUDESONIDE, METHYLPREDNISOLONE), AZATHIOPRINE, MERCAPTOPURINE, METHOTREXATE, OR MESALAMINE. RENEWAL: PSO, PSA: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

ROPEGINTERFERON ALFA-2B-NJFT

Products Affected

- BESREMI

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

RUCAPARIB

Products Affected

- RUBRACA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: ONE OF THE FOLLOWING: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

RUXOLITINIB

Products Affected

- JAKAFI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | MYELOFIBROSIS: INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS. POLYCYTHEMIA VERA, GVHD: 12 MONTHS. |
| Other Criteria | MYELOFIBROSIS: RENEWAL: PATIENT CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

SAPROPTERIN

Products Affected

- *javygtor oral tablet, soluble*
- *sapropterin oral tablet, soluble*

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | HYPERPHENYLALANINEMIA (HPA): INITIAL: NOT CONCURRENTLY USING PALYNZIQ. RENEWAL: 1) CONTINUES TO BENEFIT FROM TREATMENT, AND 2) NOT CONCURRENTLY USING PALYNZIQ. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

SARILUMAB

Products Affected

- KEVZARA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | RHEUMATOID ARTHRITIS (RA): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. |
| Coverage Duration | 12 MONTHS |
| Other Criteria | RA: INITIAL: ONE OF THE FOLLOWING: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA, ENBREL, XELJANZ, RINVOQ, OR 2) TRIAL OF A TNF INHIBITOR AND PHYSICIAN HAS INDICATED THE PATIENT CANNOT USE A JAK INHIBITOR DUE TO THE BLACK BOX WARNING FOR INCREASED RISK OF MORTALITY, MALIGNANCIES, AND SERIOUS CARDIOVASCULAR EVENTS. RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

SECUKINUMAB

Products Affected

- COSENTYX (2 SYRINGES)
- COSENTYX PEN (2 PENS)
- COSENTYX SUBCUTANEOUS SYRINGE
75 MG/0.5 ML
- COSENTYX UNOREADY PEN

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, OR FACE. NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN (CRP) LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI). |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR A DERMATOLOGIST. ANKYLOSING SPONDYLITIS (AS), NR-AXSPA, ENTHESITIS-RELATED ARTHRITIS (ERA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS |
| Other Criteria | INITIAL: PSO: TRIAL OF OR CONTRAINDICATION TO ONE CONVENTIONAL THERAPY SUCH AS A PUVA (PHOTOTHERAPY ULTRAVIOLET LIGHT A), UVB (ULTRAVIOLET LIGHT B), TOPICAL CORTICOSTEROIDS, CALCIPOTRIENE, ACITRETIN, METHOTREXATE, OR CYCLOSPORINE. PSA: TRIAL OF OR CONTRAINDICATION TO ONE DMARD (DISEASE-MODIFYING ANTI-RHEUMATIC DRUG). AS, NR-AXSPA: TRIAL OF OR CONTRAINDICATION TO AN NSAID (NON-STEROIDAL ANTI-INFLAMMATORY DRUG). ERA: TRIAL OF OR CONTRAINDICATION TO ONE NSAID, SULFASALAZINE, OR METHOTREXATE. RENEWAL: PSO, PSA, AS, NR-AXSPA, ERA: CONTINUES TO BENEFIT FROM THE MEDICATION. |

| PA Criteria | Criteria Details |
|----------------------------|-------------------------------|
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

SELEXIPAG

Products Affected

- UPTRAVI ORAL TABLET 1,000 MCG, 1, 200 MCG, 1,400 MCG, 1,600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG
- UPTRAVI ORAL TABLETS,DOSE PACK

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: 1) CONFIRMATORY DIAGNOSIS BASED ON RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: A) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, B) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) 15 MMHG OR LESS, AND C) PULMONARY VASCULAR RESISTANCE (PVR) 3 WOOD UNITS OR GREATER, AND 2) NYHA-WHO FUNCTIONAL CLASS (FC) II-IV SYMPTOMS. |
| Age Restrictions | |
| Prescriber Restrictions | PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS |
| Other Criteria | PAH: INITIAL: WHO FC II-III SYMPTOMS: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING AGENTS, EACH FROM A DIFFERENT DRUG CLASS: 1) FORMULARY VERSION OF AN ORAL ENDOTHELIAL RECEPTOR ANTAGONIST, 2) FORMULARY VERSION OF AN ORAL PHOSPHODIESTERASE TYPE-5 INHIBITOR, OR 3) FORMULARY VERSION OF AN ORAL CGMP STIMULATOR. WHO FC III SYMPTOMS AND EVIDENCE OF RAPID PROGRESSION OR POOR PROGNOSIS, WHO FC IV SYMPTOMS: NO STEP. RENEWAL: 1) IMPROVEMENT FROM BASELINE IN THE 6-MINUTE WALK DISTANCE TEST, OR 2) REMAINED STABLE FROM BASELINE IN THE 6-MINUTE WALK DISTANCE TEST AND WHO FC HAS IMPROVED OR REMAINED STABLE. |
| Indications | All FDA-approved Indications. |

| PA Criteria | Criteria Details |
|----------------------------|-------------------------|
| Off Label Uses | |
| Part B Prerequisite | No |

SELINEXOR

Products Affected

- XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40 MG/WEEK (40 MG X 1), 40MG TWICE WEEK (40 MG X 2), 60 MG/WEEK (60 MG X 1), 60MG TWICE WEEK (120 MG/WEEK), 80 MG/WEEK (40 MG X 2), 80MG TWICE WEEK (160 MG/WEEK)

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

SELPERCATINIB

Products Affected

- RETEVMO ORAL CAPSULE 40 MG, 80 MG
- RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

SELUMETINIB

Products Affected

- KOSELUGO ORAL CAPSULE 10 MG, 25 MG

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

SIPONIMOD

Products Affected

- MAYZENT ORAL TABLET 0.25 MG, 1 MG, 2 MG
- MAYZENT STARTER(FOR 1MG MAINT)
- MAYZENT STARTER(FOR 2MG MAINT)

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | MULTIPLE SCLEROSIS: RENEWAL: 1) DEMONSTRATION OF CLINICAL BENEFIT COMPARED TO PRE-TREATMENT BASELINE AND 2) DOES NOT HAVE LYMPHOPENIA. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

SODIUM OXYBATE

Products Affected

- *sodium oxybate*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: ALL INDICATIONS: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, PSYCHIATRIST, OR SPECIALIST IN SLEEP MEDICINE. |
| Coverage Duration | INITIAL 6 MONTHS. RENEWAL: 12 MONTHS |
| Other Criteria | INITIAL: EXCESSIVE DAYTIME SLEEPINESS (EDS) IN NARCOLEPSY: 1) NOT CURRENTLY TAKING A SEDATIVE HYPNOTIC AGENT, 2) FOR PATIENTS 18 YEARS OR OLDER: TRIAL OF OR CONTRAINDICATION TO THE FORMULARY VERSION OF MODAFINIL, ARMODAFINIL, PITOLISANT OR SOLRIAMFETOL AND ONE OTHER GENERIC STIMULANT INDICATED FOR EDS IN NARCOLEPSY, AND 3) FOR PATIENTS 7 TO 17 YEARS OF AGE: TRIAL OF OR CONTRAINDICATION TO ONE OTHER GENERIC STIMULANT INDICATED FOR EDS IN NARCOLEPSY. CATAPLEXY IN NARCOLEPSY: NOT CURRENTLY TAKING A SEDATIVE HYPNOTIC AGENT. RENEWAL (ALL INDICATIONS): 1) SUSTAINED IMPROVEMENT OF SYMPTOMS COMPARED TO BASELINE, AND 2) NOT CURRENTLY TAKING A SEDATIVE HYPNOTIC AGENT. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

SOFOSBUVIR/VELPATASVIR

Products Affected

- EPCLUSA ORAL PELLETS IN PACKET
150-37.5 MG, 200-50 MG
- EPCLUSA ORAL TABLET 200-50 MG
- *sofosbuvir-velpatasvir*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | HCV RNA LEVEL WITHIN PAST 6 MONTHS. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE. |
| Other Criteria | 1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, 2) NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING MEDICATIONS: AMIODARONE, CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, HIV REGIMEN THAT CONTAINS EFAVIRENZ, ROSUVASTATIN AT DOSES ABOVE 10MG, TIPRANAVIR/RITONAVIR, TOPOTECAN, SOVALDI (AS A SINGLE AGENT), HARVONI, ZEPATIER, MAVYRET, OR VOSEVI, AND 3) PATIENTS WITH DECOMPENSATED CIRRHOSIS REQUIRE CONCURRENT RIBAVIRIN UNLESS RIBAVIRIN INELIGIBLE. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR

Products Affected

- VOSEVI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | HCV RNA LEVEL WITHIN PAST 6 MONTHS |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE. |
| Other Criteria | 1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, 2) NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING MEDICATIONS: AMIODARONE, CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, CYCLOSPORINE, PITAVASTATIN, PRAVASTATIN (DOSES ABOVE 40MG), ROSUVASTATIN, METHOTREXATE, MITOXANTRONE, IMATINIB, IRINOTECAN, LAPATINIB, SULFASALAZINE, TOPOTECAN, OR HIV REGIMEN THAT CONTAINS EFAVIRENZ, ATAZANAVIR, LOPINAVIR, TIPRANAVIR/RITONAVIR, SOVALDI (AS A SINGLE AGENT), EPCLUSA, HARVONI, ZEPATIER, OR MAVYRET, AND 3) DOES NOT HAVE MODERATE OR SEVERE HEPATIC IMPAIRMENT (CHILD-PUGH B OR C). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

SOMATROPIN - NORDITROPIN

Products Affected

- NORDITROPIN FLEXPRO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | INITIAL/RENEWAL: ATHLETIC ENHANCEMENT, ANTI-AGING PURPOSES. |
| Required Medical Information | INITIAL: PEDIATRIC GROWTH HORMONE DEFICIENCY (GHD), IDIOPATHIC SHORT STATURE (ISS), SMALL FOR GESTATIONAL AGE (SGA), TURNER SYNDROME (TS), NOONAN SYNDROME: HEIGHT AT LEAST 2 STANDARD DEVIATIONS (SD) BELOW THE MEAN HEIGHT FOR NORMAL CHILDREN OF THE SAME AGE AND GENDER. PRADER WILLI SYNDROME (PWS): CONFIRMED GENETIC DIAGNOSIS. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL/RENEWAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |

| PA Criteria | Criteria Details |
|----------------------------|---|
| Other Criteria | <p>INITIAL: ADULT GHD: GROWTH HORMONE DEFICIENCY ALONE OR ASSOCIATED WITH MULTIPLE HORMONE DEFICIENCIES (HYPOPITUITARISM), AS A RESULT OF PITUITARY DISEASES, HYPOTHALAMIC DISEASE, SURGERY, RADIATION THERAPY, TRAUMA, OR CONTINUATION OF THERAPY FROM CHILDHOOD ONSET GROWTH HORMONE DEFICIENCY. PEDIATRIC GHD, ISS, SGA, TS, NOONAN SYNDROME: OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF THE WRIST AND HAND. RENEWAL: PEDIATRIC GHD: 1) IMPROVEMENT WHILE ON THERAPY (I.E., INCREASED HEIGHT OR INCREASED GROWTH VELOCITY), AND 2) OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF THE WRIST AND HAND OR PATIENT HAS NOT COMPLETED PREPUBERTALGROWTH. ISS, SGA, TS, NOONAN SYNDROME: 1) IMPROVEMENT WHILE ON THERAPY (I.E., INCREASED HEIGHT OR INCREASED GROWTH VELOCITY), AND 2) OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF THE WRIST AND HAND. PWS: IMPROVEMENT IN BODY COMPOSITION.</p> |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

SOMATROPIN - SEROSTIM

Products Affected

- SEROSTIM SUBCUTANEOUS RECON
SOLN 4 MG, 5 MG, 6 MG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | INITIAL/RENEWAL: ATHLETIC ENHANCEMENT, ANTI-AGING PURPOSES |
| Required Medical Information | INITIAL: HIV/WASTING: MEETS ONE OF THE FOLLOWING CRITERIA FOR WEIGHT LOSS: 1) 10% UNINTENTIONAL WEIGHT LOSS OVER 12 MONTHS, 2) 7.5% UNINTENTIONAL WEIGHT LOSS OVER 6 MONTHS, 3) 5% BODY CELL MASS (BCM) LOSS WITHIN 6 MONTHS, 4) BODY CELL MASS (BCM) LESS THAN 35% (MEN) OF TOTAL BODY WEIGHT AND BODY MASS INDEX (BMI) LESS THAN 27 KG PER METER SQUARED, 5) BCM LESS THAN 23% (WOMEN) OF TOTAL BODY WEIGHT AND A BODY MASS INDEX (BMI) LESS THAN 27 KG PER METER SQUARED, OR 6) BMI LESS THAN 18.5 KG PER METER SQUARED. |
| Age Restrictions | |
| Prescriber Restrictions | HIV/WASTING: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST, NUTRITIONAL SUPPORT SPECIALIST, OR INFECTIOUS DISEASE SPECIALIST. |
| Coverage Duration | INITIAL/RENEWAL: 3 MONTHS. |
| Other Criteria | HIV/WASTING: INITIAL: 1) CURRENTLY ON HIV ANTIRETROVIRAL THERAPY, AND 2) INADEQUATE RESPONSE TO ONE PREVIOUS THERAPY (E.G., MEGACE, APPETITE STIMULANTS, ANABOLIC STEROIDS). RENEWAL: 1) CURRENTLY ON HIV ANTIRETROVIRAL THERAPY, AND 2) CLINICAL BENEFIT IN MUSCLE MASS AND WEIGHT. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

SONIDEGIB

Products Affected

- ODOMZO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | LOCALLY ADVANCED BASAL CELL CARCINOMA (BCC): BASELINE SERUM CREATINE KINASE (CK) AND SERUM CREATININE LEVELS |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

SORAFENIB

Products Affected

- *sorafenib*

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

SOTORASIB

Products Affected

- LUMAKRAS ORAL TABLET 120 MG, 320 MG

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

STIRIPENTOL

Products Affected

- DIACOMIT ORAL CAPSULE 250 MG, 500 MG
- DIACOMIT ORAL POWDER IN PACKET 250 MG, 500 MG

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | DRAVET SYNDROME: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

SUNITINIB

Products Affected

- *sunitinib malate*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | GASTROINTESTINAL STROMAL TUMORS (GIST): TRIAL OF OR CONTRAINDICATION TO IMATINIB (GLEEVEC). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TADALAFIL

Products Affected

- *tadalafil oral tablet 2.5 mg, 5 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | ERECTILE DYSFUNCTION WITHOUT DIAGNOSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH). |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | BPH: 1) TRIAL OF ONE ALPHA BLOCKER (E.G., DOXAZOSIN, TERAZOSIN, TAMSULOSIN, ALFUZOSIN), AND 2) TRIAL OF ONE 5-ALPHA-REDUCTASE INHIBITOR (E.G., FINASTERIDE, DUTASTERIDE). APPLIES TO 2.5MG AND 5MG STRENGTHS ONLY. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TAFAMIDIS

Products Affected

- VYNDAMAX

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TALAZOPARIB

Products Affected

- TALZENNA

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | NONE |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TASIMELTEON

Products Affected

- HETLIOZ LQ
- *tasimelteon*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | LIFETIME |
| Other Criteria | NON-24 HOUR SLEEP-WAKE DISORDER: PATIENT IS LIGHT-INSENSITIVE OR HAS TOTAL BLINDNESS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TAZEMETOSTAT

Products Affected

- TAZVERIK

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TEDUGLUTIDE

Products Affected

- GATTEX 30-VIAL

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | SHORT BOWEL SYNDROME (SBS): INITIAL/RENEWAL: PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST |
| Coverage Duration | INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS |
| Other Criteria | SBS: INITIAL: PATIENT IS DEPENDENT ON INTRAVENOUS PARENTERAL NUTRITION DEFINED AS REQUIRING PARENTERAL NUTRITION AT LEAST THREE TIMES PER WEEK. RENEWAL: ACHIEVED OR MAINTAINED A DECREASED NEED FOR PARENTERAL SUPPORT COMPARED TO BASELINE. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TELOTRISTAT

Products Affected

- XERMELO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | CARCINOID SYNDROME DIARRHEA: PRESCRIBED BY OR IN CONSULTATION WITH AN ONCOLOGIST OR GASTROENTEROLOGIST |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TEPOTINIB

Products Affected

- TEPMETKO

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TERIFLUNOMIDE

Products Affected

- *teriflunomide*

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TESAMORELIN

Products Affected

- EGRIFTA SV

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 3 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TETRABENAZINE

Products Affected

- *tetrabenazine*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | HUNTINGTONS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR MOVEMENT DISORDER SPECIALIST |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TEZACAFTOR/IVACAFTOR

Products Affected

- SYMDEKO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | CYSTIC FIBROSIS (CF): INITIAL: CONFIRMED MUTATION IN CFTR GENE ACCEPTABLE FOR THE TREATMENT OF CYSTIC FIBROSIS. |
| Age Restrictions | |
| Prescriber Restrictions | CF: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CYSTIC FIBROSIS EXPERT |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: LIFETIME |
| Other Criteria | CF: RENEWAL: MAINTAINED, IMPROVED, OR DEMONSTRATED LESS THAN EXPECTED DECLINE IN FEV1 OR BODY MASS INDEX (BMI), OR REDUCTION IN NUMBER OF PULMONARY EXACERBATIONS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

THALIDOMIDE

Products Affected

- THALOMID

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TIVOZANIB

Products Affected

- FOTIVDA

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TOFACITINIB

Products Affected

- XELJANZ
- XELJANZ XR

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS), POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS (PCJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF A PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. PSA, PCJIA: TRIAL OF OR CONTRAINDICATION TO ONE DMARD. AS: TRIAL OF OR CONTRAINDICATION TO AN NSAID. UC: TRIAL OF OR CONTRAINDICATION TO ONE CONVENTIONAL THERAPY SUCH AS A CORTICOSTEROID (E.G., BUDESONIDE, METHYLPREDNISOLONE), AZATHIOPRINE, MERCAPTOPYRINE, METHOTREXATE, OR MESALAMINE. RENEWAL: RA, PSA, AS, PCJIA: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications | All FDA-approved Indications. |

| PA Criteria | Criteria Details |
|----------------------------|-------------------------|
| Off Label Uses | |
| Part B Prerequisite | No |

TOPICAL TRETINOIN

Products Affected

- *tretinoin topical cream 0.025 %, 0.05 %, 0.1 %*
- *tretinoin topical gel*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | COSMETIC INDICATIONS SUCH AS WRINKLES, PHOTOAGING, MELASMA. |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TRAMETINIB

Products Affected

- MEKINIST ORAL TABLET 0.5 MG, 2 MG

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TRIENTINE

Products Affected

- *trientine oral capsule 250 mg, 500 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | WILSONS DISEASE: INITIAL: KNOWN FAMILY HISTORY OF WILSONS DISEASE OR PHYSICAL EXAMINATION CONSISTENT WITH WILSONS DISEASE. CONFIRMATION OF ONE OF THE FOLLOWING: 1) PLASMA COPPER-PROTEIN CERULOPLASMIN LESS THAN 20 MG/DL, 2) LIVER BIOPSY POSITIVE FOR AN ABNORMALLY HIGH CONCENTRATION OF COPPER (GREATER THAN 250 MCG/G DRY WEIGHT) OR THE PRESENCE OF KAYSER-FLEISCHER RINGS, OR 3) CONFIRMATION BY GENETIC TESTING FOR ATP7B MUTATIONS. |
| Age Restrictions | |
| Prescriber Restrictions | WILSONS DISEASE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEPATOLOGIST OR GASTROENTEROLOGIST. |
| Coverage Duration | INITIAL: 12 MONTHS, RENEWAL: LIFETIME. |
| Other Criteria | WILSONS DISEASE: INITIAL: TRIAL OF OR CONTRAINDICATION TO FORMULARY VERSION OF PENICILLAMINE (DEPEN). RENEWAL: PATIENT CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TRIFLURIDINE/TIPIRACIL

Products Affected

- LONSURF ORAL TABLET 15-6.14 MG,
20-8.19 MG

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TRIPTORELIN-TRELSTAR

Products Affected

- TRELSTAR INTRAMUSCULAR
SUSPENSION FOR RECONSTITUTION

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS. |
| Other Criteria | THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TRUQAP

Products Affected

- TRUQAP

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | None |
| Required Medical Information | Diagnosis of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with 1 or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test and, A.) patient has had disease progression following 1 or more endocrine-based regimen(s) in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy, and B.) will be used in combination with fulvestrant injection. |
| Age Restrictions | 18 years of age and older |
| Prescriber Restrictions | Prescribed by or in consultation with an oncologist or hematologist |
| Coverage Duration | 12 months |
| Other Criteria | None |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TUCATINIB

Products Affected

- TUKYSA ORAL TABLET 150 MG, 50 MG

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

UBROGEPANT

Products Affected

- UBRELVY

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | ACUTE MIGRAINE TREATMENT: INITIAL: TRIAL OF OR CONTRAINDICATION TO ONE TRIPTAN (E.G., SUMATRIPTAN, RIZATRIPTAN). RENEWAL: 1) IMPROVEMENT FROM BASELINE IN A VALIDATED ACUTE TREATMENT PATIENT-REPORTED OUTCOME QUESTIONNAIRE, OR 2) THERAPY WORKS CONSISTENTLY IN MAJORITY OF MIGRAINE ATTACKS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

UPADACITINIB

Products Affected

- RINVOQ

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI). |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: RA, AS, NR-AXSPA: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSA: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. AD: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST, ALLERGIST, OR IMMUNOLOGIST. UC: PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |

| PA Criteria | Criteria Details |
|----------------------------|---|
| Other Criteria | <p>INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF A PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. PSA: TRIAL OF OR CONTRAINDICATION TO ONE DMARD. ATOPIC DERMATITIS: 1) ATOPIC DERMATITIS COVERING AT LEAST 10 PERCENT OF BODY SURFACE AREA OR ATOPIC DERMATITIS AFFECTING THE FACE, HEAD, NECK, HANDS, FEET, GROIN, OR INTERTRIGINOUS AREAS, 2) INTRACTABLE PRURITUS OR CRACKING/OOZING/BLEEDING OF AFFECTED SKIN, 3) TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING: TOPICAL CORTICOSTEROID, TOPICAL CALCINEURIN INHIBITOR, TOPICAL PDE4 INHIBITOR, OR TOPICAL JAK INHIBITOR, AND 4) NO CONCURRENT USE WITH OTHER SYSTEMIC BIOLOGIC/JAK INHIBITOR FOR THE TREATMENT OF ATOPIC DERMATITIS. UC: TRIAL OF OR CONTRAINDICATION TO ONE CONVENTIONAL THERAPY SUCH AS A CORTICOSTEROID (E.G., BUDESONIDE, METHYLPREDNISOLONE), AZATHIOPRINE, MERCAPTOPYRINE, METHOTREXATE, OR MESALAMINE. NR-AXSPA: TRIAL OF OR CONTRAINDICATION TO AN NSAID (NON-STEROIDAL ANTI-INFLAMMATORY DRUG). RENEWAL: RA, PSA, AS, NR-AXSPA: CONTINUES TO BENEFIT FROM THE MEDICATION. ATOPIC DERMATITIS: 1) IMPROVEMENT WHILE ON THERAPY, AND 2) NO CONCURRENT USE WITH OTHER SYSTEMIC BIOLOGIC/JAK INHIBITOR FOR THE TREATMENT OF ATOPIC DERMATITIS.</p> |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

USTEKINUMAB

Products Affected

- STELARA SUBCUTANEOUS

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, OR FACE. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: PSA: TRIAL OF OR CONTRAINDICATION TO ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG). PSO: TRIAL OF OR CONTRAINDICATION TO ONE CONVENTIONAL THERAPY SUCH AS A PUVA (PHOTOTHERAPY ULTRAVIOLET LIGHT A), UVB (ULTRAVIOLET LIGHT B), TOPICAL CORTICOSTEROIDS, CALCIPOTRIENE, ACITRETIN, METHOTREXATE, OR CYCLOSPORINE. CD, UC: TRIAL OF OR CONTRAINDICATION TO ONE CONVENTIONAL THERAPY SUCH AS A CORTICOSTEROID (E.G., BUDESONIDE, METHYLPREDNISOLONE), AZATHIOPRINE, MERCAPTOPYRINE, METHOTREXATE, OR MESALAMINE. RENEWAL: PSA, PSO: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Part B Prerequisite | No |

VALBENZAZINE

Products Affected

- INGREZZA
- INGREZZA INITIATION PK(TARDIV)

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | TARDIVE DYSKINESIA (TD): PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, PSYCHIATRIST, OR MOVEMENT DISORDER SPECIALIST. |
| Coverage Duration | 12 MONTHS |
| Other Criteria | TD: 1) PRIOR HISTORY OF USING AGENTS THAT CAUSE TARDIVE DYSKINESIA, AND 2) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT: AUSTEDO. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

VANDETANIB

Products Affected

- CAPRELSA ORAL TABLET 100 MG, 300 MG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | CURRENTLY STABLE ON CAPRELSA REQUIRES NO EXTRA CRITERIA. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

VANFLYTA

Products Affected

- VANFLYTA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | None |
| Required Medical Information | Patient must have all of the following A.) Newly diagnosed acute myeloid leukemia with FLT3-ITD mutation, B.) Used in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, and C.) Must be enrolled in the VANFLYTA REMS program |
| Age Restrictions | 18 years of age and older |
| Prescriber Restrictions | Prescribed by or in consultation with an oncologist or hematologist |
| Coverage Duration | 12 months |
| Other Criteria | None |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

VEMURAFENIB

Products Affected

- ZELBORAF

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | MELANOMA: ZELBORAF WILL BE USED ALONE OR IN COMBINATION WITH COTELLIC |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

VENETOCLAX

Products Affected

- VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG
- VENCLEXTA STARTING PACK

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

VERQUVO

Products Affected

- VERQUVO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Any of the following A.) Concomitant use of other soluble guanylate cyclase (sGC) stimulators, or B.) Pregnancy |
| Required Medical Information | Diagnosis of chronic heart failure (HF), NYHA Class II to IV and all of the following 1.) Left ventricular ejection fraction less than 45%, 2.) Previous hospitalization for HF within 6 months or outpatient IV diuretic treatment for HF within 3 months |
| Age Restrictions | 18 years of age and older |
| Prescriber Restrictions | Prescribed by or in consultation with a cardiologist |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

VIGABATRIN

Products Affected

- *vigabatin*
- *vigadrone*
- VIGAFYDE
- *vigpoder*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | REFRACTORY COMPLEX PARTIAL SEIZURES (CPS), INFANTILE SPASMS: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST. |
| Coverage Duration | 12 MONTHS |
| Other Criteria | CPS: 1) TRIAL OF OR CONTRAINDICATION TO TWO ANTIEPILEPTIC AGENTS AND 2) BENEFITS OUTWEIGH THE POTENTIAL FOR VISION LOSS. INFANTILE SPASMS: BENEFITS OUTWEIGH THE POTENTIAL FOR VISION LOSS. |
| Indications | Some FDA-approved Indications Only. |
| Off Label Uses | |
| Part B Prerequisite | No |

VISMODEGIB

Products Affected

- ERIVEDGE

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

VORICONAZOLE SUSPENSION

Products Affected

- *voriconazole oral suspension for reconstitution*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | CANDIDA INFECTIONS: 3 MOS. ALL OTHER INDICATIONS: 6 MOS. |
| Other Criteria | CANDIDA INFECTIONS: TRIAL OF OR CONTRAINDICATION TO FLUCONAZOLE. ALL INDICATIONS: INABILITY TO SWALLOW TABLETS OR AN INDICATION FOR ESOPHAGEAL CANDIDIASIS. CONTINUATION OF THERAPY AFTER HOSPITAL DISCHARGE REQUIRES NO EXTRA CRITERIA. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ZANUBRUTINIB

Products Affected

- BRUKINSA

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ZURZUVAE

Products Affected

- ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------------|
| Exclusion Criteria | None |
| Required Medical Information | Diagnosis of postpartum depression |
| Age Restrictions | 18 years of age and older |
| Prescriber Restrictions | None |
| Coverage Duration | 14 days |
| Other Criteria | None |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

INDEX

| | | | |
|---------------------------------------|-----|-------------------------------------|-----|
| 1ST TIER UNIFINE PENTP 5MM 31G... | 125 | ALUNBRIG ORAL TABLETS,DOSE | |
| 1ST TIER UNIFINE PNTIP 4MM 32G..... | 125 | PACK..... | 42 |
| 1ST TIER UNIFINE PNTIP 6MM 31G..... | 125 | <i>alyq</i> | 195 |
| 1ST TIER UNIFINE PNTIP 8MM 31G | | <i>ambrisentan</i> | 14 |
| STRL,SINGLE-USE,SHRT..... | 125 | <i>apomorphine</i> | 17 |
| 1ST TIER UNIFINE PNTIP 29GX1/2"..... | 125 | AQINJECT PEN NEEDLE 31G 5MM..... | 125 |
| 1ST TIER UNIFINE PNTIP 31GX3/16..... | 125 | AQINJECT PEN NEEDLE 32G 4MM..... | 125 |
| 1ST TIER UNIFINE PNTIP 32GX5/32..... | 125 | <i>armodafinil</i> | 174 |
| <i>abiraterone</i> | 4 | ASSURE ID DUO PRO NDL 31G 5MM.. | 125 |
| ABOUTTIME PEN NEEDLE 30G X | | ASSURE ID DUO-SHIELD 30GX3/16" ... | 125 |
| 8MM..... | 125 | ASSURE ID DUO-SHIELD 30GX5/16" ... | 125 |
| ABOUTTIME PEN NEEDLE 31G X | | ASSURE ID INSULIN SAFETY | |
| 5MM..... | 125 | SYRINGE 1 ML 29 GAUGE X 1/2"..... | 125 |
| ABOUTTIME PEN NEEDLE 31G X | | ASSURE ID PEN NEEDLE 30GX3/16" ... | 125 |
| 8MM..... | 125 | ASSURE ID PEN NEEDLE 30GX5/16" ... | 125 |
| ABOUTTIME PEN NEEDLE 32G X | | ASSURE ID PEN NEEDLE 31GX3/16" ... | 125 |
| 4MM..... | 125 | ASSURE ID PRO PEN NDL 30G 5MM... | 125 |
| ACTHAR..... | 57 | ASSURE ID SYR 0.5 ML 29GX1/2" (RX) | |
| ACTHAR SELFJECT..... | 57 | | 125 |
| ACTIMMUNE..... | 136 | ASSURE ID SYR 0.5 ML 31GX15/64".... | 125 |
| ADEMPAS..... | 220 | ASSURE ID SYR 1 ML 31GX15/64"..... | 125 |
| ADVOCATE INS 0.3 ML 30GX5/16"..... | 125 | AUGTYRO ORAL CAPSULE 40 MG..... | 22 |
| ADVOCATE INS 0.3 ML 31GX5/16"..... | 125 | AUSTEDO ORAL TABLET 12 MG, 6 | |
| ADVOCATE INS 0.5 ML 30GX5/16"..... | 125 | MG, 9 MG..... | 71 |
| ADVOCATE INS 0.5 ML 31GX5/16"..... | 125 | AUSTEDO XR ORAL TABLET | |
| ADVOCATE INS 1 ML 31GX5/16"..... | 125 | EXTENDED RELEASE 24 HR 12 MG, 18 | |
| ADVOCATE INS SYR 0.3 ML 29GX1/2. 125 | | MG, 24 MG, 30 MG, 36 MG, 42 MG, 48 | |
| ADVOCATE INS SYR 0.5 ML 29GX1/2. 125 | | MG, 6 MG..... | 71 |
| ADVOCATE INS SYR 1 ML 29GX1/2" .. 125 | | AUSTEDO XR TITRATION KT(WK1-4).. | 71 |
| ADVOCATE INS SYR 1 ML 30GX5/16.. 125 | | AVONEX INTRAMUSCULAR PEN | |
| ADVOCATE PEN NDL 12.7MM 29G..... | 125 | INJECTOR KIT..... | 134 |
| ADVOCATE PEN NEEDLE 32G 4MM... 125 | | AVONEX INTRAMUSCULAR | |
| ADVOCATE PEN NEEDLE 4MM 33G... 125 | | SYRINGE KIT..... | 134 |
| ADVOCATE PEN NEEDLES 5MM 31G. 125 | | AVONEX PEN 30 MCG/0.5 ML..... | 134 |
| ADVOCATE PEN NEEDLES 8MM 31G. 125 | | AYVAKIT..... | 24 |
| AJOVY AUTOINJECTOR..... | 107 | BALVERSA ORAL TABLET 3 MG, 4 | |
| AJOVY SYRINGE..... | 107 | MG, 5 MG..... | 94 |
| AKEEGA..... | 11 | BD AUTOSHIELD DUO NDL | |
| ALCOHOL 70% SWABS..... | 125 | 5MMX30G..... | 125 |
| ALCOHOL PADS..... | 125 | BD ECLIPSE 30GX1/2" SYRINGE..... | 125 |
| ALCOHOL PREP SWABS..... | 125 | BD ECLIPSE NEEDLE 30GX1/2" (OTC) | 125 |
| ALECENSA..... | 12 | BD INS SYR 0.3 ML 8MMX31G(1/2)..... | 125 |
| ALUNBRIG ORAL TABLET 180 MG, 30 | | BD INS SYRINGE 1/2 ML 6MMX31G | |
| MG, 90 MG..... | 42 | (ONLY FOR 500 UNIT/ML INSULIN).... | 125 |

| | | | |
|--|-----|---|-----|
| BD INS SYRN UF 1 ML 12.7MMX30G NOT FOR RETAIL SALE..... | 125 | BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG..... | 41 |
| BD INSULIN SYR 1 ML 25GX1"..... | 125 | BRAFTOVI..... | 89 |
| BD INSULIN SYR 1 ML 25GX5/8"..... | 125 | BRONCHITOL..... | 43 |
| BD INSULIN SYR 1 ML 26GX1/2"..... | 125 | BRUKINSA..... | 286 |
| BD INSULIN SYR 1 ML 27GX12.7MM.. | 125 | CABLIVI INJECTION KIT..... | 48 |
| BD INSULIN SYR 1 ML 27GX5/8" MICRO-FINE..... | 125 | CABOMETYX ORAL TABLET 20 MG, 40 MG, 60 MG..... | 46 |
| BD INSULIN SYRINGE 1 ML W/O NEEDLE..... | 125 | CALQUENCE..... | 6 |
| BD LUER-LOK SYRINGE 1 ML..... | 125 | CALQUENCE (ACALABRUTINIB MAL)..... | 6 |
| BD NANO 2 GEN PEN NDL 32G 4MM.. | 125 | CAPRELSA ORAL TABLET 100 MG, 300 MG..... | 278 |
| BD SAFETGLD INS 0.3 ML 29G 13MM. | 125 | CAREFINE PEN NEEDLE 12.7MM 29G. | 125 |
| BD SAFETGLD INS 0.5 ML 13MMX29G | 125 | CAREFINE PEN NEEDLE 4MM 32G..... | 125 |
| BD SAFETYGLD INS 0.3 ML 31G 8MM | 125 | CAREFINE PEN NEEDLE 5MM 32G..... | 125 |
| BD SAFETYGLD INS 0.5 ML 30G 8MM | 125 | CAREFINE PEN NEEDLE 6MM 31G..... | 125 |
| BD SAFETYGLD INS 1 ML 29G 13MM. | 125 | CAREFINE PEN NEEDLE 8MM 30G..... | 125 |
| BD SAFETYGLID INS 1 ML 6MMX31G | 125 | CAREFINE PEN NEEDLES 6MM 32G... | 125 |
| BD SAFETYGLIDE SYRINGE 27GX5/8 | 125 | CAREFINE PEN NEEDLES 8MM 31G... | 125 |
| BD SAFTYGLD INS 0.3 ML 6MMX31G | 125 | CARETOUCH ALCOHOL 70% PREP PAD..... | 125 |
| BD SAFTYGLD INS 0.5 ML 29G 13MM | 125 | CARETOUCH PEN NEEDLE 29G 12MM | 125 |
| BD SAFTYGLD INS 0.5 ML 6MMX31G | 125 | CARETOUCH PEN NEEDLE 31GX1/4". | 125 |
| BD SINGLE USE SWAB..... | 125 | CARETOUCH PEN NEEDLE 31GX3/16" | 125 |
| BD UF MICRO PEN NEEDLE 6MMX32G..... | 125 | CARETOUCH PEN NEEDLE 31GX5/16" | 125 |
| BD UF MINI PEN NEEDLE 5MMX31G. | 125 | CARETOUCH PEN NEEDLE 32GX3/16" | 125 |
| BD UF NANO PEN NEEDLE 4MMX32G | 125 | CARETOUCH PEN NEEDLE 32GX5/32" | 125 |
| BD UF ORIG PEN NDL 12.7MMX29G... | 125 | CARETOUCH SYR 0.3 ML 31GX5/16" .. | 125 |
| BD UF SHORT PEN NEEDLE 8MMX31G..... | 125 | CARETOUCH SYR 0.5 ML 30GX5/16" .. | 125 |
| BD VEO INS 0.3 ML 6MMX31G (1/2).... | 125 | CARETOUCH SYR 0.5 ML 31GX5/16" .. | 125 |
| BD VEO INS SYRING 1 ML 6MMX31G | 125 | CARETOUCH SYR 1 ML 28GX5/16" .. | 125 |
| BD VEO INS SYRN 0.3 ML 6MMX31G. | 125 | CARETOUCH SYR 1 ML 29GX5/16" .. | 125 |
| BD VEO INS SYRN 0.5 ML 6MMX31G. | 125 | CARETOUCH SYR 1 ML 30GX5/16" .. | 125 |
| BENLYSTA SUBCUTANEOUS..... | 31 | CARETOUCH SYR 1 ML 31GX5/16" .. | 125 |
| BESREMI..... | 225 | <i>carglumic acid</i> | 50 |
| <i>betaine</i> | 36 | CAYSTON..... | 28 |
| BETASERON SUBCUTANEOUS KIT | 135 | CERDELGA..... | 86 |
| <i>bexarotene oral</i> | 37 | CIMZIA SUBCUTANEOUS SYRINGE KIT 400 MG/2 ML (200 MG/ML X 2)..... | 52 |
| <i>bexarotene topical</i> | 37 | CLICKFINE 31G X 5/16" NEEDLES 8MM, UNIVERSAL..... | 125 |
| BORDERED GAUZE 2"X2"..... | 125 | | |
| <i>bosentan</i> | 39 | | |
| BOSULIF ORAL CAPSULE 100 MG, 50 MG..... | 41 | | |

| | | | |
|---|-----|--|-----|
| CLICKFINE PEN NEEDLE 32GX5/32" 32GX4MM, STERILE..... | 125 | COMFORT EZ SYR 0.5 ML 28GX1/2" | 125 |
| CLICKFINE UNIVERSAL 31G X 1/4" 6MM, STORE BRAND..... | 125 | COMFORT EZ SYR 0.5 ML 29GX1/2" | 125 |
| COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1), 140 MG/DAY(80 MG X1-20 MG X3), 60 MG/DAY (20 MG X 3/DAY)..... | 45 | COMFORT EZ SYR 0.5 ML 30GX1/2" | 125 |
| COMFORT EZ 0.3 ML 31G 15/64" | 125 | COMFORT EZ SYR 1 ML 28GX1/2" | 125 |
| COMFORT EZ 0.5 ML 31G 15/64" | 125 | COMFORT EZ SYR 1 ML 29GX1/2" | 125 |
| COMFORT EZ INS 0.3 ML 30GX1/2" | 125 | COMFORT EZ SYR 1 ML 30GX1/2" | 125 |
| COMFORT EZ INS 0.3 ML 30GX5/16" ... | 125 | COMFORT EZ SYR 1 ML 30GX5/16" | 125 |
| COMFORT EZ INS 1 ML 31G 15/64" | 125 | COMFORT POINT PEN NDL 31GX1/3" . | 125 |
| COMFORT EZ INS 1 ML 31GX5/16" | 125 | COMFORT POINT PEN NDL 31GX1/6" . | 125 |
| COMFORT EZ INSULIN SYR 0.3 ML.... | 125 | COMFORT TOUCH PEN NDL 31G 4MM | 125 |
| COMFORT EZ INSULIN SYR 0.5 ML.... | 125 | COMFORT TOUCH PEN NDL 31G 5MM | 125 |
| COMFORT EZ PEN NEEDLE 12MM 29G..... | 125 | COMFORT TOUCH PEN NDL 31G 6MM | 125 |
| COMFORT EZ PEN NEEDLES 4MM 32G SINGLE USE, MICRO..... | 125 | COMFORT TOUCH PEN NDL 31G 8MM | 125 |
| COMFORT EZ PEN NEEDLES 4MM 33G..... | 125 | COMFORT TOUCH PEN NDL 32G 4MM | 125 |
| COMFORT EZ PEN NEEDLES 5MM 31G MINI..... | 125 | COMFORT TOUCH PEN NDL 32G 5MM | 125 |
| COMFORT EZ PEN NEEDLES 5MM 32G SINGLE USE,MINI,HRI..... | 125 | COMFORT TOUCH PEN NDL 32G 6MM | 125 |
| COMFORT EZ PEN NEEDLES 5MM 33G..... | 125 | COMFORT TOUCH PEN NDL 32G 8MM | 125 |
| COMFORT EZ PEN NEEDLES 6MM 31G..... | 125 | COMFORT TOUCH PEN NDL 33G 4MM | 125 |
| COMFORT EZ PEN NEEDLES 6MM 32G..... | 125 | COMFORT TOUCH PEN NDL 33G 6MM | 125 |
| COMFORT EZ PEN NEEDLES 6MM 33G..... | 125 | COMFORT TOUCH PEN NDL 33GX5MM..... | 125 |
| COMFORT EZ PEN NEEDLES 8MM 31G SHORT..... | 125 | COPIKTRA..... | 79 |
| COMFORT EZ PEN NEEDLES 8MM 32G..... | 125 | COSENTYX (2 SYRINGES)..... | 230 |
| COMFORT EZ PEN NEEDLES 8MM 33G..... | 125 | COSENTYX PEN (2 PENS)..... | 230 |
| COMFORT EZ PRO PEN NDL 30G 8MM | 125 | COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML..... | 230 |
| COMFORT EZ PRO PEN NDL 31G 4MM | 125 | COSENTYX UNOREADY PEN | 230 |
| COMFORT EZ PRO PEN NDL 31G 5MM | 125 | COTELLIC..... | 56 |
| COMFORT EZ SYR 0.3 ML 29GX1/2" | 125 | CURAD GAUZE PADS 2" X 2" | 125 |
| | | CURITY ALCOHOL PREPS 2 PLY,MEDIUM..... | 125 |
| | | CURITY GAUZE SPONGES (12 PLY)- 200/BAG..... | 125 |
| | | CURITY GUAZE PADS 1'S(12 PLY)..... | 125 |
| | | CYSTARAN..... | 59 |
| | | <i>dalfampridine</i> | 62 |

| | | | |
|--|-----|--|-----|
| DAURISMO ORAL TABLET 100 MG, 25 MG..... | 114 | DROPLET PEN NEEDLE 30GX5/16"..... | 125 |
| <i>deferasirox</i> | 67 | DROPLET PEN NEEDLE 31GX1/4"..... | 125 |
| <i>deferiprone</i> | 69 | DROPLET PEN NEEDLE 31GX3/16"..... | 125 |
| DERMACEA 2"X2" GAUZE 12 PLY, USP TYPE VII..... | 125 | DROPLET PEN NEEDLE 31GX5/16"..... | 125 |
| DERMACEA GAUZE 2"X2" SPONGE 8 PLY..... | 125 | DROPLET PEN NEEDLE 32GX1/4"..... | 125 |
| DERMACEA NON-WOVEN 2"X2" SPNGE..... | 125 | DROPLET PEN NEEDLE 32GX3/16"..... | 125 |
| DIACOMIT ORAL CAPSULE 250 MG, 500 MG..... | 247 | DROPLET PEN NEEDLE 32GX5/16"..... | 125 |
| DIACOMIT ORAL POWDER IN PACKET 250 MG, 500 MG..... | 247 | DROPLET PEN NEEDLE 32GX5/32"..... | 125 |
| <i>diclofenac sodium topical gel 3 %</i> | 72 | DROPSAFE ALCOHOL 70% PREP PADS..... | 125 |
| <i>diclofenac sodium topical solution in metered-dose pump</i> | 73 | DROPSAFE INS SYR 0.3 ML 31G 6MM | 125 |
| <i>dimethyl fumarate oral capsule, delayed release(dr/ec) 120 mg, 120 mg (14)- 240 mg (46), 240 mg</i> | 74 | DROPSAFE INS SYR 0.3 ML 31G 8MM | 125 |
| DOPTELET (10 TAB PACK)..... | 25 | DROPSAFE INS SYR 0.5 ML 31G 6MM | 125 |
| DOPTELET (15 TAB PACK)..... | 25 | DROPSAFE INS SYR 0.5 ML 31G 8MM | 125 |
| DOPTELET (30 TAB PACK)..... | 25 | DROPSAFE INSUL SYR 1 ML 31G 6MM..... | 125 |
| <i>dronabinol</i> | 76 | DROPSAFE INSUL SYR 1 ML 31G 8MM..... | 125 |
| DROPLET 0.5 ML 29GX12.5MM(1/2)..... | 125 | DROPSAFE INSULN 1 ML 29G 12.5MM..... | 125 |
| DROPLET 0.5 ML 30GX12.5MM(1/2)..... | 125 | | 125 |
| DROPLET INS 0.3 ML 29GX12.5MM..... | 125 | DROPSAFE PEN NEEDLE 31GX1/4"..... | 125 |
| DROPLET INS 0.3 ML 30GX12.5MM..... | 125 | DROPSAFE PEN NEEDLE 31GX3/16"..... | 125 |
| DROPLET INS 0.5 ML 30GX6MM(1/2)..... | 125 | DROPSAFE PEN NEEDLE 31GX5/16"..... | 125 |
| DROPLET INS 0.5 ML 30GX8MM(1/2)..... | 125 | <i>droxidopa</i> | 77 |
| DROPLET INS 0.5 ML 31GX6MM(1/2)..... | 125 | DRUG MART ULTRA COMFORT SYR. | 125 |
| DROPLET INS 0.5 ML 31GX8MM(1/2)..... | 125 | DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML, 300 MG/2 ML..... | 78 |
| DROPLET INS SYR 0.3 ML 30GX6MM..... | 125 | DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 100 MG/0.67 ML, 200 MG/1.14 ML, 300 MG/2 ML..... | 78 |
| DROPLET INS SYR 0.3 ML 30GX8MM..... | 125 | EASY CMFT SFTY PEN NDL 31G 5MM | 125 |
| DROPLET INS SYR 0.3 ML 31GX6MM..... | 125 | EASY CMFT SFTY PEN NDL 31G 6MM | 125 |
| DROPLET INS SYR 0.3 ML 31GX8MM..... | 125 | EASY CMFT SFTY PEN NDL 32G 4MM | 125 |
| DROPLET INS SYR 1 ML 29GX12.5MM..... | 125 | EASY COMFORT 0.3 ML 31G 1/2"..... | 125 |
| | 125 | EASY COMFORT 0.3 ML 31G 5/16"..... | 125 |
| DROPLET INS SYR 1 ML 30GX12.5MM..... | 125 | EASY COMFORT 0.3 ML SYRINGE..... | 125 |
| | 125 | EASY COMFORT 0.5 ML 30GX1/2"..... | 125 |
| DROPLET INS SYR 1 ML 30GX6MM..... | 125 | EASY COMFORT 0.5 ML 31GX5/16"..... | 125 |
| DROPLET INS SYR 1 ML 30GX8MM..... | 125 | EASY COMFORT 0.5 ML 32GX5/16"..... | 125 |
| DROPLET INS SYR 1 ML 31GX6MM..... | 125 | EASY COMFORT 0.5 ML SYRINGE..... | 125 |
| DROPLET INS SYR 1 ML 31GX8MM..... | 125 | EASY COMFORT 1 ML 31GX5/16"..... | 125 |
| DROPLET MICRON 34G X 9/64"..... | 125 | EASY COMFORT 1 ML 32GX5/16"..... | 125 |
| DROPLET PEN NEEDLE 29GX1/2"..... | 125 | EASY COMFORT ALCOHOL 70% PAD | 125 |
| DROPLET PEN NEEDLE 29GX3/8"..... | 125 | EASY COMFORT INSULIN 1 ML SYR.. | 125 |
| | | EASY COMFORT PEN NDL 31GX1/4"..... | 125 |

| | | | |
|-------------------------------------|-----|-----------------------------------|-----|
| EASY COMFORT PEN NDL 31GX3/16" | 125 | EASY TOUCH SAF PEN NDL 30G 5MM | |
| EASY COMFORT PEN NDL 31GX5/16" | 125 | | 125 |
| EASY COMFORT PEN NDL 32GX5/32" | 125 | EASY TOUCH SAF PEN NDL 30G 8MM | |
| EASY COMFORT PEN NDL 33G 4MM.. | 125 | | 125 |
| EASY COMFORT PEN NDL 33G 5MM.. | 125 | EASY TOUCH SYR 0.5 ML 28G | |
| EASY COMFORT PEN NDL 33G 6MM.. | 125 | 12.7MM..... | 125 |
| EASY COMFORT SYR 1 ML 30GX1/2" | 125 | EASY TOUCH SYR 0.5 ML 29G | |
| EASY GLIDE INS 0.3 ML 31GX6MM.... | 125 | 12.7MM..... | 125 |
| EASY GLIDE INS 0.5 ML 31GX6MM.... | 125 | EASY TOUCH SYR 1 ML 27G 16MM.... | 125 |
| EASY GLIDE INS 1 ML 31GX6MM..... | 125 | EASY TOUCH SYR 1 ML 28G 12.7MM. | 125 |
| EASY GLIDE PEN NEEDLE 4MM 33G.. | 125 | EASY TOUCH SYR 1 ML 29G 12.7MM. | 125 |
| EASY TOUCH 0.3 ML SYR 30GX1/2" | 125 | EASY TOUCH UNI-SLIP SYR 1 ML..... | 125 |
| EASY TOUCH 0.5 ML SYR 27GX1/2" | 125 | EASYTOUCH SAF PEN NDL 30G 6MM | 125 |
| EASY TOUCH 0.5 ML SYR 29GX1/2" | 125 | EGRIFTA SV | 258 |
| EASY TOUCH 0.5 ML SYR 30GX1/2" | 125 | ELIGARD..... | 152 |
| EASY TOUCH 0.5 ML SYR 30GX5/16... | 125 | ELIGARD (3 MONTH)..... | 152 |
| EASY TOUCH 1 ML SYR 27GX1/2" | 125 | ELIGARD (4 MONTH)..... | 152 |
| EASY TOUCH 1 ML SYR 29GX1/2" | 125 | ELIGARD (6 MONTH)..... | 152 |
| EASY TOUCH 1 ML SYR 30GX1/2" | 125 | EMBRACE PEN NEEDLE 29G 12MM.... | 125 |
| EASY TOUCH ALCOHOL 70% PADS | | EMBRACE PEN NEEDLE 30G 5MM..... | 125 |
| GAMMA-STERILIZED..... | 125 | EMBRACE PEN NEEDLE 30G 8MM..... | 125 |
| EASY TOUCH FLIPIK 1 ML 27GX0.5 | 125 | EMBRACE PEN NEEDLE 31G 5MM..... | 125 |
| EASY TOUCH INSULIN 1 ML 29GX1/2 | 125 | EMBRACE PEN NEEDLE 31G 6MM..... | 125 |
| EASY TOUCH INSULIN 1 ML 30GX1/2 | 125 | EMBRACE PEN NEEDLE 31G 8MM..... | 125 |
| EASY TOUCH INSULIN SYR 0.3 ML.... | 125 | EMBRACE PEN NEEDLE 32G 4MM..... | 125 |
| EASY TOUCH INSULIN SYR 0.5 ML.... | 125 | EMGALITY PEN..... | 110 |
| EASY TOUCH INSULIN SYR 1 ML..... | 125 | EMGALITY SYRINGE | |
| EASY TOUCH INSULIN SYR 1 ML | | SUBCUTANEOUS SYRINGE 120 | |
| RETRACTABLE..... | 125 | MG/ML, 300 MG/3 ML (100 MG/ML X | |
| EASY TOUCH INSULN 1 ML 29GX1/2" | 125 | 3)..... | 110 |
| EASY TOUCH INSULN 1 ML 30GX1/2" | 125 | ENBREL MINI..... | 96 |
| EASY TOUCH INSULN 1 ML 30GX5/16 | 125 | ENBREL SUBCUTANEOUS SOLUTION.. | 96 |
| EASY TOUCH INSULN 1 ML 31GX5/16 | 125 | ENBREL SUBCUTANEOUS SYRINGE... | 96 |
| EASY TOUCH LUER LOK INSUL 1 ML | 125 | ENBREL SURECLICK..... | 96 |
| EASY TOUCH PEN NEEDLE 29GX1/2" | 125 | ENDARI..... | 156 |
| EASY TOUCH PEN NEEDLE 30GX5/16 | 125 | EPCLUSA ORAL PELLETS IN PACKET | |
| EASY TOUCH PEN NEEDLE 31GX1/4" | 125 | 150-37.5 MG, 200-50 MG..... | 239 |
| EASY TOUCH PEN NEEDLE 31GX3/16 | 125 | EPCLUSA ORAL TABLET 200-50 MG.. | 239 |
| EASY TOUCH PEN NEEDLE 31GX5/16 | 125 | EPIDIOLEX..... | 47 |
| EASY TOUCH PEN NEEDLE 32GX1/4" | 125 | EQL INSULIN 0.3 ML SYRINGE | |
| EASY TOUCH PEN NEEDLE 32GX3/16 | 125 | SHORT NEEDLE..... | 125 |
| EASY TOUCH PEN NEEDLE 32GX5/32 | 125 | EQL INSULIN 0.5 ML SYRINGE | |
| EASY TOUCH SAF PEN NDL 29G 5MM | | SHORT NEEDLE..... | 125 |
| | 125 | EQL INSULIN 1 ML SYRINGE SHORT | |
| EASY TOUCH SAF PEN NDL 29G 8MM | | NEEDLE..... | 125 |
| | 125 | ERIVEDGE..... | 284 |

| | | | |
|---|-----|--|-----|
| ERLEADA ORAL TABLET 240 MG, 60 MG..... | 16 | GNP ULT C 0.3 ML 29GX1/2" (1/2) 1/2 UNIT..... | 125 |
| <i>erlotinib oral tablet 100 mg, 150 mg, 25 mg.....</i> | 95 | GNP ULTRA COMFORT 0.5 ML SYR.... | 125 |
| <i>everolimus (antineoplastic) oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg.....</i> | 98 | GNP ULTRA COMFORT 1 ML SYRINGE..... | 125 |
| <i>everolimus (antineoplastic) oral tablet for suspension.....</i> | 98 | GNP ULTRA COMFORT 3/10 ML SYR.. | 125 |
| FASENRA..... | 34 | HADLIMA(CF)..... | 8 |
| FASENRA PEN..... | 34 | HADLIMA(CF) PUSH TOUCH..... | 8 |
| <i>fentanyl citrate buccal lozenge on a handle.....</i> | 100 | HAEGARDA SUBCUTANEOUS RECON SOLN 2,000 UNIT, 3,000 UNIT..... | 44 |
| FERRIPROX (2 TIMES A DAY)..... | 69 | HARVONI ORAL PELLETS IN PACKET 33.75-150 MG, 45-200 MG..... | 146 |
| FERRIPROX ORAL SOLUTION..... | 69 | HEALTHWISE INS 0.3 ML 30GX5/16" .. | 125 |
| FIFTY50 INS 0.5 ML 31GX5/16" SHORT NEEDLE (OTC)..... | 125 | HEALTHWISE INS 0.3 ML 31GX5/16" .. | 125 |
| FIFTY50 INS SYR 1 ML 31GX5/16" SHORT NEEDLE (OTC)..... | 125 | HEALTHWISE INS 0.5 ML 30GX5/16" .. | 125 |
| FIFTY50 PEN 31G X 3/16" NEEDLE (OTC)..... | 125 | HEALTHWISE INS 0.5 ML 31GX5/16" .. | 125 |
| <i>fingolimod.....</i> | 105 | HEALTHWISE INS 1 ML 30GX5/16" .. | 125 |
| FIRDAPSE..... | 15 | HEALTHWISE INS 1 ML 31GX5/16" .. | 125 |
| FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 120 MG, 80 MG..... | 106 | HEALTHWISE PEN NEEDLE 31G 5MM | 125 |
| FOTIVDA..... | 262 | HEALTHWISE PEN NEEDLE 31G 8MM | 125 |
| FP INSULIN 1 ML SYRINGE..... | 125 | HEALTHWISE PEN NEEDLE 32G 4MM | 125 |
| FREESTYLE PREC 0.5 ML 30GX5/16.... | 125 | HEALTHY ACCENTS PENTIP 4MM 32G..... | 125 |
| FREESTYLE PREC 0.5 ML 31GX5/16.... | 125 | HEALTHY ACCENTS PENTIP 5MM 31G..... | 125 |
| FREESTYLE PREC 1 ML 30GX5/16" .. | 125 | HEALTHY ACCENTS PENTIP 6MM 31G..... | 125 |
| FREESTYLE PREC 1 ML 31GX5/16" .. | 125 | HEALTHY ACCENTS PENTIP 8MM 31G..... | 125 |
| FRUZAQLA ORAL CAPSULE 1 MG, 5 MG..... | 108 | HEALTHY ACCENTS PENTIP 12MM 29G..... | 125 |
| FULPHILA..... | 199 | HEB INCONTROL ALCOHOL 70% PADS..... | 125 |
| GALAFOLD..... | 169 | HETLIOZ LQ..... | 252 |
| GATTEX 30-VIAL..... | 254 | HUMIRA PEN..... | 8 |
| GAUZE PAD TOPICAL BANDAGE 2 X 2 "..... | 125 | HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML..... | 8 |
| GAVRETO..... | 211 | HUMIRA(CF)..... | 8 |
| <i>gefitinib.....</i> | 112 | HUMIRA(CF) PEN..... | 8 |
| GILENYA ORAL CAPSULE 0.25 MG.... | 105 | HUMIRA(CF) PEN CROHNS-UC-HS..... | 8 |
| GILOTRIF..... | 10 | HUMIRA(CF) PEN PEDIATRIC UC..... | 8 |
| <i>glatiramer subcutaneous syringe 20 mg/ml, 40 mg/ml.....</i> | 115 | HUMIRA(CF) PEN PSOR-UV-ADOL HS... 8 | |
| <i>glatopa subcutaneous syringe 20 mg/ml, 40 mg/ml.....</i> | 115 | IBRANCE..... | 192 |
| <i>glutamine (sickle cell).....</i> | 156 | <i>icatibant.....</i> | 122 |
| | | ICLUSIG..... | 208 |
| | | IDHIFA..... | 88 |
| | | <i>imatinib oral tablet 100 mg, 400 mg.....</i> | 124 |

| | | | |
|---|-----|--|-----|
| IMBRUVICA ORAL CAPSULE 140 MG, 70 MG..... | 121 | INSULIN SYRINGE-NEEDLE U-100 SYRINGE 0.3 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2", 1/2 ML 28 GAUGE..... | 125 |
| IMBRUVICA ORAL SUSPENSION..... | 121 | INSUPEN 30G ULTRAFIN NEEDLE..... | 125 |
| IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG..... | 121 | INSUPEN 31G ULTRAFIN NEEDLE..... | 125 |
| IMPAVIDO..... | 171 | INSUPEN 32G 6MM PEN NEEDLE..... | 125 |
| INBRIJA INHALATION CAPSULE, W/INHALATION DEVICE..... | 155 | INSUPEN 32G 8MM PEN NEEDLE..... | 125 |
| INCONTROL PEN NEEDLE 12MM 29G | 125 | INSUPEN PEN NEEDLE 29GX12MM.... | 125 |
| INCONTROL PEN NEEDLE 4MM 32G.. | 125 | INSUPEN PEN NEEDLE 31GX3/16"..... | 125 |
| INCONTROL PEN NEEDLE 5MM 31G.. | 125 | INSUPEN PEN NEEDLE 32GX4MM..... | 125 |
| INCONTROL PEN NEEDLE 6MM 31G.. | 125 | INSUPEN PEN NEEDLE 33GX4MM..... | 125 |
| INCONTROL PEN NEEDLE 8MM 31G.. | 125 | <i>itraconazole oral solution</i> | 137 |
| INGREZZA..... | 277 | IV ANTISEPTIC WIPES..... | 125 |
| INGREZZA INITIATION PK(TARDIV).. | 277 | <i>ivermectin oral</i> | 139 |
| INLYTA ORAL TABLET 1 MG, 5 MG..... | 26 | IWILFIN..... | 141 |
| INQOVI..... | 66 | JAKAFI..... | 227 |
| INREBIC..... | 99 | <i>javygtor oral tablet,soluble</i> | 228 |
| INSULIN SYR 0.3 ML 31GX1/4(1/2)..... | 125 | JAYPIRCA ORAL TABLET 100 MG, 50 MG..... | 206 |
| INSULIN SYRIN 0.3 ML 30GX1/2" SHORT NEEDLE..... | 125 | KALYDECO ORAL GRANULES IN PACKET 25 MG, 5.8 MG, 50 MG, 75 MG | 138 |
| INSULIN SYRIN 0.5 ML 28GX1/2" (OTC)..... | 125 | KALYDECO ORAL TABLET..... | 138 |
| INSULIN SYRIN 0.5 ML 29GX1/2" (OTC)..... | 125 | KENDALL ALCOHOL 70% PREP PAD.. | 125 |
| INSULIN SYRIN 0.5 ML 30GX1/2" SHORT NEEDLE (OTC)..... | 125 | KERENDIA..... | 104 |
| INSULIN SYRIN 0.5 ML 30GX5/16" SHORT NEEDLE (OTC)..... | 125 | KESIMPTA PEN..... | 180 |
| INSULIN SYRING 0.5 ML 27G 1/2" INNER..... | 125 | KEVZARA..... | 229 |
| INSULIN SYRINGE 0.3 ML..... | 125 | KISQALI FEMARA CO-PACK ORAL TABLET 200 MG/DAY(200 MG X 1)-2.5 MG, 400 MG/DAY(200 MG X 2)-2.5 MG, 600 MG/DAY(200 MG X 3)-2.5 MG..... | 216 |
| INSULIN SYRINGE 0.3 ML 31GX1/4..... | 125 | KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1), 400 MG/DAY (200 MG X 2), 600 MG/DAY (200 MG X 3)..... | 216 |
| INSULIN SYRINGE 0.5 ML..... | 125 | KOSELUGO ORAL CAPSULE 10 MG, 25 MG..... | 236 |
| INSULIN SYRINGE 0.5 ML 31GX1/4..... | 125 | KRAZATI..... | 7 |
| INSULIN SYRINGE 1 ML..... | 125 | <i>lapatinib</i> | 144 |
| INSULIN SYRINGE 1 ML 27G 1/2" INNER..... | 125 | <i>ledipasvir-sofosbuvir</i> | 146 |
| INSULIN SYRINGE 1 ML 28G 1/2" INNER (RX)..... | 125 | <i>lenalidomide</i> | 147 |
| INSULIN SYRINGE 1 ML 30GX1/2" (RX)..... | 125 | LENVIMA..... | 148 |
| INSULIN SYRINGE 1 ML 30GX5/16" SHORT NEEDLE (OTC)..... | 125 | <i>leuprolide (3 month)</i> | 151 |
| INSULIN SYRINGE 1 ML 31GX1/4"..... | 125 | <i>leuprolide subcutaneous kit</i> | 150 |
| | | <i>lidocaine hcl mucous membrane solution 4 % (40 mg/ml)</i> | 157 |
| | | <i>lidocaine topical adhesive patch,medicated 5 %</i> | 157 |

| | | | |
|---|-----|---|-----|
| <i>lidocaine topical ointment</i> | 157 | MAVYRET ORAL PELLETS IN | |
| <i>lidocaine-prilocaine topical cream</i> | 158 | PACKET..... | 116 |
| LISCO SPONGES 100/BAG..... | 125 | MAVYRET ORAL TABLET..... | 116 |
| LITE TOUCH 31GX1/4" PEN NEEDLE.. | 125 | MAXICOMFORT II PEN NDL | |
| LITE TOUCH INSULIN 0.5 ML SYR..... | 125 | 31GX6MM..... | 125 |
| LITE TOUCH INSULIN 1 ML SYR..... | 125 | MAXICOMFORT INS 0.5 ML 27GX1/2" | 125 |
| LITE TOUCH INSULIN SYR 1 ML..... | 125 | MAXI-COMFORT INS 0.5 ML 28G..... | 125 |
| LITE TOUCH PEN NEEDLE 29G..... | 125 | MAXICOMFORT INS 1 ML 27GX1/2" .. | 125 |
| LITE TOUCH PEN NEEDLE 31G..... | 125 | MAXI-COMFORT INS 1 ML 28GX1/2" .. | 125 |
| LITETOUCH INS 0.3 ML 29GX1/2"..... | 125 | MAXICOMFORT PEN NDL 29G X 5MM | |
| LITETOUCH INS 0.3 ML 30GX5/16"..... | 125 | | 125 |
| LITETOUCH INS 0.3 ML 31GX5/16"..... | 125 | MAXICOMFORT PEN NDL 29G X 8MM | |
| LITETOUCH INS 0.5 ML 31GX5/16"..... | 125 | | 125 |
| LITETOUCH SYR 0.5 ML 28GX1/2"..... | 125 | MAYZENT ORAL TABLET 0.25 MG, 1 | |
| LITETOUCH SYR 0.5 ML 29GX1/2"..... | 125 | MG, 2 MG..... | 237 |
| LITETOUCH SYR 0.5 ML 30GX5/16".... | 125 | MAYZENT STARTER(FOR 1MG | |
| LITETOUCH SYRIN 1 ML 28GX1/2"..... | 125 | MAINT)..... | 237 |
| LITETOUCH SYRIN 1 ML 29GX1/2"..... | 125 | MAYZENT STARTER(FOR 2MG | |
| LITETOUCH SYRIN 1 ML 30GX5/16" .. | 125 | MAINT)..... | 237 |
| LIVTENCITY..... | 163 | MEKINIST ORAL TABLET 0.5 MG, 2 | |
| LONSURF ORAL TABLET 15-6.14 MG, | | MG..... | 266 |
| 20-8.19 MG..... | 268 | MEKTOVI..... | 38 |
| LORBRENA ORAL TABLET 100 MG, | | MICRODOT PEN NEEDLE 31GX6MM.. | 125 |
| 25 MG..... | 159 | MICRODOT PEN NEEDLE 32GX4MM.. | 125 |
| LUMAKRAS ORAL TABLET 120 MG, | | MICRODOT PEN NEEDLE 33GX4MM.. | 125 |
| 320 MG..... | 246 | MICRODOT READYGARD NDL 31G | |
| LUPRON DEPOT..... | 153 | 5MM OUTER..... | 125 |
| LUPRON DEPOT (3 MONTH)..... | 153 | <i>mifepristone oral tablet 300 mg</i> | 168 |
| LUPRON DEPOT (4 MONTH)..... | 153 | <i>miglustat</i> | 170 |
| LUPRON DEPOT (6 MONTH)..... | 153 | MINI PEN NEEDLE 32G 4MM..... | 125 |
| LYBALVI..... | 184 | MINI PEN NEEDLE 32G 5MM..... | 125 |
| LYNPARZA..... | 185 | MINI PEN NEEDLE 32G 6MM..... | 125 |
| LYTGOBI ORAL TABLET 12 MG/DAY | | MINI PEN NEEDLE 32G 8MM..... | 125 |
| (4 MG X 3), 16 MG/DAY (4 MG X 4), 20 | | MINI PEN NEEDLE 33G 4MM..... | 125 |
| MG/DAY (4 MG X 5)..... | 109 | MINI PEN NEEDLE 33G 5MM..... | 125 |
| MAGELLAN INSUL SYRINGE 0.3 ML.. | 125 | MINI PEN NEEDLE 33G 6MM..... | 125 |
| MAGELLAN INSUL SYRINGE 0.5 ML.. | 125 | MINI ULTRA-THIN II PEN NDL 31G | |
| MAGELLAN INSULIN SYR 0.3 ML..... | 125 | STERILE..... | 125 |
| MAGELLAN INSULIN SYR 0.5 ML..... | 125 | <i>modafinil oral tablet 100 mg, 200 mg</i> | 174 |
| MAGELLAN INSULIN SYRINGE 1 ML | 125 | MONOJECT 0.5 ML SYRN 28GX1/2"..... | 125 |
| MAVENCLAD (10 TABLET PACK)..... | 54 | MONOJECT 1 ML SYRN 27X1/2"..... | 125 |
| MAVENCLAD (4 TABLET PACK)..... | 54 | MONOJECT 1 ML SYRN 28GX1/2" | |
| MAVENCLAD (5 TABLET PACK)..... | 54 | (OTC)..... | 125 |
| MAVENCLAD (6 TABLET PACK)..... | 54 | MONOJECT INSUL SYR U100 (OTC).... | 125 |
| MAVENCLAD (7 TABLET PACK)..... | 54 | MONOJECT INSUL SYR U100 | |
| MAVENCLAD (8 TABLET PACK)..... | 54 | .5ML,29GX1/2" (OTC)..... | 125 |
| MAVENCLAD (9 TABLET PACK)..... | 54 | | |

| | | | |
|--|-----|---|-----|
| MONOJECT INSUL SYR U100 0.5 ML CONVERTS TO 29G (OTC)..... | 125 | OJEMDA ORAL SUSPENSION FOR RECONSTITUTION..... | 182 |
| MONOJECT INSUL SYR U100 1 ML..... | 125 | OJEMDA ORAL TABLET..... | 182 |
| MONOJECT INSUL SYR U100 1 ML 3'S, 29GX1/2" (OTC)..... | 125 | OJJAARA..... | 183 |
| MONOJECT INSUL SYR U100 1 ML W/O NEEDLE (OTC)..... | 125 | ONUREG..... | 27 |
| MONOJECT INSULIN SYR 0.3 ML..... | 125 | OPSUMIT..... | 162 |
| MONOJECT INSULIN SYR 0.3 ML (OTC)..... | 125 | ORENCIA..... | 1 |
| MONOJECT INSULIN SYR 0.5 ML..... | 125 | ORENCIA CLICKJECT..... | 1 |
| MONOJECT INSULIN SYR 0.5 ML (OTC)..... | 125 | ORGOVYX..... | 215 |
| MONOJECT INSULIN SYR 1 ML 3'S (OTC)..... | 125 | ORLISSA ORAL TABLET 150 MG, 200 MG..... | 83 |
| MONOJECT INSULIN SYR U-100..... | 125 | ORKAMBI ORAL GRANULES IN PACKET..... | 161 |
| MONOJECT SYRINGE 0.3 ML..... | 125 | ORKAMBI ORAL TABLET..... | 161 |
| MONOJECT SYRINGE 0.5 ML..... | 125 | ORSERDU ORAL TABLET 345 MG, 86 MG..... | 82 |
| MONOJECT SYRINGE 1 ML..... | 125 | OTEZLA ORAL TABLET 20 MG, 30 MG..... | 18 |
| <i>morphine concentrate oral solution</i> | 120 | OTEZLA STARTER..... | 18 |
| MOUNJARO..... | 118 | <i>oxycodone oral concentrate</i> | 120 |
| NERLYNX..... | 175 | OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG (2 MG/3 ML), 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML)..... | 118 |
| NEULASTA..... | 196 | <i>pazopanib</i> | 194 |
| NINLARO..... | 142 | PC UNIFINE PENTIPS 8MM NEEDLE SHORT..... | 125 |
| <i>nitisinone oral capsule 10 mg, 2 mg, 5 mg</i> | 179 | PEMAZYRE..... | 201 |
| NIVESTYM..... | 102 | PEN NEEDLE 30G 5MM OUTER..... | 125 |
| NORDITROPIN FLEXPRO..... | 241 | PEN NEEDLE 30G 8MM INNER..... | 125 |
| NOVOFINE 30..... | 125 | PEN NEEDLE 30G X 5/16"..... | 125 |
| NOVOFINE 32G NEEDLES..... | 125 | PEN NEEDLE, DIABETIC NEEDLE 29 GAUGE X 1/2"..... | 125 |
| NOVOFINE PLUS PEN NDL 32GX1/6"..... | 125 | PEN NEEDLES 12MM 29G 29GX12MM,STRL..... | 125 |
| NOVOTWIST NEEDLE 32G 5MM..... | 125 | PEN NEEDLES 4MM 32G..... | 125 |
| NOXAFIL ORAL SUSP,DELAYED RELEASE FOR RECON..... | 210 | PEN NEEDLES 6MM 31G 31GX6MM, STRL..... | 125 |
| NUBEQA..... | 63 | PEN NEEDLES 8MM 31G 31GX8MM,STRL,SHORT.(OTC)..... | 125 |
| NUCALA SUBCUTANEOUS AUTO- INJECTOR..... | 164 | <i>penicillamine oral tablet</i> | 202 |
| NUCALA SUBCUTANEOUS RECON SOLN..... | 164 | PENTIPS PEN NEEDLE 29G 1/2"..... | 125 |
| NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML, 40 MG/0.4 ML..... | 164 | PENTIPS PEN NEEDLE 31G 1/4"..... | 125 |
| NUPLAZID..... | 204 | PENTIPS PEN NEEDLE 31GX3/16" MINI, 5MM..... | 125 |
| NURTEC ODT..... | 218 | PENTIPS PEN NEEDLE 31GX5/16" SHORT, 8MM..... | 125 |
| NYVEPRIA..... | 197 | PENTIPS PEN NEEDLE 32G 1/4"..... | 125 |
| ODOMZO..... | 244 | | |
| OFEV..... | 177 | | |
| OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MG..... | 181 | | |

| | | | |
|--|-----|--|-----|
| PENTIPS PEN NEEDLE 32GX5/32" 4MM..... | 125 | RADICAVA ORS STARTER KIT SUSP... 80 | |
| PIP PEN NEEDLE 31G X 5MM..... | 125 | RAYA SURE PEN NEEDLE 29G 12MM.. | 125 |
| PIP PEN NEEDLE 32G X 4MM..... | 125 | RAYA SURE PEN NEEDLE 31G 4MM... | 125 |
| PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1), 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2)..... | 13 | RAYA SURE PEN NEEDLE 31G 5MM... | 125 |
| <i>pirfenidone oral capsule</i> | 205 | RAYA SURE PEN NEEDLE 31G 6MM... | 125 |
| <i>pirfenidone oral tablet 267 mg, 534 mg, 801 mg</i> | 205 | REGRANEX..... | 29 |
| POMALYST..... | 207 | RELION INS SYR 0.3 ML 31GX6MM.... | 125 |
| <i>posaconazole oral</i> | 209 | RELION INS SYR 0.5 ML 31GX6MM.... | 125 |
| PREVENT PEN NEEDLE 31GX1/4"..... | 125 | RELION INS SYR 1 ML 31GX15/64"..... | 125 |
| PREVENT PEN NEEDLE 31GX5/16"..... | 125 | RELI-ON INSULIN 0.5 ML SYR..... | 125 |
| PREVYMIS ORAL..... | 149 | RELI-ON INSULIN 1 ML SYR..... | 125 |
| PRO COMFORT 0.5 ML 30GX1/2"..... | 125 | RELION MINI PEN 31G X 1/4" NDL..... | 125 |
| PRO COMFORT 0.5 ML 30GX5/16"..... | 125 | RELION NEEDLES..... | 125 |
| PRO COMFORT 0.5 ML 31GX5/16"..... | 125 | RELION PEN NEEDLES..... | 125 |
| PRO COMFORT 1 ML 30GX1/2"..... | 125 | RELISTOR ORAL..... | 166 |
| PRO COMFORT 1 ML 30GX5/16"..... | 125 | RELISTOR SUBCUTANEOUS SOLUTION..... | 165 |
| PRO COMFORT 1 ML 31GX5/16"..... | 125 | RELISTOR SUBCUTANEOUS SYRINGE 12 MG/0.6 ML, 8 MG/0.4 ML.. | 165 |
| PRO COMFORT ALCOHOL 70% PADS | 125 | RETACRIT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/2 ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML, 40,000 UNIT/ML..... | 92 |
| PRO COMFORT PEN NDL 31GX5/16"... | 125 | RETEVMO ORAL CAPSULE 40 MG, 80 MG..... | 235 |
| PRO COMFORT PEN NDL 32G X 1/4"... | 125 | RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG..... | 235 |
| PRO COMFORT PEN NDL 4MM 32G.... | 125 | REVCОВI..... | 84 |
| PRO COMFORT PEN NDL 5MM 32G.... | 125 | REZLIDHIA..... | 186 |
| PRODIGY INS SYR 1 ML 28GX1/2"..... | 125 | REZUROCK..... | 32 |
| PRODIGY SYRNG 0.5 ML 31GX5/16"... | 125 | RINVOQ..... | 273 |
| PRODIGY SYRNGE 0.3 ML 31GX5/16"... | 125 | ROZLYTREK ORAL CAPSULE 100 MG, 200 MG..... | 90 |
| PROMACTA ORAL POWDER IN PACKET 12.5 MG, 25 MG..... | 87 | ROZLYTREK ORAL PELLETS IN PACKET..... | 90 |
| PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG..... | 87 | RUBRACA..... | 226 |
| PURE CMFT SFTY PEN NDL 31G 5MM | 125 | RYBELSUS..... | 118 |
| PURE CMFT SFTY PEN NDL 31G 6MM | 125 | RYDAPT..... | 167 |
| PURE CMFT SFTY PEN NDL 32G 4MM | 125 | SAFESNAP INS SYR UNITS-100 0.3 ML 30GX5/16",10X10..... | 125 |
| PURE COMFORT ALCOHOL 70% PADS..... | 125 | SAFESNAP INS SYR UNITS-100 0.5 ML 29GX1/2",10X10..... | 125 |
| PURE COMFORT PEN NDL 32G 4MM.. | 125 | SAFESNAP INS SYR UNITS-100 0.5 ML 30GX5/16",10X10..... | 125 |
| PURE COMFORT PEN NDL 32G 5MM.. | 125 | SAFESNAP INS SYR UNITS-100 1 ML 28GX1/2",10X10..... | 125 |
| PURE COMFORT PEN NDL 32G 6MM.. | 125 | | |
| PURE COMFORT PEN NDL 32G 8MM.. | 125 | | |
| <i>pyrimethamine</i> | 212 | | |
| QINLOCK..... | 222 | | |
| <i>quinine sulfate</i> | 213 | | |
| QULIPTA..... | 21 | | |

| | | | |
|---|-----|---|-----|
| SAFESNAP INS SYR UNITS-100 1 ML 29GX1/2",10X10..... | 125 | SURE COMFORT 3/10 ML SYRINGE INSULIN SYRINGE..... | 125 |
| SAFETY PEN NEEDLE 31G 4MM..... | 125 | SURE COMFORT 30G PEN NEEDLE..... | 125 |
| SAFETY PEN NEEDLE 5MM X 31G..... | 125 | SURE COMFORT ALCOHOL PREP PADS..... | 125 |
| SAFETY SYRINGE 0.5 ML 30G 1/2"..... | 125 | SURE COMFORT INS 0.3 ML 31GX1/4..... | 125 |
| <i>sajazir</i> | 122 | SURE COMFORT INS 0.5 ML 31GX1/4..... | 125 |
| <i>sapropterin oral tablet,soluble</i> | 228 | SURE COMFORT INS 1 ML 31GX1/4"..... | 125 |
| SCSEMBLIX..... | 20 | SURE COMFORT PEN NDL 29GX1/2" 12.7MM..... | 125 |
| SECURES SAFE PEN NDL 30GX5/16" OUTER..... | 125 | SURE COMFORT PEN NDL 31G 5MM..... | 125 |
| SECURES SAFE SYR 0.5 ML 29G 1/2" OUTER..... | 125 | SURE COMFORT PEN NDL 31G 8MM..... | 125 |
| SECURES SAFE SYRNG 1 ML 29G 1/2" OUTER..... | 125 | SURE COMFORT PEN NDL 32G 4MM..... | 125 |
| SEROSTIM SUBCUTANEOUS RECON SOLN 4 MG, 5 MG, 6 MG..... | 243 | SURE COMFORT PEN NDL 32G 6MM..... | 125 |
| SIGNIFOR..... | 193 | SURE-FINE PEN NEEDLES 12.7MM..... | 125 |
| <i>sildenafil (pulm.hypertension) oral tablet</i> .. | 195 | SURE-FINE PEN NEEDLES 5MM..... | 125 |
| SIMLANDI(CF) AUTOINJECTOR..... | 8 | SURE-FINE PEN NEEDLES 8MM..... | 125 |
| SIRTURO..... | 30 | SURE-JECT INSU SYR U100 0.3 ML..... | 125 |
| SKY SAFETY PEN NEEDLE 30G 5MM..... | 125 | SURE-JECT INSU SYR U100 0.5 ML..... | 125 |
| SKY SAFETY PEN NEEDLE 30G 8MM..... | 125 | SURE-JECT INSU SYR U100 1 ML..... | 125 |
| SKYRIZI SUBCUTANEOUS PEN INJECTOR..... | 223 | SURE-JECT INSUL SYR U100 1 ML..... | 125 |
| SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML..... | 223 | SURE-JECT INSULIN SYRINGE 1 ML..... | 125 |
| SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML), 360 MG/2.4 ML (150 MG/ML)..... | 223 | SURE-PREP ALCOHOL PREP PADS..... | 125 |
| SM ULT CFT 0.3 ML 31GX5/16(1/2)..... | 125 | SYMDEKO..... | 260 |
| <i>sodium oxybate</i> | 238 | SYMPAZAN..... | 55 |
| <i>sofosbuvir-velpatasvir</i> | 239 | SYNAREL..... | 172 |
| SOMAVERT..... | 200 | TABRECTA..... | 49 |
| <i>sorafenib</i> | 245 | <i>tadalafil (pulm. hypertension)</i> | 195 |
| SPRYCEL ORAL TABLET 100 MG, 140 MG, 20 MG, 50 MG, 70 MG, 80 MG..... | 65 | <i>tadalafil oral tablet 2.5 mg, 5 mg</i> | 249 |
| STELARA SUBCUTANEOUS..... | 275 | TAFINLAR ORAL CAPSULE..... | 60 |
| STERILE PADS 2" X 2"..... | 125 | TAGRISSO..... | 190 |
| STIVARGA..... | 214 | TAKHZYRO SUBCUTANEOUS SOLUTION..... | 143 |
| <i>sunitinib malate</i> | 248 | TAKHZYRO SUBCUTANEOUS SYRINGE 150 MG/ML, 300 MG/2 ML (150 MG/ML)..... | 143 |
| SURE CMFT SFTY PEN NDL 31G 6MM..... | 125 | TALZENNA..... | 251 |
| SURE CMFT SFTY PEN NDL 32G 4MM..... | 125 | TASIGNA ORAL CAPSULE 150 MG, 200 MG, 50 MG..... | 176 |
| SURE COMFORT 0.5 ML SYRINGE..... | 125 | <i>tasimelteon</i> | 252 |
| SURE COMFORT 1 ML SYRINGE..... | 125 | TAVNEOS..... | 23 |
| SURE COMFORT 3/10 ML SYRINGE.... | 125 | TAZVERIK..... | 253 |
| | | TECHLITE 0.3 ML 29GX12MM (1/2)..... | 125 |
| | | TECHLITE 0.3 ML 30GX12MM (1/2)..... | 125 |
| | | TECHLITE 0.3 ML 30GX8MM (1/2)..... | 125 |
| | | TECHLITE 0.3 ML 31GX6MM (1/2)..... | 125 |
| | | TECHLITE 0.3 ML 31GX8MM (1/2)..... | 125 |

| | | | |
|--|-----|--------------------------------------|-----|
| TECHLITE 0.5 ML 29GX12MM (1/2)..... | 125 | TRIKAFTA ORAL TABLETS, | |
| TECHLITE 0.5 ML 30GX12MM (1/2)..... | 125 | SEQUENTIAL..... | 85 |
| TECHLITE 0.5 ML 30GX8MM (1/2)..... | 125 | TRUE CMFRT PRO 0.5 ML 30G 5/16" | 125 |
| TECHLITE 0.5 ML 31GX6MM (1/2)..... | 125 | TRUE CMFRT PRO 0.5 ML 31G 5/16" | 125 |
| TECHLITE 0.5 ML 31GX8MM (1/2)..... | 125 | TRUE CMFRT PRO 0.5 ML 32G 5/16" | 125 |
| TECHLITE INS SYR 1 ML 29GX12MM. | 125 | TRUE CMFT SFTY PEN NDL 31G 5MM | 125 |
| TECHLITE INS SYR 1 ML 30GX12MM. | 125 | TRUE CMFT SFTY PEN NDL 31G 6MM | 125 |
| TECHLITE INS SYR 1 ML 30GX8MM... | 125 | TRUE CMFT SFTY PEN NDL 32G 4MM | 125 |
| TECHLITE INS SYR 1 ML 31GX6MM... | 125 | TRUE COMFORT 0.5 ML 30G 1/2" | 125 |
| TECHLITE INS SYR 1 ML 31GX8MM... | 125 | TRUE COMFORT 0.5 ML 30G 5/16" | 125 |
| TECHLITE PEN NEEDLE 29GX1/2" | 125 | TRUE COMFORT 0.5 ML 31G 5/16" | 125 |
| TECHLITE PEN NEEDLE 29GX3/8" | 125 | TRUE COMFORT 0.5 ML 31GX5/16" | 125 |
| TECHLITE PEN NEEDLE 31GX1/4" | 125 | TRUE COMFORT 1 ML 31GX5/16" | 125 |
| TECHLITE PEN NEEDLE 31GX3/16" | 125 | TRUE COMFORT ALCOHOL 70% | |
| TECHLITE PEN NEEDLE 31GX5/16" | 125 | PADS..... | 125 |
| TECHLITE PEN NEEDLE 32GX1/4" | 125 | TRUE COMFORT PEN NDL 31G 8MM.. | 125 |
| TECHLITE PEN NEEDLE 32GX5/16" | 125 | TRUE COMFORT PEN NDL 31GX5MM | 125 |
| TECHLITE PEN NEEDLE 32GX5/32" | 125 | TRUE COMFORT PEN NDL 31GX6MM | 125 |
| TECHLITE PLUS PEN NDL 32G 4MM.. | 125 | TRUE COMFORT PEN NDL 32G 5MM.. | 125 |
| TEPMETKO | 256 | TRUE COMFORT PEN NDL 32G 6MM.. | 125 |
| <i>teriflunomide</i> | 257 | TRUE COMFORT PEN NDL 32GX4MM | 125 |
| TERUMO INS SYRINGE U100-1 ML..... | 125 | TRUE COMFORT PEN NDL 33G 4MM.. | 125 |
| TERUMO INS SYRINGE U100-1/2 ML.. | 125 | TRUE COMFORT PEN NDL 33G 5MM.. | 125 |
| TERUMO INS SYRINGE U100-1/3 ML.. | 125 | TRUE COMFORT PEN NDL 33G 6MM.. | 125 |
| TERUMO INS SYRNG U100-1/2 ML..... | 125 | TRUE COMFORT PRO 1 ML 30G 1/2" ... | 125 |
| <i>tetrabenazine</i> | 259 | TRUE COMFORT PRO 1 ML 30G 5/16" . | 125 |
| THALOMID | 261 | TRUE COMFORT PRO 1 ML 31G 5/16" . | 125 |
| THINPRO INS SYRIN U100-0.3 ML..... | 125 | TRUE COMFORT PRO 1 ML 32G 5/16" . | 125 |
| THINPRO INS SYRIN U100-0.5 ML..... | 125 | TRUE COMFORT PRO ALCOHOL | |
| THINPRO INS SYRIN U100-1 ML..... | 125 | PADS..... | 125 |
| TIBSOVO..... | 140 | TRUE COMFORT SFTY 1 ML 30G 1/2" . | 125 |
| TOPCARE CLICKFINE 31G X 1/4" | 125 | TRUE COMFRT PRO 0.5 ML 30G 1/2" ... | 125 |
| TOPCARE CLICKFINE 31G X 5/16" | 125 | TRUE COMFRT SFTY 1 ML 30G 5/16" .. | 125 |
| TOPCARE ULTRA COMFORT | | TRUE COMFRT SFTY 1 ML 31G 5/16" .. | 125 |
| SYRINGE..... | 125 | TRUE COMFRT SFTY 1 ML 32G 5/16" .. | 125 |
| <i>torpenz oral tablet 10 mg, 2.5 mg, 5 mg,</i> | | TRUEPLUS PEN NEEDLE 29G 12MM... | 125 |
| <i>7.5 mg</i> | 98 | TRUEPLUS PEN NEEDLE 31G 5MM..... | 125 |
| TRELSTAR INTRAMUSCULAR | | TRUEPLUS PEN NEEDLE 31G 8MM..... | 125 |
| SUSPENSION FOR RECONSTITUTION | 269 | TRUEPLUS PEN NEEDLE 31G X 1/4" ... | 125 |
| TREMFYA SUBCUTANEOUS AUTO- | | TRUEPLUS PEN NEEDLE 32GX5/32" ... | 125 |
| INJECTOR..... | 119 | TRUEPLUS SYR 0.3 ML 29GX1/2" | 125 |
| TREMFYA SUBCUTANEOUS | | TRUEPLUS SYR 0.3 ML 30GX5/16" | 125 |
| SYRINGE 100 MG/ML..... | 119 | TRUEPLUS SYR 0.3 ML 31GX5/16" | 125 |
| <i>tretinoin topical cream 0.025 %, 0.05 %,</i> | | TRUEPLUS SYR 0.5 ML 28GX1/2" | 125 |
| <i>0.1 %</i> | 265 | TRUEPLUS SYR 0.5 ML 29GX1/2" | 125 |
| <i>tretinoin topical gel</i> | 265 | TRUEPLUS SYR 0.5 ML 30GX5/16" | 125 |
| <i>trientine oral capsule 250 mg, 500 mg</i> | 267 | TRUEPLUS SYR 0.5 ML 31GX5/16" | 125 |

| | | | |
|--------------------------------------|-----|--------------------------------------|-----|
| TRUEPLUS SYR 1 ML 28GX1/2"..... | 125 | ULTIGUARD SAFEPAK 32G 6MM..... | 125 |
| TRUEPLUS SYR 1 ML 29GX1/2"..... | 125 | ULTIGUARD SAFEPK 0.3 ML 31G | |
| TRUEPLUS SYR 1 ML 30GX5/16"..... | 125 | 8MM..... | 125 |
| TRUEPLUS SYR 1 ML 31GX5/16"..... | 125 | ULTIGUARD SAFEPK 0.5 ML 31G | |
| TRULICITY..... | 118 | 8MM..... | 125 |
| TRUQAP..... | 270 | ULTILET ALCOHOL STERL SWAB..... | 125 |
| TUKYSA ORAL TABLET 150 MG, 50 | | ULTILET INSULIN SYRINGE 0.3 ML... | 125 |
| MG..... | 271 | ULTILET INSULIN SYRINGE 0.5 ML... | 125 |
| UBRELVY..... | 272 | ULTILET INSULIN SYRINGE 1 ML..... | 125 |
| UDENYCA..... | 198 | ULTILET PEN NEEDLE..... | 125 |
| UDENYCA AUTOINJECTOR..... | 198 | ULTILET PEN NEEDLE 4MM 32G..... | 125 |
| ULTICAR INS 0.3 ML 31GX1/4(1/2)..... | 125 | ULTRA COMFORT 0.3 ML SYRINGE... | 125 |
| ULTICARE INS 1 ML 31GX1/4"..... | 125 | ULTRA COMFORT 0.5 ML 28GX1/2" | |
| ULTICARE INS SYR 0.3 ML 30G 8MM. | 125 | CONVERTS TO 29G..... | 125 |
| ULTICARE INS SYR 0.3 ML 31G 6MM. | 125 | ULTRA COMFORT 0.5 ML 29GX1/2".... | 125 |
| ULTICARE INS SYR 0.3 ML 31G 8MM. | 125 | ULTRA COMFORT 0.5 ML SYRINGE... | 125 |
| ULTICARE INS SYR 0.5 ML 31G 6MM. | 125 | ULTRA COMFORT 1 ML 31GX5/16"..... | 125 |
| ULTICARE INS SYR 1 ML 30GX1/2"..... | 125 | ULTRA COMFORT 1 ML SYRINGE..... | 125 |
| ULTICARE PEN NEEDLE 31GX3/16"..... | 125 | ULTRA FLO 0.3 ML 30G 1/2" (1/2)..... | 125 |
| ULTICARE PEN NEEDLE 6MM 31G..... | 125 | ULTRA FLO 0.3 ML 30G 5/16"(1/2)..... | 125 |
| ULTICARE PEN NEEDLE 8MM 31G..... | 125 | ULTRA FLO 0.3 ML 31G 5/16"(1/2)..... | 125 |
| ULTICARE PEN NEEDLES 12MM 29G. | 125 | ULTRA FLO PEN NEEDLE 31G 5MM... 125 | |
| ULTICARE PEN NEEDLES 4MM 32G | | ULTRA FLO PEN NEEDLE 31G 8MM... 125 | |
| MICRO, 32GX4MM..... | 125 | ULTRA FLO PEN NEEDLE 32G 4MM... 125 | |
| ULTICARE PEN NEEDLES 6MM 32G... | 125 | ULTRA FLO PEN NEEDLE 33G 4MM... 125 | |
| ULTICARE SAFE PEN NDL 30G 8MM.. | 125 | ULTRA FLO PEN NEEDLES 12MM 29G | |
| ULTICARE SAFE PEN NDL 5MM 30G.. | 125 | | 125 |
| ULTICARE SYR 0.3 ML 29G 12.7MM.... | 125 | ULTRA FLO SYR 0.3 ML 29GX1/2"..... | 125 |
| ULTICARE SYR 0.3 ML 30GX1/2"..... | 125 | ULTRA FLO SYR 0.3 ML 30G 5/16"..... | 125 |
| ULTICARE SYR 0.3 ML 31GX5/16" | | ULTRA FLO SYR 0.3 ML 31G 5/16"..... | 125 |
| SHORT NDL..... | 125 | ULTRA FLO SYR 0.5 ML 29G 1/2"..... | 125 |
| ULTICARE SYR 0.5 ML 30GX1/2"..... | 125 | ULTRA THIN PEN NDL 32G X 4MM..... | 125 |
| ULTICARE SYR 0.5 ML 31GX5/16" | | ULTRACARE INS 0.3 ML 30GX5/16"..... | 125 |
| SHORT NDL..... | 125 | ULTRACARE INS 0.3 ML 31GX5/16"..... | 125 |
| ULTICARE SYR 1 ML 31GX5/16"..... | 125 | ULTRACARE INS 0.5 ML 30GX1/2"..... | 125 |
| ULTIGUARD SAFE 1 ML 30G 12.7MM. | 125 | ULTRACARE INS 0.5 ML 30GX5/16"..... | 125 |
| ULTIGUARD SAFE0.3 ML 30G 12.7MM | | ULTRACARE INS 0.5 ML 31GX5/16"..... | 125 |
| | 125 | ULTRACARE INS 1 ML 30G X 5/16"..... | 125 |
| ULTIGUARD SAFE0.5 ML 30G 12.7MM | | ULTRACARE INS 1 ML 30GX1/2"..... | 125 |
| | 125 | ULTRACARE INS 1 ML 31G X 5/16"..... | 125 |
| ULTIGUARD SAFEPAK 1 ML 31G | | ULTRACARE PEN NEEDLE 31GX1/4"..... | 125 |
| 8MM..... | 125 | ULTRACARE PEN NEEDLE 31GX3/16"..... | 125 |
| ULTIGUARD SAFEPAK 29G 12.7MM | 125 | ULTRACARE PEN NEEDLE 31GX5/16"..... | 125 |
| ULTIGUARD SAFEPAK 31G 5MM..... | 125 | ULTRACARE PEN NEEDLE 32GX1/4"..... | 125 |
| ULTIGUARD SAFEPAK 31G 6MM..... | 125 | ULTRACARE PEN NEEDLE 32GX3/16"..... | 125 |
| ULTIGUARD SAFEPAK 31G 8MM..... | 125 | ULTRACARE PEN NEEDLE 32GX5/32"..... | 125 |
| ULTIGUARD SAFEPAK 32G 4MM..... | 125 | ULTRACARE PEN NEEDLE 33GX5/32"..... | 125 |

| | | | |
|--------------------------------------|-----|---|-----|
| ULTRA-THIN II 1 ML 31GX5/16" | 125 | UPTRAVI ORAL TABLET 1,000 MCG, | |
| ULTRA-THIN II INS 0.3 ML 30G | 125 | 1,200 MCG, 1,400 MCG, 1,600 MCG, 200 | |
| ULTRA-THIN II INS 0.3 ML 31G | 125 | MCG, 400 MCG, 600 MCG, 800 MCG | 232 |
| ULTRA-THIN II INS 0.5 ML 29G | 125 | UPTRAVI ORAL TABLETS,DOSE | |
| ULTRA-THIN II INS 0.5 ML 30G | 125 | PACK | 232 |
| ULTRA-THIN II INS 0.5 ML 31G | 125 | VANFLYTA | 279 |
| ULTRA-THIN II INS SYR 1 ML 29G | 125 | VANISHPOINT 0.5 ML 30GX1/2" SY | |
| ULTRA-THIN II INS SYR 1 ML 30G | 125 | OUTER | 125 |
| ULTRA-THIN II PEN NDL 29GX1/2" | 125 | VANISHPOINT INS 1 ML 30GX3/16" | 125 |
| ULTRA-THIN II PEN NDL 31GX5/16 | 125 | VANISHPOINT U-100 29X1/2 SYR | 125 |
| UNIFINE PEN NEEDLE 32G 4MM | 125 | VENCLEXTA ORAL TABLET 10 MG, | |
| UNIFINE PENTIPS 12MM 29G | | 100 MG, 50 MG | 281 |
| 29GX12MM, STRL | 125 | VENCLEXTA STARTING PACK | 281 |
| UNIFINE PENTIPS 31GX3/16" | | VEOZAH | 101 |
| 31GX5MM,STRL,MINI | 125 | VERIFINE INS SYR 1 ML 29G 1/2" | 125 |
| UNIFINE PENTIPS 32GX1/4" | 125 | VERIFINE PEN NEEDLE 29G 12MM | 125 |
| UNIFINE PENTIPS 32GX5/32" | | VERIFINE PEN NEEDLE 31G 5MM | 125 |
| 32GX4MM, STRL, NANO | 125 | VERIFINE PEN NEEDLE 31G X 6MM | 125 |
| UNIFINE PENTIPS 33GX5/32" | 125 | VERIFINE PEN NEEDLE 31G X 8MM | 125 |
| UNIFINE PENTIPS 6MM 31G | 125 | VERIFINE PEN NEEDLE 32G 6MM | 125 |
| UNIFINE PENTIPS MAX 30GX3/16" | 125 | VERIFINE PEN NEEDLE 32G X 4MM | 125 |
| UNIFINE PENTIPS NEEDLES 29G | 125 | VERIFINE PEN NEEDLE 32G X 5MM | 125 |
| UNIFINE PENTIPS PLUS 29GX1/2" | | VERIFINE PLUS PEN NDL 31G 5MM | 125 |
| 12MM | 125 | VERIFINE PLUS PEN NDL 31G 8MM | 125 |
| UNIFINE PENTIPS PLUS 30GX3/16" | 125 | VERIFINE PLUS PEN NDL 32G 4MM | 125 |
| UNIFINE PENTIPS PLUS 31GX1/4" | | VERIFINE PLUS PEN NDL 32G 4MM- | |
| ULTRA SHORT, 6MM | 125 | SHARPS CONTAINER | 125 |
| UNIFINE PENTIPS PLUS 31GX3/16" | | VERIFINE SYRING 0.5 ML 29G 1/2" | 125 |
| MINI | 125 | VERIFINE SYRING 1 ML 31G 5/16" | 125 |
| UNIFINE PENTIPS PLUS 31GX5/16" | | VERIFINE SYRNG 0.3 ML 31G 5/16" | 125 |
| SHORT | 125 | VERIFINE SYRNG 0.5 ML 31G 5/16" | 125 |
| UNIFINE PENTIPS PLUS 32GX5/32" | 125 | VERQUVO | 282 |
| UNIFINE PENTIPS PLUS 33GX5/32" | 125 | VERSALON ALL PURPOSE SPONGE | |
| UNIFINE PROTECT 30G 5MM | 125 | 25'S,N-STERILE,3PLY | 125 |
| UNIFINE PROTECT 30G 8MM | 125 | VERZENIO | 3 |
| UNIFINE PROTECT 32G 4MM | 125 | <i>vigabatrin</i> | 283 |
| UNIFINE SAFECONTROL 30G 5MM | 125 | <i>vigadrone</i> | 283 |
| UNIFINE SAFECONTROL 30G 8MM | 125 | VIGAFYDE | 283 |
| UNIFINE SAFECONTROL 31G 5MM | 125 | <i>vigpoder</i> | 283 |
| UNIFINE SAFECONTROL 31G 6MM | 125 | VITRAKVI ORAL CAPSULE 100 MG, | |
| UNIFINE SAFECONTROL 31G 8MM | 125 | 25 MG | 145 |
| UNIFINE SAFECONTROL 32G 4MM | 125 | VITRAKVI ORAL SOLUTION | 145 |
| UNIFINE ULTRA PEN NDL 31G 5MM | 125 | VIZIMPRO | 61 |
| UNIFINE ULTRA PEN NDL 31G 6MM | 125 | VONJO | 191 |
| UNIFINE ULTRA PEN NDL 31G 8MM | 125 | <i>voriconazole oral suspension for</i> | |
| UNIFINE ULTRA PEN NDL 32G 4MM | 125 | <i>reconstitution</i> | 285 |
| | | VOSEVI | 240 |

| | |
|--|-----|
| VUMERITY | 75 |
| VYNDAMAX..... | 250 |
| WEBCOL ALCOHOL PREPS | |
| 20'S,LARGE..... | 125 |
| WELIREG..... | 33 |
| XALKORI ORAL CAPSULE..... | 58 |
| XALKORI ORAL PELLETT 150 MG, 20 MG, 50 MG..... | 58 |
| XDEMVI..... | 160 |
| XELJANZ..... | 263 |
| XELJANZ XR..... | 263 |
| XERMELO..... | 255 |
| XGEVA..... | 70 |
| XIFAXAN ORAL TABLET 200 MG, 550 MG..... | 217 |
| XOLAIR..... | 187 |
| XOSPATA..... | 113 |
| XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40 MG/WEEK (40 MG X 1), 40MG TWICE WEEK (40 MG X 2), 60 MG/WEEK (60 MG X 1), 60MG TWICE WEEK (120 MG/WEEK), 80 MG/WEEK (40 MG X 2), 80MG TWICE WEEK (160 MG/WEEK)..... | 234 |
| XTANDI ORAL CAPSULE..... | 91 |
| XTANDI ORAL TABLET 40 MG, 80 MG..... | 91 |
| YONSA..... | 5 |
| ZARXIO..... | 103 |
| ZEJULA ORAL TABLET..... | 178 |
| ZELBORAF..... | 280 |
| ZTALMY..... | 111 |
| ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG..... | 287 |
| ZYDELIG..... | 123 |
| ZYKADIA..... | 51 |